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Galectins are a family of endogenous proteins defined by their binding specificity for 
β-galactosides. Galectin-1 (Gal-1) exerts immune-regulatory and anti-inflammatory 
actions. Its release into the extracellular milieu often correlates with the peak of 
inflammation suggesting that it is induced during inflammation and may serve a pro-
resolving function. Indeed, Gal-1 has been shown to be protective in T cell driven 
models of autoimmunity largely through its ability to induce T cell apoptosis, yet its 
effects on innate immune cells such as neutrophils remains to be fully elucidated. 
 
The persistent recruitment of neutrophils to the arthritic joint and their prolonged 
survival within synovial fluid is a major factor in the pathogenesis of rheumatoid arthritis 
and thus an attractive therapeutic target. This thesis presents research on the role of 
Gal-1 in neutrophil trafficking, apoptosis, and clearance in an animal model of 
inflammatory arthritis, supported by a model of acute self-resolving peritonitis and in 
vitro assays. 
 
In response to arthritogenic serum Gal-1 KO mice exhibited delayed disease 
progression compared to WT mice as well as significantly reduced paw oedema and 
weight loss, however both genotypes reached a comparable clinical score at the peak 
of disease. Importantly, remission of arthritis was delayed in Gal-1 KO mice, with a 
resolution interval of 16 days versus 12 days in WT counterparts, suggesting a defect 




To investigate this further, a model of acute self-resolving inflammation was used to 
profile cell recruitment and clearance. Gal-1 KO mice displayed enhanced neutrophil 
recruitment compared to WT. Furthermore, the administration of recombinant Gal-1 
(hrGal-1) following the peak of inflammation led to reduced neutrophil numbers at 24 
and 48 hours, shortening the resolution interval from 39 to 14 hours. 
 
In line with the hypothesis that Gal-1 enhances clearance in an inflammatory setting, 
assessment of neutrophil apoptosis in vitro demonstrated that although Gal-1 had little 
effect on survival when given alone it significantly reversed the pro-survival signals of 
GM-CSF, increasing neutrophil apoptosis. 
 
In conclusion, the delayed remission of arthritis observed in Gal-1 KO mice coupled 
with the ability of hrGal-1 to enhance resolution of acute inflammation and counter-
regulate neutrophil pro-survival signals is suggestive of a role for Gal-1 in neutrophil 
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PGES   Prostaglandin E synthase 
PGI2   Prostacyclin 
PI   Propidium iodide 
PI3-kinase  Phosphoinositide 3-kinase 
Poly-LacNAc  Poly-N-acetyllactosame 
PPAR   Peroxisome proliferator-activated receptor 
ProS1   Protein S 
25 
 
PS   Phosphatidylserine 
PSR   Phosphatidylserine receptor 
PSGL-1  P-selectin glycoprotein ligand 1 
PTPN22  Protein tyrosine phosphatase, non-receptor type 22 
RA   Rheumatoid arthritis 
RAGE   Receptor for advanced glycosylation end products 
RAMP   Resolution associated molecular pattern 
RANK   Receptor activator of nuclear factor-κB 
RANKL  Receptor activator of nuclear factor-κB ligand 
RBC   Red blood cell 
RF   Rheumatoid factor 
Ri   Resolution interval 
RNase  Ribonuclease 
ROS   Reactive oxygen species 
RPMI   Roswell Park Memorial Institute 
RT   Room temperature 
SAA   Serum amyloid A 
SKG   Sakaguchi 
SSC   Side light scatter  
SSC-A  Side scatter area 
SSC-W  Side scatter width 
STAT4  Signal transducer and activator of transcription 4 
STIA   Serum transfer induced arthritis 
T50   50% of the maximum magnitude of inflammatory response 
TAE   Tris-acetate EDTA 
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TAM   Tyro3, Axl, and MerTK 
TBS   Tris buffered saline 
TBS-T   Tris buffered saline with Tween  
TCR   T-cell receptor 
Th   T helper 
Tim   T cell immunoglobulin and mucin domain-containing molecule 
Tmax   Maximum magnitude of inflammatory response 
TLR   Toll-like receptor 
TNF   Tumour necrosis factor 
TRAIL   TNF-related apoptosis-inducing ligand 
Twy   Tiptoe walking-Yoshimura 
VCAM   Vascular cell adhesion molecule 
WBC   White blood cell 
w/v   Weight/volume 
WT   Wildtype 




Chapter 1: Introduction 
 
1.1. Inflammation and Resolution 
  
Inflammatory responses initially arise when the equilibrium of a usually constant or 
relatively stable environment is disturbed. Despite tight regulation by the immune 
system, an abnormal response means the return to homeostasis is not always 
restored. Instead, the mediators that initiate, maintain and shut down the inflammatory 
response become imbalanced (Choy, 2011) commonly resulting in the persistent 
infiltration of inflammatory cells. 
  
Often considered the hallmark of an inflammatory response, the recruitment of 
leukocytes from the bloodstream to the surrounding tissue is a fundamental feature in 
both acute and chronic inflammation (Cooper et al., 2012). Traversing the endothelial 
barrier first are neutrophils. Acting as the first responders, neutrophils are phagocytes 
that arrive at the site of inflammation with powerful enzymes, oxidants and 
antimicrobial properties (Hampton et al., 1998). The migration of neutrophils out of the 
circulatory system towards the target tissue site initiates a stream of other 
mononuclear leukocytes to follow. Depending on the stimulus, T lymphocytes or 
monocytes are next to take up a role within the multistep process. In the case of acute 
inflammation, bioactive mediators are produced to promote resolution, bringing the 
short-term immune response to an end (Serhan and Savill, 2005).  
  
To return the targeted site to homeostasis, cessation of infiltration and disposal of the 
already present cells is essential (as shown in summary figure 1). To facilitate the 
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latter, inflammatory leukocytes must take one of two main exit routes: cells that remain 
live and viable will most often re-enter the systemic circulatory system whilst cells that 
have undergone local cell death are targeted for efferocytosis. Regardless of the 
assigned course, cell clearance needs to be both controlled and effective (Serhan et 
al., 2007), requiring a switch in the cellular environment from pro-inflammatory to pro-
resolving. Evidence indicate that resolution of inflammation is an active biosynthetic 
programmed response regulated by the production of mediators with specialised 
actions (Fredman et al., 2012). 
  
If the resolution process fails, persistent recruitment and infiltration of leukocytes into 
the tissue may occur, resulting in chronic inflammation. Therefore although the swift 
recruitment of immune cells is required for effective host defence, such recruitment 
has a detrimental effect when directed to healthy peripheral tissues (Sadik and Luster, 
2012), whereby either the unrequired recruitment of immune cells or retention of the 
inflammatory milieu facilitates the pathogenesis of autoimmune inflammatory 





Figure 1. Dynamics of inflammation and resolution. 
The inflammatory response occurs in a number of co-ordinated and temporal phases. Inflammatory mediators initiate 
an innate immune response characterised by rapid mast cell degranulation and mass infiltration of neutrophils, 
respectively resulting in oedema and the onset of an acute phase response. Recruited neutrophils are followed by 
monocytes that differentiate into macrophages in the tissue. Once migrated into the tissue, leukocytes produce 
numerous mediators, which govern the profile of the inflammatory response. The switch in mediator production from 
pro-inflammatory to pro-resolving is critical to the shift from inflammation to resolution. In the resolution phase, 
neutrophils, which have performed their role phagocytosing foreign material, undergo apoptosis and are subsequently 
cleared by macrophages termed efferocytosis. An imbalance of these behaviours can dysregulate the inflammatory 






As the most abundant white blood cell in humans, neutrophils account for between 50-
70% of leukocytes (compared with 10-25% in mice). Neutrophils undergo diapedesis 
to quickly migrate towards sites of inflammation and once positioned can provide an 
anti-microbial function through processes such as NETosis, phagocytosis and 
degranulation, thereby having a crucial role in clearance of infection. As the 
understanding of the inflammatory response has progressed neutrophils are now also 
regarded for their facilitation in chronic inflammatory conditions and adaptive immune 
responses (Caielli et al., 2012; Soehnlein et al., 2017). 
  
Under physiological conditions the bone marrow, spleen, liver and lungs serve as 
reservoirs of mature neutrophils (Summers et al., 2010). In particular, a large number 
of mature pulmonary neutrophils exist (Sibille and Marchandise, 1993; Kolaczkowska 
and Kubes, 2013), persisting for longer than commonly seen at other sites (Ussov et 
al., 1995). It is generally considered that the concentrated populations in the 
aforementioned organs provide two main functions, both constantly patrolling their 
environment for any disturbances as well as being braced for cues to swiftly migrate 
in response to signals of disruption. 
  
Circulating neutrophils are short lived. Cells maintained in the periphery have a half-
life of only 8 hours (Galli et al., 2011) and although neutrophils that have traversed the 
endothelium in to the tissue are afforded a more extended lifespan, under regulatory 
conditions they will still die after 1-2 days (Blumenreich, 1990). However at sites of 
inflammation the presence of entities that induce pro-survival signalling (including 
certain cytokines  (A. S. Cowburn et al., 2002), bacterial products (Lee et al., 1993) 
31 
 
and a hypoxic environment (Hannah et al., 1995)) extend neutrophil longevity resulting 
in sustained presence of primed neutrophils. In any case, with a continuous demand 
for fresh neutrophils promyelocytic progenitors in the bone marrow are tasked with 
generating approximately 1011 new neutrophils daily (Rosales, 2018). 
 
1.2.1. Neutrophil Trafficking 
  
Neutrophil recruitment from the vasculature to the tissue occurs in several sequential 
steps, commonly recognised to be tethering, rolling, adhesion, crawling and 
transmigration, as summarised in figure 2. Inflammatory mediators initiate changes on 
the surface of the endothelium such that expression of adhesion molecules (P-selectin 
and E-selectin) are increased. Specifically, pre-stored P-selectin is upregulated and 
facilitates the tethering/capturing of free circulating neutrophils, with a partially 
overlapping function, E-selectin is synthesized de novo and later expressed 
(Bevilacqua et al., 1989; Hattori et al., 1989; Geng et al., 1990). Neutrophils continue 
to form ‘catch slip’ bonds with these ligands thus ‘rolling’ along the endothelium (Sundd 
et al., 2011). 
  
Upon activation, the surface of the endothelium becomes adorned with chemokines. 
Upregulation of the ELR-CXC chemokines, which signal via CXCR2, is particularly 
significant for neutrophil adhesion to the endothelium (Girbl et al., 2018). For firm 
adhesion to take place, binding of integrins (transmembrane receptors) to cell 
adhesion molecules (on the endothelial cell surface) is essential. Binding of integrins 
to their respective cell-surface ligands triggers internal neutrophil pathways and as 
such is assigned the term ‘outside-in signalling’ which acts to steady adhesion and 
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start cell motility (Fan and Ley, 2015). At this stage neutrophils are prepared for 
transmigration. 
  
Junctions formed between neighbouring endothelial cells serve as the preferred sites 
for transmigration and neutrophils will actively ‘crawl’ towards these spots (Phillipson 
et al., 2006; Shulman et al., 2009). The elongated endothelial cell architecture that has 
resulted from shear stress, aids this integrin-mediated behaviour whereby neutrophils 
can move with, against or perpendicular to the direction of blood flow as required 
(Sumagin et al., 2010). 
  
The process of transmigration out of the vasculature occurs in two phases, the cell 
must first pass through the endothelium before then crossing the basement 
membrane. In both cases interactions between integrins and members of the Ig 
superfamily of cell adhesion molecules (ICAMs), including ICAM-1 (CD54) and ICAM-
2 (CD102), have a key role. Other essential molecules include vascular cell adhesion 
molecule 1 (VCAM-1/CD106) as well as junctional proteins including; 
platelet/endothelial cell adhesion molecule 1 (PECAM-1/CD31), junctional adhesion 
molecules (JAMs), endothelial cell-selective adhesion molecule (ESAM) and the cell 
surface glycoprotein CD99 (Wegmann et al., 2006; Woodfin et al., 2009; Voisin and 
Nourshargh, 2013; Muller, 2016). 
  
Once in the tissue emigrated neutrophils must continue to navigate towards their 
destination. It is suggested that this occurs due to a hierarchy of chemotactic 
molecules (in infected tissues in comparison to the endothelium) with the ability to 
dethrone previous stimuli. In this manner neutrophils advance from following 
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‘intermediate’ to favouring ‘end-target’ chemoattractants, with the ‘go’ and ‘stop’ 
instructions shown to be signalled via mitogen-activated protein kinase (MAPK) 
pathways, specifically p38 MAPK and extracellular signal regulated kinase (ERK) (Liu 











  Figure 2. Neutrophil trafficking. 
Upon stimulation tissue resident monocytes/macrophages release inflammatory mediators, which signal for 
neutrophil recruitment from the vasculature to the tissue. A sequential process of tethering, rolling, adhesion, crawling 
and finally transmigration facilitate neutrophil trafficking along the endothelium. (1) Inflammatory mediators induce 
rapid expression of adhesion molecules (pre-formed P-selectin and newly synthesised E-selectin) on the surface of 
the endothelium. (2) Selectins form ‘catch slip’ bonds with their glycoprotein ligands on the neutrophil surface 
promoting a ‘rolling’ motion along the endothelium. (3) Chemokines on the endothelium activate integrins on the 
surface of neutrophils, which bind firmly to cell adhesion molecules on the endothelium and neutrophils actively ‘crawl’ 
towards migratory junctions between neighbouring endothelial cells. (4) Interactions between integrins and adhesion 
molecules support neutrophil migration, first through the endothelium and then traversing the basement membrane, 




1.2.2. Neutrophil Functions 
  
Evidence is beginning to emerge that indicates the existence of different neutrophil 
subtypes. Their pleiotropic functions under pathologic conditions, but also at steady 
state, suggests that various neutrophil populations exist. This heterogeneity provides 
for diverse immunologic roles (including phagocytosis, degranulation, respiratory 
burst, NETosis, microparticle release and cytokine production) and selective 
recruitment from the circulation (Christoffersson et al., 2012). Furthermore neutrophil 
production of cytokines and chemokines and membrane expression of Toll-like 
receptors (TLRs) and integrins has been shown to exist in diverse arrangements 
(reviewed in (Rosales, 2018)). As such, these variable characteristics determine 
neutrophil phenotype (pro-inflammatory or anti-inflammatory) and consequently the 
course of the immunological response and induction of macrophage phenotype (M1 
or M2 respectively) (Tsuda et al., 2004; Jaiswal et al., 2009; Pillay et al., 2012; Chen 
et al., 2014).  
 
In general, neutrophil behaviour is a direct response to stimuli, either from the 
surrounding environment or from intrinsic cues. These external and internal factors, 
such as recognition of pathogens or survival signals respectively, will dictate their 
actions. Neutrophils can then directly and/or indirectly shape both the innate and 
adaptive immune responses. The importance of neutrophil anti-inflammatory and/or 
pro-resolving actions has long been established for acute immune responses however 
emerging research suggests the potential of these behaviours for taming chronic 
inflammation (as discussed in (Jones et al., 2016)). Indeed, production of neutrophil 
extracellular-traps (NETs) and microvesicles, have been shown within a variety of 
inflammatory microenvironments to aid in combating inflammation (Schauer et al., 
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2014; Rhys et al., 2018). Exuberant immune cell activation resulting in over production 
of inflammatory mediators can be dampened by neutrophil driven mechanisms with 
some neutrophil phenotypes suggested to contribute to the resolution of inflammation 
through their release of anti-inflammatory mediators (Cuartero et al., 2013). 
Furthermore, neutrophils are the major phagocyte of innate immunity and their ability 
to rapidly clear invading entities is an essential role in host defence (van Kesse et al., 
2014). 
 
Degranulation is the main mechanism utilised by neutrophils for the release of their 
mediators contained in granules. The act of degranulation may occur in one of two 
distinct ways. For smaller granules, that are more easily stimulated and mobilised, 
internal vesicles fuse with the plasma membrane and their content spills out of the cell. 
Alternatively, a phagolysosome is formed by internal vesicles binding with phagocytic 
vacuoles and delivering antibacterial proteins and enzymes (Nauseef and Borregaard, 
2014; Cowland and Borregaard, 2016). In any case the substrates found contained in 
granules are potentially toxic meaning that it is critical that they are well contained and 
tightly regulated in order to avoid damage both intrinsically (neutrophil auto 
destruction) and extrinsically (inflammation and host tissue damage). It is universally 
accepted that excessive neutrophil degranulation is a common feature of many 
inflammatory disorders (Lacy, 2006).  
  
The respiratory burst, or oxidative burst, is the rapid release of reactive oxygen species 
(ROS). The toxic metabolites including nitric oxide (NO), superoxide (O2-) and 
hydrogen peroxide (H2O2) as well as cytochrome b558 (the central component of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase), are generated as 
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additional contents within neutrophil granules (Nguyen et al., 2017). Respiratory burst 
plays a particularly valuable role in the immune system, with NADPH oxidase crucial 
in the degradation mechanisms following phagocytosis. The production of oxidants is 
commonly considered to be the most powerful defence mechanism utilised by the 
neutrophil. However, under certain circumstances such as during RA, neutrophils can 
be triggered to release ROS and proteases extracellularly causing damage to host 
tissues, worsening disease (Glennon-Alty et al., 2018).  
  
Neutrophils have also been shown to have a role in the production of pro-inflammatory 
mediators, with potent examples including arachidonic acid (AA) metabolites and 
certain cytokines. Particularly during acute inflammation neutrophils enzymatically 
biosynthesise leukotrienes and prostaglandins from AA. Leukotrienes are synthesised 
by inflammatory cells via the 5-lipoxygenase (5-LO) pathway, with neutrophils 
specifically producing leukotriene B4 (LTB4). LTB4 is a particularly potent mediator of 
chemoattraction and can induce cell adhesion and activation (Samuelsson et al., 
1987). Presence of the enzymes cyclooxygenase (COX) and terminal prostaglandin E 
synthases (PGES) results in AA being transformed into prostaglandin E2 (PGE2) (Park 
et al., 2006), an inflammatory mediator possessing potent effects. 
  
Numerous cytokines/chemokines are produced by neutrophils (e.g. IL-8, IL-12, TGF-
β and MCP-1, to name a few). Although the amount of cytokine produced is relatively 
small in comparison to other leukocytes the number of neutrophils present at 
inflammatory sites is much larger, thus neutrophil cytokine production has the potential 




A number of neutrophil derived anti-inflammatory and pro-resolving products also 
exist, including Annexin A1 (AnxA1) and lipid mediators (e.g. resolvins and lipoxins). 
Neutrophils contain AnxA1 within their tertiary (gelatinase) granules and cytosol 
(Perretti and Flower, 2004). In response to high intracellular Ca2+ AnxA1 will localise 
to the plasma membrane to bind phosphatidylserine. Furthermore, direct neutrophil 
and AnxA1 interaction functions to inhibit recruitment to sites of inflammation as well 
as to induce neutrophil apoptosis, thus promoting efferocytosis by macrophages. 
Mechanistically the latter occurs as a consequence of AnxA1 attracting recruitment of 
monocytes and macrophages following its secretion from neutrophils as they undergo 
apoptosis (Jones et al., 2016). Promotion of neutrophil apoptosis and clearance in this 
manner is essential to the resolution of both acute and chronic inflammation. 
 
Lipoxins and resolvins can also promote neutrophil apoptosis. The uptake of apoptotic 
neutrophils by resident macrophages promotes lipoxin A4 production, resulting in lipid 
class switching from the 5-LO pathway (leukotriene and prostaglandin synthesis) to 
the 15-LO pathway (Freire-de-Lima et al., 2006). Resolvins act to reduce vascular 
permeability (consequently reducing neutrophil recruitment) and induce neutrophil 
apoptosis (subsequently increasing monocyte/macrophage recruitment and 
efferocytosis). Specifically, D-series and E-series resolvins mediate increased 
chemokine receptor five (CCR5) expression on apoptotic neutrophils thus providing 
them with the ability to ‘scavenge’ (gather and reduce) chemokines (e.g CCL3 and 
CCL5) (Ariel et al., 2006). A decrease in further cell recruitment and activation occurs 




Identification of neutrophils extracellular traps (NETs) is a comparatively recent finding 
within neutrophil biology, nonetheless rapid advances have been made in many areas 
of their study including structure/composition, anti-microbial activity and regulation of 
NETosis. Alongside phagocytosis and secretion of mediators, NETs are principally 
considered a novel third mechanism for killing invading pathogens, with their release 
providing neutrophils a final act of killing at the end of their lifespan (Fuchs et al., 2007). 
NETs are networks of extracellular meshes composed mainly of chromatin with 
neutrophil granular proteins attached (Brinkmann et al., 2004). Upon cellular activation 
NETs are released outside the cell to be formed in tissues and within blood vessels as 
a form of innate response. These extracellular fibres bind microorganisms, preventing 
their spreading. Aggregation of the fibres forms larger threads, generally around 50nm 
in diameter (Brinkmann et al., 2004) however larger structures have been detected 
under flow conditions (Clark et al., 2007). Their scaffold-like structure simultaneously 
provides a physical barrier and facilitates trapping of bacteria whilst also locally 
concentrating anti-microbial components. These high localised concentrations 
consequently bind, disarm and kill microbes thus providing an extracellular mechanism 
of killing independent of phagocytic uptake. 
 
One major caveat to the process of NETosis is that more often than not it will result in 
the death of the neutrophil. Therefore, it is commonly referred to as ‘suicidal NETosis’ 
as a result of the processes of chromatin decondensation, nuclear swelling and 
membrane perforation that occur. However, it is worth noting that NETosis does not 
universally result in destruction of the neutrophil. Although occurrence is less common 
‘vital NETosis’ also takes place, in this case nuclear material is still lost but instead of 
rapid formation and release blebbing of the nucleus occurs. As a consequence of the 
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mechanistic differences the neutrophil maintains its ability to chemotax and 
phagocytose (Yipp and Kubes, 2013). Following neutrophil activation the regulation of 
NET formation is primarily controlled by the lipoxygenase pathway (Clark et al., 2011). 
Afterwards clearance of the released content is facilitated by macrophages in a 
manner similar to the clear up of apoptotic neutrophils (Farrera and Fadeel, 2013) . 
 
Phagocytosis is utilised by the immune system for the removal of foreign entities, the 
process involves engulfment, digestion and expulsion of the waste products. Although 
one of the main functions of neutrophils, it is not unique to this cell type and several 
other types of white blood cells including monocytes (Dale et al., 2008), macrophages 
(Silva and Correia-Neves, 2012) and dendritic cells also function as phagocytes 
(Savina and Amigorena, 2007). The difference in small molecule motifs on the surface 
of harmful particles, such as bacteria and viruses, from those on indigenous cells, 
enables detection of an infectious agent and alerts the immune response. Human 
neutrophils express Toll-like receptors (TLRs), which recognize the structurally 
conserved molecules, specifically known as pathogen-associated molecular patterns 
(PAMPs), as unusual. This antigen recognition step is aided by the process of 
opsonization, whereby the attachment of opsonins is especially important for 
engulfment by neutrophils, which are generally poor at phagocytosing unmodified 
targets (Shah et al., 2017). 
  
The efficiency of neutrophil phagocytosis has important implications in inflammation 
due to the ability of these cells to express varying Fc receptors (FcR). Under steady 
state neutrophil surface receptors detect and interact with the Fc portion of complexed 
or aggregated IgG, however upon stimulation (e.g. by infectious agents, interferon or 
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G-CSF) neutrophils will express receptors that recognise monomeric IgG. In addition 
to receptor switching, polymorphisms in the amino acids coding these receptors can 
also reduce phagocytic efficiency (Shah et al., 2017). Ineffective FcR recognition of 
complexed IgG has significant impact in inflammatory diseases, such as Rheumatoid 
Arthritis, in which immune complexes (ICs) have a facilitating role. Furthermore, recent 
studies have shown that neutrophils engaged in FcγR‐dependent IC phagocytosis 
undergo accelerated apoptosis (Gamberale et al., 1998).  
 
A very specific form of phagocytosis is efferocytosis, where phagocytes clear dead 
cells that have undergone apoptosis. Clearance of apoptotic neutrophils by 
macrophages in this manner has a particularly important role in inflammation (as 
described in section 1.2.4). 
 
1.2.3. Neutrophil Apoptosis 
  
Although a choreographed response, the increased neutrophil number and activity at 
sites of inflammation has the capacity to have adverse effects if the cell population 
prevails. Fortunately, following their activity, neutrophils are inherently programmed to 
undergo cell death via apoptosis. This initiation of self-destruction is both normal and 
controlled. Apoptosis is crucial for the maintenance of tissue homeostasis in both the 
short and long term. Not only does it prevent the extracellular release of the 
neutrophil’s cytotoxic contents, conferring short-term protection, it also facilitates their 
removal from the site, offering long term conservation. Constitutive apoptosis of 
circulating neutrophils is also paramount, serving a critical role for the balancing of 




The main characteristics of neutrophil apoptosis are externalisation of 
phosphatidylserine (PS), DNA fragmentation, a loss of mitochondrial membrane 
potential and membrane blebbing (Denecker et al., 2000), the former being particularly 
key for efferocytosis to follow. Initiation of neutrophil apoptosis occurs in one of two 
ways, either via the intrinsic or extrinsic signalling pathways as outlined below and 
summarised in figure 3.  
 
For the intrinsic pathway to be activated an imbalance between intracellular apoptotic 
factors must occur, specifically a shift from anti-apoptotic to pro-apoptotic. Indeed, 
whether the cell will survive or undergo apoptosis in response to internal stimuli, such 
as a lack of growth factors, DNA damage or biochemical stress, is a balance between 
groups of molecules within the Bcl-2 family. Bcl-2 family members reported to be 
present in human neutrophils include the apoptosis suppressing proteins Mcl-1 and 
A1/Bfl-1 as well as apoptosis potentiating proteins Bax, Bad and Bak (Moulding et al., 
2001). The function of these proteins is controlled by their localization, conformation, 
and phosphorylation state. The activation of Bax and Bak are critical in apoptosis 
regulation through the intrinsic mitochondrial pathway, however the presence of Mcl-
1 and A1 respectively protects against Bax and Bak mediated cell death (McCracken 
and Allen, 2014). Loss of Mcl-1 or A1 allows Bax and Bak to oligomerize and form 
pores in the outer mitochondrial membrane, resulting in the release of cytochrome C 
from mitochondria into the cytosol, followed by the actions of caspase 9 and 3 
(McCracken and Allen, 2014).  For the extrinsic pathway, caspase 8 activates caspase 
3 via receptors expressed on the surface of neutrophils. These ‘death’ receptors 
respond to soluble proteins, specifically those related or belonging to the tumour 
necrosis factor (TNF) family, such as Fas ligand (Fas-L), TNF-related apoptosis-
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inducing ligand (TRAIL) and TNF-α itself (Kumar et al., 2005). Regardless of the 
chosen pathway caspases (cysteine-aspartic proteases) play an essential role in all 
forms of cell death and inflammation, with caspase activation ensuring that cellular 
components are degraded in a controlled manner.  
  
Despite being a tightly regulated process neutrophil apoptosis can be modulated by a 
number of factors resulting in its acceleration, deceleration or at times complete 
derailment. The inflammatory microenvironment can provide neutrophils with both 
survival and pro-apoptotic signals. For example neutrophil lifespan can be extended 
and/or apoptosis suppressed in response to granulocyte colony-stimulating factor (G-
CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin-8 (IL-
8), bacterial components (e.g. LPS) and other pro-inflammatory mediators (Klein et 
al., 2000, 2001; Andrew S Cowburn et al., 2002; Glynn et al., 2002; Martins et al., 
2010). In addition, in vitro studies have shown that treatment with glucocorticoids 
delays neutrophil apoptosis (Cox, 1995) as do certain environmental conditions, such 
as hypoxia (Hannah et al., 1995; Murray et al., 2003). Interestingly, in a severely 
hypoxic environment (~1% O2) the ability of glucocorticoids to delay neutrophil 
apoptosis is lost, furthermore the treatment of neutrophils with glucocorticoids in 
severely hypoxic conditions was able to override the pro-survival effect of GM-CSF, 
resulting in increased apoptosis (Marwick et al., 2013). Importantly, this suggests a 
potential therapeutic mechanism to augment the hypoxia-mediated delay in apoptosis 
at an inflamed site (Marwick et al., 2013). 
 
Accelerated activation of apoptosis may occur following neutrophil exposure to viral 
and bacterial pathogens, as well as in response to their phagocytosis. Indeed, both 
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fragment crystallisable region receptor (FcR) and complement receptor (CR) mediated 
phagocytosis has been demonstrated to promote programmed cell death, with 
apoptosis induced earlier following the engagement of both FcRs and CRs as opposed 
to either receptor alone (Kobayashi et al., 2002). Neutrophil apoptosis has also been 
shown to be regulated via the β2 integrin Macrophage-1 antigen (Mac-1), in contrast 
to the suppression of apoptosis following engagement of ICAM-1, fibrinogen and 
myeloperoxidase, Mac-1 mediated bacterial phagocytosis increases neutrophil 
apoptosis (El Kebir and Filep, 2013). Additionally, and perhaps more obviously, 
reactive oxygen species, cellular survival/death signalling pathways and mitochondria 
have also all been implicated to have a role in influencing apoptosis. 
 
As a consequence of neutrophil apoptosis changes in cell morphology arise, 
specifically the cell shrinks, chromatin compacts and the characteristic multilobular 
nucleus is lost. Additionally, functional properties are altered, whereby apoptosis of 
neutrophils disables their activation pathways and consequently results in the loss of 
their ability to operate as usual, particularly regarding chemotaxis, degranulation and 
respiratory burst. Furthermore, a decrease in the epitopes for immunoglobulins and 
surface receptor expression occurs and consequently competency in binding ligands 
is compromised (Dransfield et al., 1994, 1995; Hart et al., 2000).  
  
During apoptosis, the typical symmetry of the plasma membrane phospholipids is lost, 
and PS exposure occurs as a result of its translocation from the inner to the outer 
membrane. Usually in a healthy cell, phospholipids are arranged asymmetrically in the 
plasma membrane. The negatively charged phospholipids, PS, along with 
phosphatidylethanolamine (PE), face the inner cytosolic side of the cell. These two 
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amine-containing phospholipids are positioned and maintained by ATP-dependent 
aminophospholipid translocases, called flippases, which move lipids from the 
exoplasmic to the cytosolic face. Whereas the outer exoplasmic membrane is rich in 
the positively charged phospholipids, phosphatidylcholine (PC) and sphingomyelin, 
which are moved in the reverse direction (cytosolic to exoplasmic) by floppases which 
are another type of ATP-dependent aminophospholipid translocase (Hankins et al., 
2015). In addition, ATP-independent enzymes, known as phospholipid scramblases, 
non-specifically and bidirectionally translocate phospholipids between the inner and 
outer membrane leaflets, randomising lipid distribution (Sahu et al., 2007). When 
apoptosis is underway activated caspases cleave flippases and simultaneously 
activate scramblases. The capacity of scramblases to translocate PS rapidly and the 





Figure 3. Overview of neutrophil apoptosis pathways. 
Initiation of neutrophil apoptosis occurs either via the intrinsic or extrinsic signalling pathways. For the intrinsic 
pathway to be activated an imbalance between intracellular apoptotic factors must occur. The proapoptotic Bcl-2 
family members Bax and Bak become more abundant than their anti-apoptotic counterparts Mcl-1 and A1, and their 
oligomerisation is no longer blocked. The joining of Bax and Bak at the mitochondrial membrane results in pore 
formation and a decrease in mitochondrial membrane potential (ΔΨm) allowing the release of cytochrome C and 
calcium ions into the cytosol. Cytochrome C activates caspase-9 which signals downstream to caspase-3. Following 
particle uptake, the formation of the phagosome results in NADPH oxidase derived ROS release, which acts on 
cytochrome C and initiates the intrinsic apoptosis pathway. The extrinsic pathway is initiated by ‘death’ receptors 
responding to soluble proteins (Fas-L, TRAIL and TNF-α). Ligand receptor binding signals activation of caspase-8, 
which signals to caspase-3. In all cases the activation of casapase-3 results in its cleavage and marks the final 




1.2.4. Neutrophil Clearance 
 
Both professional and non-professional phagocytes recognise PS on apoptotic cells 
as an ‘eat me’ signal. Furthermore, some professional phagocytes have the ability to 
bind PS either directly via a cell surface receptor or indirectly through a secreted 
protein able to bind PS as well as their own membrane protein (as discussed in 
(Segawa and Nagata, 2015)). These different cell surface and soluble ligands are 
discussed in more detail later, importantly for the successful resolution of inflammation 
these various recognition ligands, bridge molecules and receptors play a key role in 
determining inflammatory response and mediator production. In any case, the 
exposure of PS is key for the recognition of a dead cell by a phagocyte and serves as 
a fundamental ‘eat me’ signal. The engulfment of apoptotic cells follows, an action 
performed primarily by macrophages but also to a lesser extent by dendritic cells 
epithelial cells and mesenchymal cells. Of the aforementioned cells, macrophages, 
which are present throughout (almost all) animal tissues, are broadly regarded as the 
most competent phagocyte. Thus, the focus for the remaining text will be on 
macrophage phagocytosis of apoptotic neutrophils termed efferocytosis. 
 
Macrophage ingestion of damaged host cells was first observed by Elie Metchnikoff in 
the late nineteenth century, however, this behaviour was for many years referred to 
simply as ‘physiologic inflammation’ and it wasn’t until the twenty-first century that the 
term ‘efferocytosis’, latin for ‘to carry to the grave’ was used for this action 
(deCathelineau and Henson, 2003). 
 
Efferocytosis serves as the penultimate step in cell clearance (a process completed 
when the phagocyte transports the ingested cellular material away from the site). 
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Clearance of apoptotic cells in this manner is a necessity for the resolution of 
inflammation and is a behaviour that confers tissue protection by preventing the over 
activation of the innate immune response and consequent development of chronic 
inflammatory diseases, such as arthritis (as discussed in (Nagata et al., 2010)). At the 
site of inflammation phagocytic removal of dead/dying neutrophils by macrophages 
prevents exposure to their toxic contents. However, when there is an overwhelming 
level of apoptosis greater than macrophage capacity or a direct impairment to the 
efferocytosis mechanism, macrophages may fail to intervene and clear the apoptotic 
cells (Silva et al., 2008). In this way apoptotic neutrophils that fail to be cleared are 
suggested to undergo a process of autolytic disintegration, termed as secondary 
necrosis, involving activation of self-hydrolytic enzymes, cell swelling and irreversible 
damage to the cytoplasmic membrane (Silva et al., 2008). During this process specific 
autoantigens undergo additional proteolytic degradation and the subsequent rupture 
of the neutrophil plasma membrane facilitates the release of these intracellular 
damage associated molecular patterns (DAMPs) (Wu et al., 2001; Sachet et al., 2017). 
These post apoptotic remnants and fragments may in turn stimulate autoantibody 
responses under proinflammatory conditions, thus perpetuating the inflammatory 
response (Mũnoz et al., 2010) (and reviewed in (Rovere et al., 2000)).  
 
In many contexts the safe removal of apoptotic cells by macrophages is critical for the 
regulation of immune responses. In addition to the advantage of eliminating apoptotic 
cells from the local environment efferocytosis by macrophages modulates their 
mediator release and cell killing, restores tissue homeostasis and further co-ordinates 
adaptive immune responses. As such, inflammation is suppressed by increased 
release of anti-inflammatory mediators such as IL-10, TGF-β and PGE2 and decreased 
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TNF-α. Tissue remodelling is controlled by phagocyte directed cell killing via 
modulated release of nitric oxide (NO) and death-inducing cytokine CD95 (Apo-1/Fas) 
ligand and regulated presentation of peptides by major histocompatibility complex 
class I (MHC-I) and class II (MHC-II) (as reviewed in (Savill and Fadok, 2000)). 
 
Macrophages utilise cell surface receptors and/or secreted proteins to detect both the 
‘find me’ signals that first evoke them as well as the ‘eat me’ signals displayed on 
apoptotic cells. PS is broadly considered the most prominent ‘eat me’ signal on 
apoptotic cells, however other less conspicuous signals exist (e.g. calreticulin). PS is 
recognised by many different cell surface receptors, direct receptors include 
phosphatidylserine receptor (PSR) (Li et al., 2003), T cell immunoglobulin and mucin 
domain-containing molecule (Tim) -1, -3, -4  (Miyanishi et al., 2007; Ichimura et al., 
2008; Nakayama et al., 2009), CD300 (members a, b & f) (Choi et al., 2011; Simhadri 
et al., 2012; Murakami et al., 2014), brain-specific angiogenesis inhibitor 1 (BAI1) 
(Park et al., 2007), stabilin 1 and 2 (Park et al., 2008, 2009), receptor for advanced 
glycosylation end products (RAGE) (Friggeri et al., 2011) and lectin-like oxidized low-
density lipoprotein receptor (LOX-1) (Murphy et al., 2006). Whereas Tyro3, Axl, and 
MerTK (TAM) tyrosine kinase receptors (Seitz et al., 2007), integrin-αvβ3 (Hanayama 
et al., 2002), CD36 (Tait and Smith, 1999),  calreticulin and LRP1 (CD91) (Gardai et 
al., 2005) are supported by  bridging  molecules.  
 
Bridging molecules are proteins secreted from macrophages to bind PS and aid in 
apoptotic cell engulfment, the use of these different sets of molecules is governed by 
tissue specific conditions (Okabe and Medzhitov, 2014). Macrophage secreted 
proteins include growth arrest-specific 6 (Gas6) and protein S (ProS1), both of which 
49 
 
form bridges via the TAM (Tyro3, Axl, and MerTK) tyrosine kinase receptors (Nakano 
et al., 1997; Rothlin et al., 2015), thrombospondin which acts as a bridging ligand for 
CD36 (Savill et al., 1992), complement component 1q (C1q) and mannose binding 
lectin (MBL) which bridge to calreticulin and LRP1 (CD91) (Ogden et al., 2001) and 
milk fat globule EGF factor 8 (MFG-E8) which binds integrin-αvβ3 on phagocytes 
(Hanayama et al., 2002). Indeed, in the absence of MFG-E8 thioglycolate-elicited 
peritoneal macrophages exhibited impaired uptake of apoptotic cells (Hanayama et 
al., 2004), therefore indicating that these bridging molecules are both context specific 
and essential for facilitating efferocytosis. Importantly, oxidation of the phospholipids 
exposed on the apoptotic cell, resulting in oxidised PS (oxPS), has been suggested to 
enhance the binding of some of these receptors (as reviewed by (Matsura, 2014)). 
 
In addition to ligand receptor binding interactions efferocytosis is influenced by both 
the local microenvironment and macrophage programming. Regarding the former 
factors in the cellular milieu readily impact on the readiness of efferocytosis, for 
example the availability of the required appropriate bridging molecules is of significant 
consequence. Additionally a number of different lipid mediators and proteins (or their 
derived peptides) have been recognised for their ability to enhance efferocytosis 
including Annexin 1 (Scannell et al., 2007), lipoxins, protectins, resolvins and maresins 
(Serhan et al., 2011). In contrast there are also proteins, such as TNF-α, that when 
present within the inflammatory microenvironment can inhibit apoptosis and 
consequently clearance (Michlewska et al., 2009), similarly presence of oxidants has 




Macrophages conditioned by alternative activation towards an anti-inflammatory (M2) 
phenotype are more adept at engulfing apoptotic cells in comparison to their classically 
activated (M1 phenotype) counterparts. In this case efferocytic receptors and bridge 
molecules are upregulated in response to the activation of nuclear receptors 
(peroxisome proliferator-activated receptors (PPARs) (Majai et al., 2007; Mukundan 
et al., 2009) and liver x receptors (LXRs) (A-Gonzalez et al., 2009)) by macrophages. 
It has also been shown that PS on the surface of apoptotic neutrophils has the capacity 
to drive macrophage expression of these nuclear receptors (Fernandez-Boyanapalli 
et al., 2009) thus further supporting their role in efferocytosis. 
  
Usual practice following recognition of apoptotic cells is their removal, whereby 
neutrophils and their debris are digested within the macrophage phagolysosome. The 
apoptotic cell engulfment process is proposed to take place in two separate PS 
dependent steps (Hoffmann et al., 2001). First the ‘tethering’ step, where PS binding 
its receptors on the surface of the macrophage results in the apoptotic cell becoming 
tethered to the macrophage surface. Followed by the tickling/uptake step, where 
soluble proteins from the macrophage bind PS on the apoptotic cell, thus ‘tickling’ and 
activating the receptors on the phagocyte, subsequent downstream signalling results 
in the polymerisation of actin (via signalling through the GTPase Rac1) and the uptake 
of the apoptotic cell (Nakaya et al., 2008; Schlam et al., 2015). 
  
From what is known about the process of efferocytosis and the mechanisms that 
facilitate it, it is apparent that apoptotic cells and phagocytes can collaborate to 
carefully orchestrate the ingestion of the former by the latter. However, there are many 
aspects of the process that remain elusive and although many molecules have been 
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proposed to play a role, many of those that have been identified are yet to be 
comprehensively confirmed.  
  
Macrophages change phenotype following efferocytosis. Whether apoptotic 
neutrophils act as an M2 differential signal and if the macrophage that comes in to 
contact with them adopts a ‘true’ M2 phenotype is yet to be ascertained. One proposed 
theory is that ‘M2-like’ macrophages undergo a sort of metamorphosis, altering their 
surface molecule expression to specifically become CD11b low upon interaction with 
apoptotic cells (Ariel and Serhan, 2012). The protein profile becoming increasingly 
pro-resolving in preparation for ingestion of apoptotic cells provides the rationale 
behind this modulation. Furthermore, macrophage treatment with resolvins and 
glucocorticoids was shown to reduce the apoptotic leukocyte ingestion required for 
CD11b low macrophage generation, indicating that macrophages may develop a 
‘satiated’ phenotype (Schif-Zuck et al., 2011). 
  
Efferocytosis is generally considered to promote macrophage resolution programmes. 
One study that investigated directed migration in resolving macrophages showed that 
efferocytosis induces different chemokine receptors on macrophages (specifically 
upregulating CXCR4) (Angsana et al., 2016) thus directly influencing cell trafficking. 
In any case efferocytosis has many immunomodulatory properties that further 
emphasize the significance of this process in inflammation related diseases. However, 
there is a need to better understand the pathways that regulate and enhance 




1.3. Rheumatoid Arthritis 
  
Inflammatory arthritis (IA) covers a range of severe pathological medical conditions, 
which primarily affect the body’s immune system, included within these is Rheumatoid 
Arthritis (RA), ankylosing spondylitis and psoriatic arthritis. The inflammation of the 
joints (and other tissues) that is characteristic of these conditions results from the long-
term persistence of an abnormal immune response and consequently classifies them 
as Chronic Inflammatory diseases (CID) (Dorland, 1980). The globally high prevalence 
of CIDs (Cicchitti et al., 2015) and the debilitating nature of the conditions stresses the 
importance of elucidating the fine details of the immunological pathways that result in 
RA developing and its mechanisms of maintenance. Identifying such details is 
paramount to the discovery of how to manage RA and develop suitable therapies. 
  
RA is the most common inflammatory joint disorder in the UK, with upwards of 400,000 
sufferers within the UK population (Arthritis Research UK, 2018). Around three 
quarters of diagnoses are made in female patients and onset, regardless of gender, is 
typically between 40 and 50 years of age (Symmons et al., 2002). However, RA affects 
all ages and overall, there is a growing number of patients with a condition that 




The characteristic symptoms of RA are a result of an ongoing inflammatory response 
being led by abnormal feedback from the immune system. Principally this affects the 
joints yet the chronic and systemic nature of the disorder is reflected throughout the 
body and symptoms of the disease can occur in a number of tissues and organs (skin, 
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blood vessels, heart, lung and muscles) (Prete et al., 2011). The severe effect on the 
joints is primarily the result of proliferative inflammation of the synovium commonly 
causing pain, swelling, oedema, erythema and stiffness. Long term affliction can result 
in a loss of bone density and architecture resulting in joint destruction (Nandakumar 
and Holmdahl, 2006). Although RA can cause problems in any joint anatomically, the 
small diarthrodial joints of the hands, feet, wrists and ankles are most affected, often 
in a symmetrical manner. As the disease becomes more active and severity increases 
additional intra-articular damage often manifests. Likewise, extra-articular problems 
with other tissues and organs within the body are more frequently observed (Cojocaru 
et al., 2010), as well as fatigue, weight loss and formation of firm local tissue swellings, 
known as rheumatoid nodules, that occur close to the inflamed joint. 
  
The most severe morphologic alterations that result from RA manifest in the joints. 
The primitive phase of this damage is characterised by oedema in the synovium, 
meaning an abnormal accumulation of tissue fluid occurs in the interstitial spaces of 
the connective tissue that lines the inner surface of the synovial joints. Consequently 
hyperplasia, enlargement caused by an increase in cell proliferation and thus amount 
of tissue, occurs and the synovium becomes thicker often losing its previously smooth 
contour (Rooney et al., 1988). One of the key affirmations of RA is growth of an 
abnormal layer of fibrovascular/granulation tissue known as pannus, which forms over 
the surface of the joint. Pannus formation is the result of inflammation and exuberant 
proliferation of the synovium resulting in a proliferative mass of thickened synovial 
tissue, composed primarily of inflammatory cells and synovial fibroblasts. Specifically, 
pannus growth occurs over the articular cartilage and with progression will go on to 
invade and destroy cartilage and consequently erode bone (Yin et al., 2002). As 
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disease progresses pannus formation may develop into ankylosis, initially of the 
fibrous form this can ossify and result in bony ankylosis. 
 
Additionally, the inflammatory infiltrate invades the spaces surrounding the blood 
vessels within the synovial stroma, and increased vascularity results from the 
occurrence of angiogenesis (Elshabrawy et al., 2015). Localised death occurs within 
regions of synovial tissue which for this reason is then shed into the joint to later be 
encased by fibronectin to form ‘rice bodies’ with a cartilage-like appearance 
(Jeevannavar and Baindoor, 2014). These free corpuscles float within the intra-
articular space and may reach hundreds in number. In addition, neutrophils can 
accumulate in the synovium as well as within the synovial fluid (Mohr et al., 1981). 
  
Overall, this results in amplification of the disease process by gradually destroying 
collagen, decreasing joint space and causing damage to the bones of the joint. Bone 
erosion (via the actions of osteoclasts), thinning cartilage, stretched ligaments and 
tendons, and an inflamed synovium cumulate resulting in penetration of the synovium 
into the bone, decreased synovial fluid and swelling of the affected area. Furthermore, 
this deterioration of the joint structure is typically accompanied by inflammation, 
stiffness and pain (as discussed in (Guo et al., 2018)).   
  
A number of complications or comorbidities can occur as a result of having RA. 
Medical conditions regularly attributed with the illness include lung disease, 
cardiovascular (CV) disease and osteoporosis. Interstitial lung disease is reported in 
10% of RA patients, (Bongartz et al., 2010) and pulmonary problems result in 29% of 
early death in RA (Young et al., 2006). However, the main cause of premature death 
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is CV disease which occurs in around 1 in 20 RA patients (Norton et al., 2013; 
Dougados et al., 2014). RA doubles the risk of heart attack (Solomon et al., 2006) and 
increases the risk of stroke by 30% (Lindhardsen et al., 2012) compared to the general 
population. Osteoporosis and therefore fragility fractures are also common amongst 
RA patients, with a reported 2-fold increase in the likelihood of the former (Michaud 
and Wolfe, 2007). 
  
Both quality of life and working capacity are impacted for many, with 68% of individuals 
with RA being physically inactive (Platonova et al., 1979). Frequently a vicious cycle 
commences whereby disease progression, increased pain and both physical and 
mental health influence one another. Increased levels of pain and functional disability 
in turn influences mentality in many cases, with major depression being reported to 
affect one in six (Matcham et al., 2013). Despite the best research efforts being made 
to try to understand the disease the specific causes of RA currently remain 
unidentified. However, some factors including genetics, gender, age, weight and 
smoking have been acknowledged for influencing the risk of developing disease 
(Alamanos and Drosos, 2005). 
 
The gene encoding the major MHC- II, DR beta 1 (HLA-DRB1) protein, which plays a 
central role in the immune system by presenting peptides derived from extracellular 
proteins, is the main genetic risk factor linked with RA (Kerlan-Candon et al., 2001). It 
is presumed that the antigens capable of causing or accelerating joint disease 
(arthritogens) can bind to this shared epitope and initiate inflammatory synovitis. The 
gene encoding protein tyrosine phosphatase, non-receptor type 22 (PTPN22) protein, 
a lymphoid-specific intracellular phosphatase functioning in the T-cell receptor 
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signalling pathway, has also been proposed to be linked with RA. In this case specific 
polymorphisms of this gene are suggested to have a protective effect, reducing the 
risk of RA (Muñoz-Valle et al., 2017). Opposingly, carriers of the major risk allele of 
PTPN22 have altered B cell receptor signalling resulting in increased self-reactive B 
cells causing breakdown of immune tolerance and autoimmune disease checkpoints 
(Menard et al., 2011). Peptidyl arginine deiminase-4 (PAD-4), leading to increased 
citrullination of chemokines, as well as signal transducer and activator of transcription 
4 (STAT4) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), both involved in 
T cell activation, have also been proposed for genetic susceptibility to RA, however 
links are yet to be well defined (Verma and Sobha, 2015). 
 
The process of disease initiation remains uncertain, however environmental factors 
have been implicated for their potential facilitation. The main environmental risk factor 
for anti-citrullinated protein antibody (ACPA)-positive RA patients is smoking (Perry et 
al., 2014) due to increased citrullination in lung tissue, however being overweight also 
significantly increases the risk of disease. Risk increases by 15% from being 
overweight (body mass index (BMI) ≥ 25) and over 20% by being obese (BMI ≥ 30) 
(Yin et al., 2002; Feng et al., 2016). Gender and age also influence the likelihood of 
RA development, with the disease approximately three times more common in women 
than it is in men (Gabriel et al., 1999; Riise et al., 2000) and prevalence increases with 
age. Proposed microbial agents include Epstein-Barr virus (Trier et al., 2018),  
Retrovirus (Tugnet et al., 2013), mycobacteria (Winthrop and Iseman, 2013) and 
mycoplasma (Ataee et al., 2015). These agents all share the ability to induce a loss of 







RA is classified as an autoimmune disease, whereby aberrant behaviour of the body's 
own immune system results in healthy tissue being destroyed. The immune system 
normally maintains the tight regulation of the inflammatory response and a controlled 
defence system, however in the case of RA an erroneous response targets self-
antigen instead of foreign. When this behaviour is sustained chronic inflammation 
ensues as an imbalance between pro-inflammatory and anti-inflammatory mediators 
manifests. In brief, a breakdown of immunological self-tolerance, induction of 
autoimmunity, chronic inflammation and consequently joint damage are favoured at 
the targeted sites (McInnes and Schett, 2007). 
 
Numerous inflammatory cells and mediators are responsible for arthritis in the joint. It 
is a multistep, multicellular process that includes infiltration of lymphocytes and 
granulocytes into the articular cartilage as well as proliferation of synovial fibroblasts 
and macrophages resulting in an abundance of chemokines and proinflammatory 
cytokines (Mellado et al., 2015). In addition to these cellular components 
(macrophages, dendritic cells, fibroblast-like synoviocytes, mast cells, eosinophils, 
neutrophils, T cells and B cells), cell surface molecules (adhesion molecules e.g. 
integrins), signalling components (ZAP70, PTPN22, JAK, mitogen activated protein 
kinase and Stat1) and humoral mediators (antibodies, cytokines, chemokines, 
metalloproteinases, serine proteases and aggrecanases) interact to drive the 
inflammatory response and therefore disease progression (Nandakumar and 
Holmdahl, 2006). Certainly, in RA the presence of autoantibodies such as rheumatoid 
factor (RF) and ACPA are highly associated with disease activity and progression (De 
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Rycke et al., 2004). Likewise, it is the persistent participation of all these molecules, 
particularly increased expression of adhesion molecules and chemokines in the 
endothelium, which facilitates leukocyte infiltration to the site of inflammation. In the 
case of RA, continuous inflammation is targeted mainly to the synovium, providing the 
location where many cell types are activated and transformed (Harris, 1986). 
  
Activated neutrophils are found in large numbers within both RA synovial fluid and 
pannus (as discussed in (Wright et al., 2014)). Their release of cytotoxic products has 
long been thought of as their key contribution to disease, however it is now recognised 
that they have a more active role in regulating the functions of other immune cells 
(Mantovani et al., 2011). The manner in which they do this has been categorised into 
four main ways: secretion of cytokines and chemokines, upregulation of plasma 
membrane receptors, direct cell-cell interaction and release of proteases (Wright et 
al., 2014). Many differences in neutrophil phenotype can be detected in RA compared 
to healthy individuals, mainly that they are already primed for ROS production, have 
increased cytokine and chemokine secretion, and an extended lifespan (Raza et al., 
2006) courtesy of a hypoxic environment and presence of anti-apoptotic cytokines 
(GM-CSF and TNF-α).  
 
A considerable contribution towards RA pathogenesis is also provided by an 
autoimmune reaction in which T cells play a pivotal role. High levels of activated CD4+ 
T cells will appear within affected joints very early in disease and are necessary for 
disease initiation (Wong et al., 2006). The additional presence of Th17 cells, which 
induce the migration and activation of neutrophils and monocytes, and interferon-γ 
producing Th1 cells follows (Mellado et al., 2015). Furthermore, the secretion of 
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cytokines by T cells is paramount for development of disease by stimulating 
synoviocytes and macrophages to produce additional pro-inflammatory mediators, 
which in turn drives the inflammatory response of other immune cells including their 
recruitment, survival and clearance. For example, endothelial cells in the synovium 
are activated resulting in enhanced leukocyte adhesion and transmigration.  
 
Production of cytokines by fibroblast like synoviocytes (FLS) contributes to 
inflammation and cartilage destruction in RA, an imbalance between cell proliferation, 
survival, and death in the synovium results in increased proliferation of FLS with an 
aggressive phenotype encourages extracellular matrix invasion and increased 
deterioration of the joint (Bartok and Firestein, 2010). In addition, increased production 
of cartilage matrix metalloproteinases (MMPs) results in further destruction of articular 
cartilage. 
 
Numerous pro-inflammatory mediators are found within synovial fluid that sustain the 
inflammatory response. The most prominent of the cocktail of inflammatory mediators 
produced are TNF-α, IL-1, and IL-6, which all have autocrine, paracrine and endocrine 
effects and account for many systemic manifestations, including upregulation and 
induction of additional cytokines. Interferon-γ, IL-17 (osteoclast activation), IL-23 
(Th17 differentiation), IL-8 (cellular recruitment), IL-15 (T cell proliferation), PGE2, GM-
CSF and TGF-β are all known to be included within synovial fluid milieu (van Hamburg 
and Tas, 2018). Of these, the pro-inflammatory cytokine TNF-α has been shown to 
have a particularly crucial role (Tracey et al., 1988), with levels in the synovium 
positively correlating to the degree of inflammation and bone erosion (Neidel et al., 
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1995), consequently TNF-α blockade is currently a key therapeutic strategy used to 
treat RA (see section 1.3.4. and review by (Tracey et al., 2008) for further detail). 
 
1.3.3. Role of Neutrophils 
 
Neutrophils are recognised as having an active role in both the progression and 
persistence of inflammation. As a result of their persistent recruitment and prolonged 
survival, neutrophils are the dominant cell type found within the synovial joint, 
accounting for ~90% of the 2x109 cells in a typical RA knee joint (Cross et al., 2005), 
Compared to when circulating in the blood, neutrophils in the rheumatic joint display a 
more activated phenotype with increased cytokine release, NET formation and an 
enhanced capacity to produce ROS. Furthermore, and most relevant to this study, the 
presence of pro-survival factors in the joint affords the neutrophils a prolonged life 
span as a result of delayed apoptosis. Taken together, the on-going influx, increased 
release of cytotoxic and immunoregulatory molecules and the lack of apoptosis and 
clearance of neutrophils are potent drivers in both pathogenesis and perpetuation of 
RA. 
  
In the RA joint the presence of inflammatory mediators, including soluble ICs (such as 
RF and ACPA) and cytokines, stimulate synovial fluid neutrophils. As a consequence 
of their activated or primed state these neutrophils release high levels of cytotoxic 
products (Robinson et al., 1992). At the pannus, activated neutrophils respond to 
insoluble ICs, these are generally removed by phagocytosis however when 
engulfment fails to be successfully completed, frustrated phagocytosis results, 
intracellular ROS is generated and released along with hypochlorous acid (HOCl) 
(Fossati et al., 2002; Cross et al., 2005). Together, the enhanced secretion of oxidant, 
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ROS and granule enzymes, including cathepsin G, elastase and gelatinase, act to 
override protective agents within the joint and tissue damage ensues.  
 
Large numbers of activated neutrophils are found in the pannus and synovial fluid 
within RA joints (Mohr, 1995; Cross et al., 2005; Wittkowski et al., 2007), consequently 
their release of inflammatory mediators provides an immense local effect. Beside their 
release of ROS and granule enzymes, which directly contributes to tissue damage, 
activated neutrophils also generate and release an array of additional cytokines and 
chemokines. Most notable of these include the cytokines  IL-1β, IL-12, IL-18, IL-23, 
and TNF-α (plus TNF ligand superfamily member (RANKL) and TNFSF13B (BLys or 
BAFF)) and the chemokines CCL-2, CCL-4, CCL-5, and CXCL-8 (IL-8) (as reviewed 
in (Rosas et al., 2017)). As well as IL-8, LTB4 is also produced by activated neutrophils 
and the subsequent release of these chemoattractants into the joint directly recruits 
neutrophils. Recruitment of neutrophils to the inflammatory site is further boosted by 
the increased endothelial expression of ICAM-1 and IL-8 in response to neutrophil 
cytotoxic mediators and the enhanced adhesion of neutrophils to endothelial cells 
mediated by RF (Rollet-Labelle et al., 2013).  Indeed, the addition of neutrophil 
products to the existing inflammatory milieu is a key influence in the localised shift 
towards an aggravated and pro-inflammatory environment. 
 
Activated neutrophils in the synovial joint also differ by their expression of cell surface 
receptors. It has been shown that neutrophils from the synovial fluid of RA patients 
synthesize and express large amounts of MHC-II molecules (Cross et al., 2003). 
Interestingly, MHC-II was not detected on the surface of peripheral blood neutrophils 
from patients with RA nor were co-stimulatory molecules expressed by synovial fluid 
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neutrophils, suggesting that a novel interaction involving antigen presentation to T 
cells may occur within the RA joint (Cross et al., 2003). Additionally, neutrophils from 
synovial fluid of RA patients express high affinity FcγR (CD64) on their cell surface, 
thus indicating that these neutrophils may have an altered ability to respond to 
immunoglobulin (IgG) containing ICs (Quayle et al., 1997). Furthermore, blocking the 
FcγR has been shown to prevent development of disease in a neutrophil driven model 
of RA (Tsuboi et al., 2011; Sadik et al., 2012), therefore demonstrating the importance 
of this receptor on RA synovial fluid neutrophils, indicating that it serves a key role in 
disease progression.  
 
Another augmented behaviour of neutrophils from patients with RA is their heightened 
propensity to release NETs (Khandpur et al., 2013). NET formation requires the 
citrullination of histones, however in neutrophils from patients with RA this process 
occurs aberrantly resulting in the citrullination of additional proteins, such as vimentin 
(Khandpur et al., 2013). Not only can this atypical citrullination result in the generation 
of neoantigens and thus new targets during epitope spreading (Kidd et al., 2008), but 
the release of these citrullinated residues will stimulate ACPA production, sustaining 
the inflammatory response. Indeed, citrullinated vimentin has been found contained in 
NETs and in ICs from the synovial fluid of ACPA+ RA patients (Van Steendam et al., 
2010; Khandpur et al., 2013), thus indicating NETosis as the release mechanism. 
Furthermore citrullinated vimentin is a prominent citrullinated antigen in ICs from 
synovial fluid of RA patients (Van Steendam et al., 2010), therefore its release in NETs 
may be imperative for disease pathogenesis in ACPA+ RA patients. Certainly, a 
considerable increase in the titre of autoantibodies against citrullinated proteins is 
seen shortly before the onset of disease and continues to positively correlate with 
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progression (Lundberg et al., 2005). In addition to citrullinated peptides NETs also 
contain chromatin (DNA and histones), cytoplasmic proteins and granule enzymes 
(myeloperoxidase, elastase, lactoferrin, MMP-9) (Urban et al., 2009; Parker and 
Winterbourn, 2013). Upon NETosis these contents will be expelled with the latter 
having a particularly cytotoxic effect and further contributing to proliferation of disease 
and destruction of the collagen matrix within cartilage (Baici et al., 1982; Van den 
Steen et al., 2002). Furthermore, it has been demonstrated that cytokines contained 
within the inflammatory milieu, such as IL-17 and TNF-α, induce NETosis in RA 
neutrophils and that the sera from patients with ACPA+ RA stimulates healthy 
neutrophils to undergo NETosis (Khandpur et al., 2013). In this manner, neutrophil 
release of NETs is a self-perpetuating action within the inflammatory environment of 
the RA joint.  
 
The extended lifespan afforded to these neutrophils further evidences the derailment 
of a usually well-regulated innate immune response. For the resolution of 
inflammation, apoptosis of neutrophils must occur in an effective manner and their 
safe removal co-ordinated by subsequent mechanisms of efferocytosis. Impaired 
clearance in the inflammatory joint, means that when these neutrophils do eventually 
undergo spontaneous apoptosis, there is prolonged presence of apoptotic cells in the 
joint. Consequently, the autoantigens expressed on the surface of apoptotic 
neutrophils can lead to increased autoantibody production, thus further sustaining the 
inflammatory response.  
 
Dampening down of over exuberant inflammatory actions of neutrophils may provide 
a promising target for therapeutic intervention for RA. Indeed, many current therapies  
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exert inhibitory effects on some neutrophil inflammatory functions including 
adherence, oxidant production, enzyme activity, degranulation and apoptosis  (as 
discussed in (Wright et al., 2010)). However, these therapies are not neutrophil 
specific nor are they purposed to have suppressive effects across multiple neutrophil 
inflammatory actions, suggesting that targeting neutrophils at the site of inflammation 
remains a relatively unexplored therapeutic approach. Certainly, evidence for the 
inflammatory role of neutrophils in RA is growing and it is becoming increasingly more 
apparent that their mechanisms of action in this inflammatory condition extend past 
their innate role in disease initiation and subsequent release of cytotoxic mediators. 
Thus, the direct targeting of neutrophils in the joint provides a novel therapeutic 
approach with the potential to influence their numerous downstream actions with roles 




For adults with newly diagnosed active RA the first line of treatment is usually 
monotherapy with a disease-modifying anti-rheumatic drug (DMARD), typically 
methotrexate (Kristensen et al., 2006). Methotrexate is a conventional synthetic 
DMARD (csDMARD) and along with other members of the group is a slow-acting anti-
rheumatic drug (SAARD). In contrast, biologic DMARDs (bDMARDs) which contain 
polypeptide structures (such as monoclonal antibodies) produce their effects more 
quickly. Targeted synthetic DMARDS (tsDMARDs) are the third major group of 
DMARDs and are a comparatively new group comprised of low molecular mass drugs 
which target specific processed, such as Janus kinase (JAK) and phosphodiesterase 
4 (PDE4) inhibitors. As such DMARDs, either in the form of monoclonal antibodies 
against the cytokine (or its receptor) or soluble receptors serving as decoys, act by 
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targeting cytokines in the extracellular environment. In any case DMARDs function to 
decrease inflammation, slow down joint damage and ease the systemic effects of RA 
and other inflammatory diseases.  
 
Therapy with a csDMARD, such as methotrexate, results in sustained disease-free 
remission in only 15% of RA patients (Van Der Woude et al., 2009). When remission 
or low disease activity is not achieved from DMARD monotherapy or is not maintained 
the step-up strategy is combination treatment. Combination treatment may involve 
additional DMARDs, glucocorticoid treatment or anti-TNF agents. One example is that 
a csDMARD can be combined with a bDMARD, with a widely advocated combination 
being methotrexate and an anti-TNF agent (Emery et al., 2008, 2010). There are three 
main TNF-blocking drugs which function as biologic agents to dampen down the 
inflammatory process: these include two monoclonal antibodies (adalimumab and 
infliximab) and a recombinant TNF receptor (etanercept) (Yamanaka, 2015). Despite 
this drug diversity therapeutic efficacy is not seen in all cases and around 30% of RA 
patients will be non-responders to TNF blockade (Hetland et al., 2010).  
 
Alternative therapies commonly used in the treatment of RA include tsDMARDs aimed 
at inhibiting the JAK pathway or bDMARDs targeting either specific cytokines or B 
cells, as well as a csDMARD directed at the proliferation of T helper cells.  
 
JAK inhibition works by blocking the phosphorylation activity of one or more of the 
enzyme isoforms (JAK1, JAK2, JAK3 or Tyk2), consequently the related signal 
transducers and activators of transcription (STAT) proteins remain unphosphorylated, 
thus preventing their dimerization and translocation into the nucleus (Roskoski, 2016). 
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JAK enzymes bind to many different cytokine receptors and mediate pro-inflammatory 
cytokine, interferon, and hormone signalling, therefore by blocking phosphorylation of 
JAK a cluster of downstream inflammatory targets can be downregulated.  
 
IL-6, which is released during acute inflammation by monocytes, macrophages and 
endothelial cells, is considered to be a key contributor to the shift from acute to chronic 
inflammation in RA and thus is a major mediator targeted by treatment strategies. IL-
6 functions to stimulate hepatocyte production of CRP during the acute phase 
response. Furthermore, IL-6 interplay with B cells renders the cytokine important for 
many disease driving factors including B cell maturation, antibody production and 
Th17 differentiation. The IL-6 receptor is also expressed on neutrophils, with binding 
of the cytokine to its receptor resulting in the secretion of proteolytic enzymes and 
consequently cartilage degradation. Several studies have shown therapeutic efficacy 
of anti-IL-6 (Tocilizumab) treatment demonstrating significantly less worsening of joint 
damage and improved function (Maini et al., 2006; Nishimoto et al., 2007).  
 
Inhibiting the cytokines IL-12 and IL-23 by use of a monocolonal antibody 
(Ustekinumab) against the p40 subunit common to both IL-12 and IL-23 blocks their 
interaction with the IL-12 Rβ1 receptor (to which they both bind). In this way the 
downstream actions of IL-12 and IL-23 on differentiation of naïve T cells to Th1 and 
Th17 cells respectively is inhibited and consequently so is inflammation. IL-12 and IL-
23 blocking has been shown to be successful in psoriatic arthritis (Kavanaugh et al., 
2015), with studies in RA still lacking a definite conclusion of the efficacy on disease, 
nonetheless this treatment strategy appears to have an encouraging outlook for use 




Inhibiting IL-17, an inflammatory cytokine produced by Th17 cells that plays a key role 
in bone destruction, is an additional promising approach to RA therapy. Indeed, RA 
patients show elevated levels of IL-17 in their serum and synovial fluid, thus 
decreasing the levels and/or functionality of this protein may be effective as lessening 
bone erosion and joint damage. Studies have so far been focused on psoriatic arthritis 
and psoriasis due to the significantly elevated levels of IL-17 in these diseases. 
Significant improvement has been seen using a monoclonal antibody against IL-17A 
(Secukinumab) in studies of psoriasis (Langley et al., 2014) with a trend towards a 
positive response seen in RA (Kunwar et al., 2016). 
 
Another approach to RA therapy involves using anti-CD20 (Rituximab) to target B 
cells. B cells play a pivotal role in antigen presentation to T cells thus stimulating T cell 
activation and consequently accumulation in the synovium. However, by depleting 
CD20+ B cells autoantibody production, IC formation and B cell derived cytokines 
(such as IL-6 and TNFα) are reduced and thus synovitis is improved (Korhonen and 
Moilanen, 2010).  
 
As well as B cell lymphocytes T cells may also be targeted. One mechanism of choice 
involves enzyme inhibition to limit proliferation of activated CD4+ cells. Specifically, 
inhibiting dihydroorotate dehydrogenase limits the rate of pyrimidine synthesis which 
is required for the accelerated proliferation of activated CD4+ cells commonly seen 
during progression of RA. Indeed, this is the primary mode of action for Teriflunomide 
(the active metabolite of the csDMARD Leflunomide) with secondary effects 
downregulating cytokine production, due to inhibition of NF-κB activation, and 
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decreasing production of MMPs, thus preventing joint destruction (Davis et al., 1996; 
Kullich et al., 2006). 
 
Compared to other DMARDs, bDMARDs have a more rapid response and longer half-
life. However interpatient variation, such as higher drug clearance or lower initial 
plasma concentrations of the target cytokine, means that some patients may respond 
to particular bDMARDs but not others, hence the requirement for a repertoire of target 
specific drugs. When successful these treatments, whether administered individually 
or in combination, are anti-rheumatic and thus improve quality of life, nonetheless 
there are still key issues surrounding their use. These include risk of infection, loss of 
efficacy, and primary non-response but above all limited long-term improvement 
(Emery, 2012) and the requirement for continual treatment for sustained control 
(Firestein, 2003). 
  
Although current treatment strategies aim to intervene with the course of disease as 
early as possible the therapeutic response and resistance is significantly influenced 
by the clinical evolution of disease. Furthermore, inflammation of the synovium exhibits 
great heterogeneity with different disease pathotypes categorised by their cellular and 
molecular signatures. Specifically transcriptomic clustering has observed lymphoid-
(L), Myeloid-(M) and two Fibroblast-(F,F/A) prevalent patterns when RA synovitis 
samples were assessed (Pitzalis et al., 2013), findings which may explain the 





1.3.5. Animal Models 
 
Animal models of RA have made significant contributions to the current understanding 
of the disease. Not only have they advanced what is known about RA as a disease 
but many of the discoveries are translatable to other inflammatory diseases. Overall, 
these models have broadened our knowledge on the immune response and 
importantly on the interplay between the mediators and mechanisms driving 
inflammation and resolution. As previously discussed, RA is a complex disease 
involving inflammation, tolerance and autoimmunity as such the use of animal models 
can provide the advantage of a more simplified system (Choudhary et al., 2018). 
Indeed, there are several models of RA that either develop spontaneously or can be 
induced and in either case the mechanisms driving disease and comparability to 
features of human RA is unique to each model. In this manner it is particularly 
important to carefully evaluate the choice of models when deciding which is most 
appropriate for investigating a specific research question. 
 
Spontaneous development of arthritis occurs in only a few murine strains, namely 
Murphy Roths Large (MRL)/1 mice (Hang et al., 1982), New Zealand Black mice 
(Rordorf et al., 1982), tiptoe walking-Yoshimura (twy) mice (Hosoda et al., 1981) and 
Sakaguchi (SKG) mice (Sakaguchi et al., 2003). Models of ‘spontaneous’ RA are often 
the result of gene manipulation, common models of this type include TNF-α over-
expressing transgenic mice that develop an erosive polyarthritis with a similar 
phenotype to human RA  (Keffer et al., 1991) and IL-1 receptor antagonist (IL-1Ra)-
deficient mice, which along with arthritis develop additional auto-immune conditions, 
demonstrating that excess IL-1 signalling causes autoimmunity (Horai et al., 2000). 
Importantly, TNF-α transgenic mice have helped to validate TNF-α as a dominant 
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cytokine in RA and have facilitated development of anti-TNF-α therapies (Li and 
Schwarz, 2003), as well as determining roles for IL-1 activation and non-specific 
signalling effects on T cells (Iwakura, 2002). Additional models include Human T 
Lymphotropic Virus Type-1 (HTLV-1) transgenic mice (Iwakura et al., 1991), IL-1α 
transgenic mice (Niki et al., 2001), TNF AU-rich element (ARE) deficient mice 
(Kontoyiannis et al., 1999) and K/BxN mice (Kouskoff et al., 1996), with the latter being 
discussed in more detail later.  
 
Induced arthritis models that show similar pathology to human RA include serum 
transfer induced arthritis (STIA) (Wipke and Allen, 2001), adjuvant induced arthritis 
(AIA) (Pearson, 1956), streptococcal cell wall-induced arthritis (DeJoy et al., 1989), 
pristane-induced arthritis (Potter and Wax, 1981), collagen antibody induced arthritis 
(CAIA) (Khachigian, 2006) and most notably the collagen-induced arthritis (CIA) model 
(Brand et al., 2004). CIA is the most widely used animal model for RA and is largely 
considered the ‘gold standard’ in mouse models of the disease. Similar to human RA, 
CIA is characterized by synovial infiltration and swelling as well as cartilage and bone 
erosion (Asquith et al., 2009). Induction of arthritis in this model involves immunization 
with collagen type-II (CII) in incomplete Freund’s adjuvant (IFA) with the subsequent 
development of arthritis appearing 3–5 weeks later as a result of T cell recognition of 
CII and B cell production of CII specific autoantibodies (Rosloniec et al., 1988). Thus, 
this model is dependent on T and B cells and the adaptive immune response to an 
active immunization, as such this model incorporates both the priming and effector 
phases of arthritis and is therefore the most similar model to human RA (Korganow et 




The K/BxN STIA model offers advantages over the CIA model; it can be used to solely 
study the mechanisms of the effector phase, it develops over days rather than weeks 
and it can be induced in multiple strains of mice (as reviewed in (Christensen et al., 
2016)). Disease induction by the passive transfer of autoantibodies in the K/BxN STIA 
model means that both T cells and B cells are dispensable. In this manner, the K/BxN 
STIA model is ideal for investigating the mechanisms of interaction between 
autoantibodies and components of the innate immune system in driving the 
progression of arthritis. Specifically, neutrophils have been shown to be an essential 
component in the inflammatory response in this model and their deficiency confers 
disease resistance to K/BxN STIA (Wipke and Allen, 2001). Importantly, the 
inflammatory response in this model is completely dependent on autoantibodies 
whereas the inclusion of CFA in the CIA model induces an additional innate immune 
stimulation (as discussed in (Christensen et al., 2016)). Another significant advantage 
of this model over CIA is its broad application, as mentioned a wide range of strain 
backgrounds are susceptible to K/BxN STIA (Ji et al., 2001), whereas CIA is limited to 
DBA/1, B10.Q, and B.10RIII, with C57/Bl6 mice developing only a mild arthritis 
(Rosloniec et al., 1988). Taken together, the features described above make the 
K/BxN STIA the most applicable model for this study. 
 
The K/BxN mouse model of arthritis (first reported in 1996 by Mathis and Benoist) 
involves generating K/BxN mice by crossing KRN mice (transgenic for the T-cell 
receptor (TCR) responsible for recognising ribonuclease peptide (RNase) 43-56) on a 
C57BL/6 background with non-obese diabetic (NOD) mice. The NOD mice are a strain 
genetically prone to autoimmune response due to homozygous expression of the MHC 
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class II allele A(g7), this genetic background allows them to act as the secondary 
component for a successful K/BxN crossbreed (Monach et al., 2008). 
  
The offspring that result (K/BxN mice) spontaneously develop the symptoms of severe 
arthritis post-weaning at 4-5 weeks of age (Kouskoff et al., 1996). This manifestation 
has been shown to be the result of the KRN TCR recognising glucose-6-phosphate 
isomerase (G6PI), a peptide on a ubiquitously expressed self-antigen bound to NOD 
antigen-presenting cells (APCs). As a result of this recognition T cells become 
activated and interact with B cells promoting their activation as well as production of 
disease inducing IgGs (Christensen et al., 2016). Presence of the antibody brings 
about IC formation and consequently activation of numerous innate immune cells. 
Anti-G6PI autoantibodies induce joint-specific inflammation from an autoimmune 
response that results in an inflammatory arthritis. The anti-GPI antibodies are 
detectable in the serum of K/BxN mice from the onset of disease and although initially 
low, the titre level rises until around 60 days old (Maccioni et al., 2002). The transfer 
of K/BxN sera from these mice induces a robust arthritis in recipient mice (Korganow 
et al., 1999; Ji et al., 2001). Specifically the distal joints of the limbs, including the knee, 
ankle, tarsal and metatarsal regions of the hind limb along with the corresponding 
forelimb locations are the sites where inflammation will commonly manifest, with some 
regions of the spine also being mildly susceptible (Kouskoff et al., 1996). A rapid 
response and highly robust disease incidence ensues, which is reproducible in a 
considerable number of mice strains, furthermore by modifying the serum dosing 
strategy the onset and manifestation of systemic disease can vary, consequently 
shaping the overall disease profile to fit specific experimental purposes. As such, 
K/BxN serum transfer is a well-utilised model of murine arthritis for many preclinical 
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studies with the model baring particular benefit for investigating the interaction of 
innate immune components involved in the progression of RA. 
  
Transfer of K/BxN serum into recipient mice elicits a rapid immune response (Wipke 
et al., 2002). The first step following intra-peritoneal (i.p.) administration of K/BxN 
serum involves autoantibodies entering the circulation, as such the early stage of 
disease initiation occurs in the blood where administered anti-G6PI autoantibodies 
bind to G6PI resulting in the formation of soluble ICs. Next, these newly formed 
complexes interact with neutrophils, whereby they bind to Fcγ-receptors (FcγR) on the 
cell surface, signaling the release of vasoactive mediators. In turn, vascular 
permeability is increased thus allowing for the diffusion of ICs and anti-G6PI antibodies 
out of the blood and into the perivascular tissue. Mast cell degranulation results in the 
release of additional vasoactive mediators further increasing vascular permeability. 
Consequently, the synovial membrane is easily penetrable allowing ICs and anti-G6PI 
antibodies (as well as additional non-specific antibodies and serum proteins) to enter 
the joint cavity. Once present in the joint the anti-G6PI antibodies bind G6PI antigens 
expressed on the articular surface, expression of which is significantly amplified on 
arthritic cartilage (Christensen et al., 2016). In the K/BxN model this process occurs 
almost exclusively in the distal joints however it is yet to be determined why increased 
vascular leakage in response to circulating ICs is localised to the extremities of the 
limbs. Additionally it is worth noting that the interaction with FcγRs is essential during 
this initiation phase, evidenced in FcγR KO mice which were shown to be protected 
from developing arthritis in response to administration of K/BxN serum (Corr and 




After the initiation phase is the effector phase. Here the progression of joint localised 
arthritis has a strong dependence on the continued interaction of anti-G6PI antibodies 
and ICs with innate immune cells. Within the joint cavity ICs activate the alternative 
complement pathway, here the hydrolysis of C3 (into C3a and C3b fragments) leads 
to the cleavage of C5 (by C3b, into C5a and C5b), a product of which (C5a) is able to 
bind neutrophils resulting in their activation. Complement activated neutrophils release 
leukotriene B4 (LTB4) which upon interaction with neutrophils stimulates their release 
of interleukin-1β (IL-1β). IL-1β induces tissue cells to release chemokine C-X-C motif 
ligands 1 and 5 (CXCL1, CXCL5) and chemokine C-C motif ligand 9 (CCL9), as well 
as neutrophil release of CXCL2 and CCL3, thus stimulating increased neutrophil 
recruitment (Chou et al., 2010). Additionally, presence of IL-1β mediates release of 
granulocyte colony stimulating factor (G-CSF) that acts to further mobilise neutrophils. 
These conditions and the activated endothelium trigger recruitment of leukocytes to 
the site, with the infiltrating cell population composed predominantly of neutrophils and 
a small contribution of monocytes (Ly6C-) (Misharin et al., 2014). 
  
In addition to neutrophil infiltration additional immune cells present at the site of 
inflammation also have essential roles during this effector phase. Macrophages in the 
joint release macrophage inhibitory factor (MIF) which in combination with neutrophil 
released IL-1β mediates cartilage degradation (Jacques et al., 2006). Release of MIF 
also contributes to receptor activator of nuclear factor κ B (RANK) interaction with its 
ligands on osteoclasts, resulting in their activation and therefore the breakdown and 
erosion of bone (Christensen et al., 2016). Tumour necrosis factor (TNF) and PGE2 
are both produced in the joint and are considered to be responsible for conveying the 
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pain associated with inflammation (Christensen et al., 2016), however whether this is 
a direct or indirect contribution is currently not well understood. 
  
In any case, common sites of affliction in the model closely resemble RA in many 
aspects. The release of pro-inflammatory cytokines TNF-α, IL-1 and IL-6 in inflamed 
joints is seen in both RA and the K/BxN model. Furthermore IL-1 and TNF-α are 
particularly important for the development of arthritis (Lubberts and Berg, 2013). 
Mouse strains deficient in TNF-α have been demonstrated to have decreased 
incidence of disease whereas an absence of IL-1 completely protected mice from 
developing arthritis in response to serum  (Ji et al., 2002). IL-17, which is implicated in 
the pathogenesis of RA has also been proposed to have a role in the K/BxN model, 
however current findings for its role in the model are discrepant (Jacobs et al., 2009; 
Katayama et al., 2013). Increased levels of prostaglandins are also found at sites of 
inflammation in RA patients and have been shown to be similarly elevated in the K/BxN 
arthritic joint. Specifically, high levels of PGE2 and 6-keto prostaglandin F1α (6-k-
PGF1α, a stable hydrolyzed product of prostacyclin (PGI2)) are detected in the 
inflamed joint, however only the latter is essential for development of disease (Chen 
et al., 2008). Integrins and their ligands are indispensable to the development of 
inflammatory arthritis in both human and mouse models. The β2 integrins are 
particularly essential, with the CD11a/CD18 complex, also known as lymphocyte 
function-associated antigen 1 (LFA-1) and the CD11b/CD18 complex, referred to as 
both Macrophage-1 antigen (MAC-1) and complement receptor 3 (CR3) shown to be 
critical (Watts et al., 2005). Recruitment of leukocytes, particularly neutrophils, into the 
joint has been shown to be dependent on expression of these integrins, with no 
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response to K/BxN serum in mice deficient for the β2 integrins or following integrin 
blockade (Watts et al., 2005). 
 
The K/BxN serum transfer model of arthritis, in the absence of continual serum dosing, 
is a self-resolving disease, thus allowing the resolution phase to also be studied. As 
autoantibody levels drop the disease begins to abate, immune cell infiltration ceases 
and inflammation ameliorates. As testimony to disease presence the architecture of 
the afflicted joint remains altered for much of the initial resolution process, however as 
inflammation continues to resolve and mice return to baseline the remaining bone and 
cartilage that once appeared eroded and irregular has been demonstrated to repair 
(Matzelle et al., 2012). A finding that provides significant benefit for research regarding 
reversal of inflammatory damage and the process of resolution. 
 
In summary, the response generated mimics the immunological mechanisms 
occurring in the effector phase of RA, similarly characterised by the activation of innate 
immune cells (largely neutrophils and macrophages) as well as cytokines, 
chemokines, complement factors, Toll-like receptors, Fc receptors and integrins 
(Christensen et al., 2016). The presence of the G6PI self-antigen in both the disease 
model and RA is of prevalent importance. Responsible for sustaining disease in the 
K/BxN model the antigen is also present on the synovial lining and arteriole endothelial 
cell surface of RA patients alongside an elevated concentration of the anti-GPI 
immunoglobulin G (IgG) detectable in the serum and synovial fluid (Schaller et al., 
2001). Despite the mass similarities the autoantibody profile also exhibits variation 
between the model and the human disease, specifically Rheumatoid Factor (RF) has 
elevated presence in upwards of 70% of RA patients, yet is undetected in the mouse 
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model, whereas Immunoglobulin G (IgG) is raised in the mouse model and binds to 
organs, a behaviour not evidenced in RA. Even though these differences exist the 
K/BxN model is broadly considered to replicate human RA whereby swelling and joint 
destruction occurs as the result from the infiltration of immune cells, increased 






It is becoming increasingly apparent that many potential immunomodulators exist 
within the superfamily of lectins. Found within a diversity of organisms (Lam and Ng, 
2011), lectins are carbohydrate binding proteins which branch into four distinct 
subgroups: C-type lectins (including the selectins); P-type lectins; pentraxins; and 
galectins (originally S-type lectins) (Barondes, Castronovo, et al., 1994) with members 
of each group being determined by their binding specificity for β-galactoside sugars 
(Nishi et al., 2005). 
  
Encoded by the LGALS gene and sharing a characteristic amino acid sequence 
(Barondes, Cooper, et al., 1994), there are currently 15 mammalian galectins that have 
been identified and named with consecutive numbers. Not all galectins have been 
identified in humans, of Gal-1 through to Gal-15, Gal-5 and Gal-6 are rodent exclusive, 
and Gal-11, Gal-14 and Gal-15 are found only in sheep and goat (Leffler et al., 2002).  
Nonetheless galectin ancestry in primitive organs and their current presence across 
vertebrates, invertebrates and protists suggests integral behaviours for the family. 
However, this does not confer uniformed expression, indeed galectin expression (both 
intracellularly and extracellularly) is highly variable being either cell type specific or 
showing a more varied distribution, as detailed in table 1.  
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Table 1. Galectin species and tissue distribution. 
 
Galectin Species Tissue Distribution References 
Gal-1 Vertebrates Diverse (Cooper, 2002) 
Gal-2 Birds, mammals, 
frogs, lizards 
Gastrointestinal tract, placenta (Hutter et al., 2015)  
(Oka et al., 1999) 
Gal-3 Vertebrates Diverse (Cooper, 2002) 
Gal-4 Vertebrates  
(not birds) 
Intestine and stomach, uterine 
epithelial cells, blood vessel walls, 
hippocampal and cortical neurons 
(Froehlich et al., 2012) 
(Huflejt and Leffler, 2004) 
(Velasco et al., 2013) 
Gal-5 Rat Lung, kidney, reticulocytes, bone 
marrow, erythrocytes 
(Cerra et al., 1985) 
(Gitt et al., 1998) 
(Lensch et al., 2006) 
Gal-6 Mice Gastrointestinal tract, liver, kidney, 
spleen, heart  
(Gitt et al., 1998) 
(Houzelstein et al., 2013) 
(Houzelstein et al., 2008) 
Gal-7 Mammals Gastrointestinal tract, stratified 
epithelia, skin, foetal heart 
(Magnaldo et al., 1998) 
(Sato et al., 2002) 
(Timmons et al., 1999) 
Gal-8 Vertebrates Liver, kidney, cardiac muscle, lung 
and brain 
(Hadari et al., 1995) 
Gal-9 Vertebrates T-lymphocytes, small intestine, 
liver, uterine epithelial cells, skin 
epidermis and oesophageal 
epithelium 
(Froehlich et al., 2012) 
(Lensch et al., 2006) 
(Matsumoto et al., 1998) 
(Wada et al., 1997) 
Gal-10 Primates and bats Eosinophils (Abedin et al., 2003) 
Gal-11 Primates/ruminants Placenta/abomasal mucosa and 
bile duct epithelial cells 
(Dunphy et al., 2000) 
(Young et al., 2012) 
(Than et al., 2009) 
Gal-12 Vertebrates Adipose Tissue (Hotta et al., 2001) 
(Yang et al., 2004) 
Gal-13 Primates Placenta (Than et al., 2004) 
Gal-14 Ruminants Eosinophils (Young et al., 2009) 
Gal-15 Ruminants Uterus (Gray et al., 2004) 
(Table adapted from (Johannes et al., 2018)) 
 
Despite all galectins containing a conserved carbohydrate-recognition domain (CRD) 
of ~130 amino acids, the position of this domain within the overall structure of the 
protein varies, as does the inclusion of additional domain regions. On the basis of their 
structural differences the galectin family is subdivided into three groups, as shown in 
table 2, where each member is classified accordingly as either prototype, chimera-
type or tandem-repeat-type (Yang et al., 2008). Gal-1, Gal-2, Gal-5, Gal-7, Gal-10, 
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Gal-11, Gal-13 and Gal-14 belong to the prototype subgroup, possessing a single 
CRD and exist as either monomers (Gal-5, Gal-10 and Gal-14) or non-covalent dimers 
(Gal-1, Gal-2, Gal-7 and Gal-11) with the exception of Gal-13 which is unique in being 
stabilised by two disulphide bonds (Rapoport et al., 2008). Chimera-type galectins 
consist of one CRD with the addition of an extended non-lectin N-terminal region, this 
structural organisation is unique to galectin-3, the only galectin classified as chimera-
type. The third subgroup are the tandem-repeat-type galectins, which include Gal-4, 
Gal-6, Gal-8, Gal-9 and Gal-12. These five galectins are characterised by having two 
CRDs connected by a short linker peptide, with different sugar binding specificities 
pertaining to each domain. The two domains provide these galectins with the capability 
to form cross links with glycoconjugates in a more variable manner, resulting in more 
galectin-glycoconjugate combinations than the prototype or chimera-type galectins 
(Nishi et al., 2005; Rapoport et al., 2008). 
 
Table 2. Galectin family subgroups and structure. 
  
 
Across the galectin family the degree of similarity between the nucleotide sequences 
of the CRDs varies considerably. As such galectins show individual carbohydrate 
binding preferences for the small sets of oligosaccharides that build the larger 
glycoproteins, with further diversity occurring in valence number and from the ability 
of some galectins to bind multiple antigens/receptors. Regardless of these differences, 
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members of the galectin family discerningly form networks with multivalent 
glycoconjugates in a carbohydrate dependent manner. In addition to the ability to exert 
extracellular actions galectins also perform roles intracellularly. In such circumstances 
it is thought their behaviours are independent of carbohydrate binding instead 
interacting with intracellular ligands and facilitating signalling pathways accordingly. 
  
Galectins do not contain a classical signal sequence, thus are not destined towards 
the secretory pathway. In spite of this lack of signal sequence for transport into the 
endoplasmic reticulum, members of the galectin family, localised mainly to the 
cytoplasm (and less frequently within the nucleus), are still able to exit cells via a non-
classical pathway. The exact mechanisms remain poorly understood, however the 
secretion of galectins has been demonstrated to require their galactoside-binding 
activity (Seelenmeyer et al., 2005). 
  
Many members of the galectin family demonstrate low level endogenous expression 
across numerous different tissues and organs, with the immune system seen to exhibit 
the most abundance (Li et al., 2013). Regarding their role in inflammation some 
immune cells, as well as vascular endothelial cells, have been shown to endogenously 
express several members of the galectin family. Although expression is relatively low 
under basal conditions levels are generally upregulated in response to cell activation. 
Recent studies have identified that galectins present at inflammatory sites have potent 
immuno-regulatory properties through both their extracellular and intracellular actions. 
Through binding to the surface of leukocytes, galectins mediate cell-cell and cell-
matrix interactions consequently modulating recruitment and trafficking of leukocytes 
(Cooper et al., 2008; Norling et al., 2009). Another more extensively studied function 
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of galectins is their regulation of apoptosis, where findings have shown that particular 
cell types (including fibroblasts and T cells) are susceptible to galectin-induced 
apoptosis (Seki et al., 2007; van Kooyk and Rabinovich, 2008). Taken together these 
findings provide evidence for a galectin-leukocyte interplay that may play a role in 
mediating various outcomes. 
  
Four of the fifteen members of the galectin family (specifically galectin-1, -3, -8 and -
9) demonstrate influential roles in inflammation. Gal-1 has been shown to inhibit 
leukocyte recruitment (La et al., 2003; Cooper et al., 2008; Norling et al., 2008) with 
an anti-inflammatory effect involving the inhibition of both soluble and cellular 
mediators of the inflammatory response (Rabinovich et al., 2000). Gal-3, Gal-8 and 
Gal-9 generally promote leukocyte recruitment (Norling et al., 2009) with Gal-3 and 
Gal-8 evidencing pro-inflammatory effects whilst the principal behaviour of Gal-9 is still 
debatable. To perform their roles influencing leukocyte trafficking galectins must be 
present at the site of inflammation. However, in certain immune diseases circulating 
galectins are also detectable in the blood serum. Specifically, Gal-1 and Gal-3 are 
detectable in both the sera and synovial fluid of patients with RA. Expression of Gal-1 
has been shown to be down regulated in the synovial fluid from RA patients (Xibillé-
Friedmann et al., 2013), yet markedly increased in the sera (Mendez-Huergo et al., 
2019). Levels of Gal-3 have also been reported to be increased in both the sera and 
synovial fluid from patients with RA (Ohshima et al., 2003). However, in an alternative 
study the opposite was shown, where in RA sera samples Gal-3 was down regulated 







Gal-1 was first identified in the mid-1970s when it was found in various organs of three 
different species around the same time.  Specifically it was detected in electric eel’s 
electric organ tissue, in calf heart and lung tissue and in chick embryos (Teichberg et 
al., 1975; de Waard et al., 1976; Kobiler and Barondes, 1977; Nowak et al., 1977), 
where in all cases the protein was noticed for its β-galactoside binding activity and its 
hemagglutinating effects on red blood cells. Highly conserved across species Gal-1 is 
encoded by the LGALS1 gene located on the 22q13.1 band of chromosome 22, the 
gene contains four exons and is 135 amino acids in length. Purification and 
crystallisation of the protein has revealed that the monomer structure with its single 
carbohydrate binding site, consists of two β-sheets, one of five strands and one of six 
strands, and that a 22-strand dimer is formed from an anti-parallel β-sandwich 
arrangement that results in the two binding sites being located on the same side of the 
molecule (Liao et al., 1994). Upon dimerization a hydrophobic core is formed between 
the monomers, an interaction that is essential for maintenance of the structure. 
 
1.4.2. Gal-1 in Inflammation and Resolution 
  
Galectins were first confirmed to act in inflammation following several studies in the 
early 1990’s that revealed members of the protein family having a role in cell adhesion 
and migration (Cooper et al., 1991; Colin Hughes, 1992). These findings followed a 
couple of much earlier studies describing a 14kDa β-galactoside binding protein (now 
known as Gal-1) with immunosuppressive effects in models of experimental 
autoimmune myasthenia gravis (EAMG) (Levi et al., 1983) and experimental 
autoimmune encephalomyelitis (EAE) (Offner et al., 1990). However, at this time 
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experimenting with the family of proteins was still particularly novel and so these early 
studies required further investigation and corroboration. Consequently, these effects 
seen in T cell mediated diseases led to increased attention being focused on the 
interactions of Gal-1 with T cells. Initial work revealed that thymic epithelial cells 
express Gal-1 which directly influences the adhesion of immature T cells (Baum, Pang, 
et al., 1995). Furthermore, unlike mature and activated cells, immature T cells were 
not able to facilitate Gal-1 binding to the cell surface. As part of these initial Gal-1 
studies the peripheral lymph nodes were also checked, here the same group showed 
that the protein is present in activated, but not resting, lymphoid tissue and that this 
expression was localised specifically to the high endothelial venules (Baum, 
Seilhamer, et al., 1995). En masse these studies were strongly indicative of an 
immunomodulatory role for Gal-1.  
 
Much of the focus of galectin research has continued to be directed by its interactions 
with T cells. More recent work has uncovered the ability of Gal-1 to target specific 
subsets of T cells (Cedeno-Laurent and Dimitroff, 2012) often inducing their apoptosis, 
a behaviour that is likely to lead to the protein’s suppressive effects in several models 
of autoimmune disease (Rabinovich, Daly, et al., 1999). Furthermore, Gal-1 has also 
been shown to inhibit trafficking of T cells through endothelial monolayers (Norling et 
al., 2008) and have an effect on tumour modulation (Astorgues-Xerri et al., 2014). 
  
Compared with studies on T-cells, the functions of Gal-1 on cells of the innate immune 
system such as macrophages and neutrophils are comparatively fewer. Exogenous 
Gal-1 induces 12/15-lipoxygenase expression and promotes macrophage conversion 
to a pro-resolving phenotype that are quicker to reach efferocytic satiation (Rostoker 
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et al., 2013). In general Gal-1 treated macrophages favour the alternative activation 
pathway (Correa et al., 2003), resulting in a more M2 like phenotype (Abebayehu et 
al., 2017), with reduced MHC-II expression (Barrionuevo et al., 2007) and decreased 
release of pro-inflammatory mediators (Rabinovich et al., 2000; Kogawa et al., 2011). 
Correspondingly, endogenous Gal-1 is associated with mature (CD11bhigh) 
macrophages but not pro-resolving (CD11blow) macrophages (Rostoker et al., 2013).   
 
The majority of studies investigating the role of Gal-1 on neutrophils indicate that this 
protein is protective, including the ability to induce surface phosphatidylserine (PS) 
exposure, indicating a potential role in neutrophil clearance (Dias-Baruffi et al., 2003; 
Stowell et al., 2007, 2009), as well as a role in neutrophil extravasation (Cooper et al., 
2008; Auvynet et al., 2013). Furthermore, and of particular relevance to this current 
study, exogenous Gal-1 has been shown to induce apoptosis in human neutrophils 
from synovial fluid of RA patients (Cedeno-Laurent et al., 2010). In vivo (in the 
carrageenan-induced paw oedema model) Gal-1 was shown to inhibit neutrophil 
recruitment to the inflamed paw (Iqbal et al., 2011) and trafficking of neutrophils is 
enhanced in Gal-1 KO mice (Cooper et al., 2008). Gal-1 has been reported to have a 
pro-inflammatory role in the neutrophil respiratory burst, causing release of NADPH 
oxidase (Almkvist et al., 2002).   
 
Importantly, amongst current findings in the literature there is increasing evidence of 
potential pro-resolving actions for Gal-1. Several studies have demonstrated that 
expression of Gal-1 peaks at the height of the inflammatory response (Ilarregui et al., 
2009; Iqbal et al., 2011; Starossom et al., 2012). Moreover, Gal-1 was identified in 
resolving exudates and was down-regulated by the resolution-toxic anaesthetic 
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lidocaine (Chiang et al., 2008). Differentiation of dendritic cells in a Gal-1 rich 
environment leads to enhanced regulatory functions and suppression of autoimmune 
disease progression thus indicating that Gal-1 acts in linking the innate and adaptive 
immune systems (Ilarregui et al., 2009). Indeed, the pro-resolving potential of Gal-1 
extends to cells of the innate immune system, where Gal-1 has been shown to induce 
12/15-lipoxygenase expression and favour conversion to a pro-resolving phenotype in 
macrophages  (Rostoker et al., 2013) and induce phosphatidylserine exposure on the 
surface of neutrophils (Stowell et al., 2007), thus suggesting Gal-1 has a pro-resolving 
role in macrophage efferocytosis of neutrophils.  
 
A summary of the various roles of Galectin-1 on both innate and adaptive immune 






Figure 4. Roles of Gal-1 in Inflammation and Resolution 
Galectin-1 (Gal-1) exerts anti-inflammatory and/or pro-resolving properties in inflammation. Anti-inflammatory actions 
include inhibitory effects on leukocyte trafficking and mast cell degranulation, as well as promotion of T cell apoptosis. 
Pro-resolving actions include instructing the adaptive immune response via T cell skewing and cytokine production 
as well as induction of tolerogenic dendritic cells. For cells of the innate immune system the pro-resolving actions of 
Gal-1 include increasing phosphatidylserine (PS) exposure on the surface of neutrophils and promotion of a pro-




1.4.3. Gal-1 and Neutrophil Biology 
  
Few studies have investigated the effects of Gal-1 in the context of acute inflammation 
with new learnings on its interactions with neutrophils seldom reported. 
  
It is well established that in the inflammatory response neutrophils are the primary 
leukocyte subset mobilised and that the initial step in this process is the establishment 
of leukocyte-endothelial interactions. Evidence in the literature has shown that Gal-1 
is produced by the endothelium during inflammation (Baum, Seilhamer, et al., 1995) a 
finding that first suggested that the protein may interact with neutrophils and play a 
role in their trafficking. To explore this potential relationship studies have been 
performed in our lab utilising both in vitro and in vivo methods with findings indicating 
that both exogenous and endogenous Gal-1 have an inhibitory effect on neutrophil 
trafficking. Furthermore, some of these earlier studies revealed Gal-1 inhibited specific 
neutrophil behaviours, including chemotaxis and trans-endothelial migration (La et al., 
2003). 
  
An in vitro flow chamber system was utilised to test the effects of Gal-1, where 
neutrophils were flowed over human umbilical vein endothelial cells (HUVEC) 
stimulated with TNF-α, to resemble physiological events occurring in the inflamed 
microcirculation. Neutrophils pre-incubated with hrGal-1 prior to flow demonstrated 
that exogenous Gal-1 was able to significantly decrease the capture, rolling and 
adhesion of neutrophils onto the activated endothelial cells (Cooper et al., 2008). 
Knockdown of endothelial Gal-1, using small interfering RNA, resulted in significantly 
increased neutrophil capture and rolling, further substantiating its role in neutrophil 
recruitment (Cooper et al., 2008). Gal-1 inhibition of neutrophil trafficking has also 
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been shown in vivo. Increased neutrophil adhesion and emigration was seen in the 
inflamed cremasteric microcirculation of Gal-1 KO mice compared to WT by intravital 
microscopy (Cooper et al., 2008). In a murine model of acute inflammation Gal-1 
administration reduced neutrophil influx and oedema formation in a model of 
carrageenan induced paw oedema (Iqbal et al., 2011) and inhibited interleukin-1β-
induced PMN recruitment into the mouse peritoneal cavity (La et al., 2003) 
demonstrating efficacy of the recombinant protein in vivo. 
 
In addition to inhibiting neutrophil trafficking hrGal-1 also modulates adhesion 
molecule expression on the surface of activated neutrophils; addition of Gal-1 inhibited 
the decrease in P-selectin glycoprotein ligand 1 (PSGL-1) expression and concomitant 
increase in CD11b expression on platelet activating factor (PAF)-stimulated 
neutrophils (Cooper et al., 2008). 
 
Along with modulating surface expression of members of the integrin family that serve 
as markers of neutrophil activation, hrGal-1 also possesses the ability to induce the 
exposure of phosphatidylserine (PS) on the surface of neutrophils (Stowell et al., 
2009), an action typically associated with initiation of apoptosis (Denecker et al., 
2000). In addition to PS exposure, neutrophil apoptosis classically encompasses 
intracellular processes including mitochondrial dysfunction (resulting in depolarisation 
of the mitochondrial transmembrane potential) (Ly et al., 2003), activation of caspases 
(proteases critical in the execution of apoptosis) (Shi, 2004) and DNA fragmentation. 
Intriguingly, these intracellular apoptotic programmes were not stimulated by hrGal-1 
in the study by Stowell et al., thus suggesting that hrGal-1 induces PS exposure on 
neutrophils in the absence of initiation of apoptosis. Observations that neutrophil PS 
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exposure brought about by cell interaction with hrGal-1 is reversible when hrGal-1 is 
removed from the cell surface further contributes to comprehensive evidence that cell 
viability remains unaltered despite membrane changes of this manner usually being 
attributed to neutrophil apoptosis (Stowell et al., 2009). 
  
Furthermore, hrGal-1 induced exposure of PS on the surface of neutrophils is 
conditional of both the form of the protein and activation status of the cell.  In this 
manner the dimeric form of the protein is required for successful signalling and the 
monomeric form of hrGal-1 is not able to induce PS exposure (Dias-Baruffi et al., 
2003). An additional study has also suggested that hrGal-1 induced surface exposure 
of PS does not occur on resting cells and is exclusive to neutrophils with an activated 
phenotype (Stowell et al., 2007).  
 
It is well established that Gal-1 readily binds to the surface of neutrophils (Dias-Baruffi 
et al., 2003; La et al., 2003; Cooper et al., 2008). Current literature suggests that Gal-
1 binding may be modulated in response to stimulation. It has been demonstrated that 
N-formyl-Methionyl-Leucyl-Phenylalanine (fMLP) stimulated neutrophils exhibited 
increased Gal-1 binding (Dias-Baruffi et al., 2003) however, stimulation with PAF had 
no notable effect (Cooper et al., 2008). Interestingly, neutrophils from the synovial fluid 
of rheumatoid arthritis patients, which are typically activated following their prolonged 
exposed to numerous mediators within the inflammatory milieu, are susceptible to Gal-
1 induced apoptosis (Cedeno-Laurent et al., 2010). Rather strikingly, this finding 
suggests that the activated phenotype of these neutrophils may render them 




The ability of Gal-1 to bind to neutrophils has been demonstrated to be carbohydrate 
dependent with binding of hrGal-1 inhibited in the presence of thiodigalactoside 
(Cooper et al., 2008). Similarly, the ‘flip’ of PS to the outer membrane of activated 
neutrophils exposed to dimeric hrGal-1 was abolished in the presence of lactose (Dias-
Baruffi et al., 2003), suggesting that hrGal-1 signalling is a carbohydrate dependent 
mechanism requiring the protein to bind to cell surface β-galactosides. 
 
Collectively these findings suggest that Gal-1 is endowed with the ability to influence 
neutrophil behaviour including neutrophil recruitment, clearance and survival, yet the 
mechanisms behind these functions remains to be fully elucidated. The specific 
behavioural features of Gal-1 have previously been shown to correspond with its 
location (Baum, Pang, et al., 1995), nonetheless the involvement of Gal-1 and its 
influences on neutrophils and the mechanisms responsible for their clearance still 
remains poorly understood. As such these aspects will be investigated as part of this 
thesis, with emphasis on their potential involvement in inflammatory arthritis. 
 
1.4.4. Gal-1 in Rheumatoid Arthritis 
 
The presence of Gal-1, -3, -8 and -9 in inflamed tissues, as seen in RA, indicates a 
key role for these galectins within inflammatory diseases (Mendez-Huergo et al., 
2019). Furthermore, galectins are detectable in the serum of RA patients (Ohshima et 
al., 2003; Mendez-Huergo et al., 2019). Of these galectin members with roles in RA, 
Gal-3 has been demonstrated to be predominantly proinflammatory and arthritogenic 
(Forsman et al., 2011), whereas Gal-1, Gal-8 and Gal-9 are considered anti-
inflammatory and protective (Rabinovich, Daly, et al., 1999; Sebban et al., 2007; Seki 




The anti-inflammatory role of Gal-1 in arthritis was first reported by Rabinovich et al. 
in 1999. Utilising a T cell dependent model of RA they showed that therapeutic 
administration of either syngeneic fibroblasts engineered to secrete Gal-1 or 
exogenous recombinant Gal-1 suppressed arthritis by enhancing T cell susceptibility 
to antigen-induced apoptosis and reducing the anti-collagen antibody levels 
(Rabinovich, Daly, et al., 1999). In the same study, exogenous Gal-1 was also shown 
to promote a shift in immune balance, by skewing the cytokine profile away from a 
type 1 T helper (Th1) cell mediated response and towards a type 2 T helper (Th2) cell 
humoral response. In line with these findings, the absence of endogenous Gal-1 
resulted in increased susceptibility to arthritis with earlier onset of disease and 
increased severity, as well as elevated anti-collagen antibody levels (Iqbal et al., 
2013). Taken together these findings clearly demonstrate the inhibitory function of Gal-
1 in the development and progression of arthritis.   
 
Additional in vitro studies have further elaborated on the effects of Gal-1 on T cells 
with an arthritogenic phenotype, showing that Gal-1 inhibited the adhesion of IL-2 
stimulated T cells to the extracellular matrix (ECM) and that this was due to blocking 
the re-organization of actin in activated T cells (Rabinovich, Ariel, et al., 1999). The 
production of TNF-α and interferon-gamma (IFN-γ) by IL-2-activated T cells was also 
reduced by Gal-1, providing further evidence of its anti-inflammatory effect on 
arthritogenic T cells (Rabinovich, Ariel, et al., 1999). Gal-1 also has a modulatory effect 
on trafficking in the inflammatory setting, a finding relevant to the augmented 
recruitment to the inflamed joint in RA. To this effect, exogenous Gal-1 reduced T cell 
trafficking along the activated endothelium whereas in the absence of the expression 
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of endogenous Gal-1 on activated endothelial cells T-cell adhesion was increased, 
thus demonstrating that Gal-1 is a negative regulator of T-cell recruitment (Norling et 
al., 2008). These in vitro studies provide further evidence of the potential anti-
inflammatory actions of Gal-1 in RA. 
 
Aside from the effects of Gal-1 on T cells in RA very little work has been conducted on 
the role of the protein on other immune cells involved in the development and/or 
progression of the disease. Studies focused on the potential interplay between Gal-1 
and the innate immune cells contributing to RA are especially limited. Findings by 
Rostoker et al. suggesting that Gal-1 promotes conversion of inflammatory 
macrophages to a pro-resolving phenotype that are quicker to reach efferocytic 
satiation (Rostoker et al., 2013), may have important translational relevance to 
macrophages present in the inflamed joint. However, this study was not performed on 
synovial macrophages and thus phenotypic differences may occur (Udalova et al., 
2016; Culemann et al., 2019). As mentioned, Gal-1 can induce apoptosis of synovial 
fluid neutrophils from patients with RA (Cedeno-Laurent et al., 2010). In the same 
study the granulocytes present in inflammatory synovial fluids from patients with RA 
were shown to express Gal-1 receptors. These results demonstrate that not only T 
cells but neutrophils from within the RA joint express Gal-1 receptors and their 
engagement with Gal-1 triggers apoptosis. 
 
Despite low basal levels, Gal-1 expression is increased in response to inflammation 
with levels markedly increased in the sera from RA patients (Mendez-Huergo et al., 
2019). Furthermore, RA patients with moderate-high disease had high levels of Gal-1 
whereas patients in remission or with low disease had comparatively lower levels (Vilar 
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et al., 2019), positively correlating with disease activity thus suggesting its potential as 
a biomarker in RA. In contrast, Gal-1 levels are significantly reduced in the synovial 
fluid from patients with RA, which could be due to presence of Gal-1 autoantibodies 
(Xibillé-Friedmann et al., 2013). It has been proposed that elevated Gal-1 
autoantibodies within the synovial fluid of RA patients limits the amount of Gal-1 and 
thus prevents its anti-inflammatory actions within the inflamed joint.   
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1.5. Hypothesis and Research Questions 
  
Inflammation can often be neutrophil driven whereby they are the dominant leukocyte 
in the infiltrate. In such cases their extended life-span (Weinmann et al., 2007) coupled 
with their cytotoxic potential prevents the successful shift from pro-inflammatory to pro-
resolving. Thus, greater understanding of mediators, such as Gal-1, that demonstrate 
the potential to limit neutrophil recruitment and/or increase neutrophil apoptosis and 





This project challenges the hypothesis that the anti-inflammatory properties of Gal-1 
are mediated through its ability to inhibit neutrophil recruitment and potentiate 
neutrophil clearance. 
  
1.5.2. Research Questions 
  
To address the hypothesis there are three research questions that this project aims to 
answer: 
1. Is Gal-1 protective in a neutrophil-driven model of inflammatory arthritis? 
2. Can Gal-1 regulate neutrophil survival? 
3. Does Gal-1 modulate macrophage phenotype and/or efferocytosis?  
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Recombinant Human Galectin-1 was provided by GalPharma (Takamatsu, Kagawa, 
Japan). The recombinant protein is a cysteine-less mutant of WT Gal-1 with all 
cysteine residues substituted with serine residues (Nishi et al., 2008). The cysteine 
residues in Gal-1 are particularly susceptible to oxidation, which renders the protein 
inactive. The cysteine-less mutant from of Gal-1 is resistant to oxidation whilst 
retaining all the known activities of WT Gal-1. 
 
2.1.2. Leukocyte Isolation 
 
21-gauge butterfly needle (Hospira, Pfizer). 60ml syringe (Terumo). Dulbecco’s 
phosphate buffered saline (DPBS) with (+/+) or without (-/-) calcium and magnesium, 
Histopaque 1077, Histopaque 1119, Sodium chloride (NaCl) and Sodium citrate 
(Sigma-Aldrich). Roswell Park Memorial Institute (RPMI) – 1640 Medium (Phenol Red 
free, without L-glutamine, with sodium bicarbonate) (Gibco, Thermo Fisher Scientific). 
Turk’s solution prepared in-house (with 3% Acetic Acid (Sigma-Aldrich) and 0.01% 





2.1.3. Cell Culture 
 
Accutase® (in DPBS-/- 0.5 mM Ethylenediaminetetraacetic acid (EDTA) with phenol 
red), Bovine Serum Albumin (BSA), L-glutamine (200mM) solution, 
Lipopolysaccharide (LPS) from Escherichia coli (E. coli) 0111:B4 and Penicillin-
Streptomycin (P/S) (10,000 units penicillin and 10 mg streptomycin/ml) solution 
(Sigma-Aldrich). Amphotericin B (Fungizone) and Foetal Bovine Serum (FBS) (Gibco, 
Thermo Fisher Scientific). Mouse Recombinant Interleukin-4 (IL-4) (eBioscience). 
Human Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), 
Human Recombinant Macrophage Colony-Stimulating Factor (hrM-CSF), Mouse 
Recombinant Macrophage Colony-Stimulating Factor (mM-CSF) and Mouse 
Recombinant Interferon-γ (IFN-γ) (PeproTech). 1.1ml Z-Gel Micro tubes (Sarstedt). 
RPMI – 1640 Medium (as listed above). 
 
2.1.4. Fluorescent Labelling and Flow Cytometry 
 
α-mouse Fcγ block (clone 2.4G2, generated in-house, the hybridoma was grown and 
the supernatant harvested, contaminating cells and debris were removed by 
centrifugation). α-human Fcγ block (γ-Globulins from human blood, (Sigma-Aldrich)). 
Anhydrous Dimethyl Sulfoxide (DMSO) (Life Technologies, Thermo Fisher Scientific). 
Annexin V Binding Buffer (BD Pharmingen, BD Biosciences). BODIPY® FL N-(2-
Aminoethyl) Maleimide, 3,3′-dihexyloxacarbocyanine iodide (DiOC6) and UltraComp 
ebeads (Invitrogen, Thermo Fisher Scientific). Carboxyfluorescein Succinimidyl Ester 
(CFSE), Fixation Buffer, Permeabilization Buffer and Fixation/Permeabilization diluent 
(eBioscience, Thermo Fisher Scientific). Paraformaldehyde (PFA) powder (Sigma-
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Aldrich). BSA and DPBS-/- (as listed above). FACS buffer prepared in-house (DPBS-/- 
with 0.02% BSA). 
 
 




  All antibodies used at working dilution in 50µl per well FACS (Fluorescent Activated 




2.1.5. In vivo and ex vivo Sample Processing 
 
0.3ml MicroFine syringe with 30-gauge needle, 0.5ml insulin syringe with 27-gauge 
needle, 1ml syringe and 5ml syringe (Terumo). 25-gauge needle (BD Microlance 3). 
DPBS tablets (Oxoid, Thermo Fisher Scientific). EDTA 0.5M solution and RNAlater® 
(Ambion, Thermo Fisher Scientific). Entellan® mounting medium and Eosin Y-solution 
(Merck Millipore). Formaldehyde Solution 37% (Fisher Scientific, Thermo Fisher 
Scientific). Heparin Sodium (Leo Pharma). Histo-Clear (Scientific Laboratory 
Supplies). Rapid-Chrome Kwik-Diff Staining System (Shandon, Thermo Fisher 
Scientific). Collagenase D (from Clostridium histolyticum), Deoxyribonuclease 
(DNAse) I (from Bovine pancreas),  Ethylenediaminetetraacetic acid disodium salt 
dehydrate (EDTA disodium salt), Mayer’s Haematoxylin, Sodium Hydroxide Pellets, 
Sodium phosphate monobasic monohydrate, Sodium phosphate monobasic dihydrate 
and Zymosan A (from Saccharomyces cerevisiae) (Sigma-Aldrich). 1.1ml Z-Gel Micro 
tube and 1.3ml EDTA Micro tube (Sarstedt). K/BxN serum (generated as described in 
section 2.2.4.1 from an in-house breeding colony crossing KRN and NOD mice). BSA, 
DPBS-/-, hrGal-1 and PFA (as listed above). 
         
2.1.6. Genotyping 
 
Agarose (Bioline), 10 x Tris-acetate EDTA (TAE) (Roche, Sigma-Aldrich). GelRed® 
(Biotium). Neutralization Solution B, oIMR6918, oIMR6919 and oIMR8306 primers, 
REDExtract-N-Amp™ Tissue PCR Kit (containing Tissue Preparation Solution, 
Extraction Solution and REDExtract-N-Amp PCR Reaction Mix) (Sigma-Aldrich). 
Quick-Load® Purple 100bp DNA Ladder (New England Biolabs). RNAse free water 
(Ambion, Thermo Fisher Scientific). 
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2.1.7. Western Blotting 
 
0.1 M 1,4-Dithiothreitol (DTT), NuPAGE® LDS Sample Buffer 4X, NuPAGE® 10% Bis-
Tris 12 well Gel and NuPAGE® MOPS SDS Running Buffer (Invitrogen). 23-gauge 
needle (BD Microlance 3). XCell SureLock™ Mini-Cell unit (Thermo Fisher). Spectra 
Multicolor Broad Range Protein Ladder (Thermo Scientific). Glycine (Fisher Scientific). 
Tris base, Tris-HCL and Tween20 (Sigma-Aldrich). Transfer tank (Bio-rad). Skimmed 
milk powder (Marvel). Immobilon forte western HRP substrate and Immobilon-P 
Transfer Membrane (Merck Millipore). Super RX-N Medical X-ray Film (Fujifilm). 1ml 
syringe, BSA and Sodium Chloride as previously listed. 
 
 
Table 4. Antibodies used for Western blotting. 
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2.2. In vivo and ex vivo Methods 
 
2.2.1. Ethics and Regulations 
 
Experiments performed in vivo all adhered to the Home Office regulations (Scientific 
Procedures Act, 1986) and were additionally approved under the guidelines set down 
by the Ethical Committee for the Use of Animals, Barts and The London School of 
Medicine. Additionally, protocols under the supervision of the above were 
accomplished baring careful consideration to the principles set out by the National 




Male wildtype (WT) C57/BL6 mice, were purchased from Charles River (Kent, UK), 
Gal-1 knock out (KO) mice were from a colony bred and housed at the same facility. 
 
The age of the mice varied from 6-14 weeks dependant on the nature of the 
experimental work and where required WT and KO mice were both age and sex 
matched. Mice were housed within individually ventilated cages (IVCs), a maximum of 
six mice per cage in a facility with a 12-hour light-dark cycle and ad libitum feeding of 
a standard laboratory chow diet and water. 
 
The genotype of the mice from the Gal-1 KO colony was routinely checked by 
extracting DNA from tissue samples of tail clippings. Genotype specific primers were 
added, and the DNA section amplified by a Polymerase Chain Reaction (PCR) cycle 
102 
 
which was followed by gel electrophoresis to visualise the final products, as described 
in section 2.4.3. 
 
2.2.3. Zymosan-induced Peritonitis 
 
Described as a simple experimental system for the study of inflammation (Cash et al., 
2009), zymosan induced peritonitis is most widely used in the assessment of short-
term acute inflammation and importantly the subsequent resolution.  The induction of 
an innate immune response in this model can be applied to investigate a variety of 
behaviours, including (but not limited to) stimulation of inflammatory mediator 
production, activation of complement and leukocyte recruitment as well as 
mechanisms of phagocytosis and efferocytosis (Aderem and Underhill, 1999). 
 
The i.p. administration of zymosan produces a common recruitment profile of 
inflammatory cells into the peritoneal cavity. Neutrophils are the first leukocyte to 
infiltrate the cavity, with their peak in number determining the peak of the inflammatory 
profile (Newson et al., 2014). Monocyte influx follows, whereby the recruited 
inflammatory monocytes mature into macrophages and neutrophil numbers decline 
respectively. The capacity of this model to quantify leukocyte recruitment has 
determined it suitable for many investigations. Thus, its applications now far extend its 
initial use to monitor the routine response seen in acute inflammation that is followed 
by self-resolution. The method is now frequently applied to the study of more novel 
factors and is suitable for considering endogenous anti-inflammatory pathways, the 
effect of mediator ablation, potential drugs and therapeutic strategies. The 
actions/responses attributed to both the endogenous and exogenous effects of 
individual cells, pathways and mediators can be assessed in this model. Specifically, 
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application to a knockout host can be used to examine the effects of endogenous 
mediators, whereas additional treatment, either prophylactically or therapeutically, can 
be used to consider the outcomes of exogenous agents.        
 
Much of the literature indicates that the inflammatory response to the typical acute 
dose of 1mg will resolve within around 72 hours post challenge although some 
resolving  mediators remain elevated until at least 96h post zymosan (Bannenberg et 
al., 2005; Damazo et al., 2006). The time point to resolution varies dependent on dose, 
with studies administering a lower 10µg dose evidencing 48 hours as the time frame 
to complete resolution (Cash et al., 2009). In this manner the 10mg high dose delayed 
resolving model will not typically be resolved until day 9 post challenge with some 
mediators still remaining increased  at day 13 post zymosan (Fujieda et al., 2013; 
Newson et al., 2014). 
 
In this current study a model of sterile peritonitis using zymosan as an inflammatory 
agonist to elicit an acute inflammatory response within the peritoneal cavity was used 
to assess the effect of Gal-1 on leukocyte recruitment and clearance. Application here 
utilised both the low (1mg) dose and high (10mg) dose models of zymosan peritonitis 
to respectively initiate an acute and delayed self-resolving inflammatory response.  
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2.2.3.1. Acute Resolving Model 
 
Peritonitis was performed with Gal-1 KO mice and WT counterparts or with WT mice 
administered hrGal-1 (10µg) to assess the effects of both endogenous and exogenous 
Gal-1. Mice aged 6-8 weeks were administered 1mg of zymosan in 500µl DPBS-/- by 
i.p. injection at the 0h time point. Mice treated with hrGal-1 were given a dose of 10µg 
in 200µl DPBS-/- i.p. at either 2h post zymosan (during the initiation phase of response) 
or at 8h post zymosan (during the peak phase of response). A 0.5ml insulin syringe 
with 27-gauge needle was used to perform the above i.p. injections. 
 
Mice were sacrificed at various time points (2, 6, 8, 24 or 48h) post zymosan, as 
depicted in figure 5A-C. Prior to its separation from the peritoneal cavity the skin above 
the peritoneum was sprayed with 70% ethanol and an incision made allowing for it to 
be pulled back and peritoneal lavage to be subsequently performed. A 25-gauge 
needle head attached to a 5ml syringe was used to administer 5ml ice cold DPBS-/- 
containing 2mM EDTA into the peritoneal cavity. The peritoneal cavity was gently 
massaged to dissociate attached cells and peritoneal lavage fluid was retrieved with a 
plastic pasteur pipette inserted into the cavity through a small incision made in the 
peritoneum. Exudate obtained was immediately transferred into 15ml falcon tubes and 





2.2.3.2. Delayed Resolving Model 
 
Peritonitis was performed with mice aged 6-8 weeks by administering 10mg zymosan 
in 500µl DPBS-/- by i.p injection at the 0h time point as described above. WT mice were 
administered hrGal-1 (10µg) or vehicle (200µl DPBS+/+) only control by daily i.p. 
injection from 24h post-zymosan (during the peak phase of response). The high dose 
of inflammogen used to initiate the inflammatory response in this model results in an 
extended period of recruitment and infiltration to the peritoneal cavity in an attempt to 
clear the insult. The influx is continuous for several days, as opposed to only hours in 
the acute (1mg) model and although the inflammation remains self-resolving resolution 
is considerably delayed in comparison.  
 
Mice were sacrificed at various time points (24, 72 and 120h) post zymosan, as 









Figure 5. Schematic time course for zymosan induced peritonitis model. 
(A) The timeline for endogenous Gal-1 protocols with peritoneal lavage performed at 2h, 6h, 24h, 48h. (B) The 
timeline for exogenous hrGal-1 protocols with treatment given at 8h and peritoneal lavage performed at 8h, 24h, 48h. 
(C) The timeline for exogenous hrGal-1 protocols with treatment given at 2h and peritoneal lavage performed at 6h. 
(D) The timeline for exogenous hrGal-1 protocol with treatment given daily from 24h and peritoneal lavage performed 





2.2.3.3. Total Cell Number 
 
Total cell numbers in the peritoneum were determined by cell counts using a Neubauer 
haemocytometer chamber. An Olympus BH-2 standard light microscope was used to 
visualise cells stained with Turk’s Solution on a Neubauer counting chamber at x40 
objective. Cells were counted in the larger four outer squares of the counting chamber, 
as indicated in figure 6. Total cell counts per mouse were calculated based on 5ml of 






Figure 6. Cell counting using a Neubauer haemocytometer chamber. 
(A) Counting grid on which cells are counted in each of the larger 4 outer corner squares (each composed of a 4x4 
grid) as indicated by the red squares. (B) Formula to calculate total number of cells per ml from the number of cells 
counted using the chamber. 
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2.2.3.4. Cell Recruitment and Clearance 
 
The peritoneal exudate retrieved was then analysed by flow cytometry for 
inflammatory cell type, neutrophil apoptosis (in vivo and ex vivo) and efferocytosis. 
Prior to staining cells with surface antibodies, the peritoneal exudate was vortexed, 
and 200µl was plated into a 96-well U-bottomed plate. Cells were pelleted by 
centrifugation (30 secs @ 800g) and the supernatant was discarded. Fc block diluted 
1:5 in FACS buffer (50µl per well) was added and cells were resuspended and 
incubated for 20 mins, on ice. After incubation addition of (100µl per well) FACS buffer 
(DPBS-/- with 0.02% BSA) was used to wash. Again, cells were pelleted by 
centrifugation and the supernatant discarded. 
 
For identifying immune cells, a panel of (CD11b, CD45, F4/80, Ly6G, SiglecF and 7/4) 
fluorescently conjugated antibodies at working dilution (Table 3) were added, cells 
were resuspended, covered and incubated for 30 mins on ice. Cells were washed 
twice with FACS buffer, pelleted by centrifugation, and the supernatant discarded 
before finally being resuspended in FACS buffer (200µl), transferred into FACS tubes 
and fixed by the addition of 4% PFA solution (50µl). The 4% PFA solution was 
prepared from PFA powder in DPBS-/- as follows: DPBS-/- was heated to 60°C on a 
heated stirring plate, PFA powder (w/v), was added followed by NaOH (dropwise) to 
elevate the pH and facilitate dissolution, once dissolved additional DPBS-/- was added 
to bring the solution to the required total final volume and the pH adjusted to 6.9 by 
addition of HCl (dropwise). 
 
Leukocyte (CD45+) subsets were identified using subtype-specific antibodies. 
Specifically populations of neutrophils (7/4+, Ly6G+) inflammatory monocytes (7/4+, 
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Ly6G-), macrophages (F4/80+) – including resolving macrophages (F4/80+, CD11b 
low) and mature macrophage (F4/80+, CD11b high) subsets and eosinophils 
(SiglecF+) were detected. Figure 7 shows the gating strategy used for this analysis. 
Firstly, doublet exclusion was performed using a forward scatter area (FSC-A) against 
forward scatter height (FSC-H) plot followed by a side scatter area (SSC-A) against 
side scatter width (SSC-W) plot. The single cell moieties were then used for subset 
specific leukocyte identification, which was quantified using CD45+ cells as the parent 
population and the subsequent percentage of positive cells by specific biomarker.  
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Figure 7. Zymosan induced peritonitis leukocyte gating strategy. 
(A) Murine leukocytes collected from peritoneal lavage were displayed on a Forward Scatter Area (FSC-A) against 
Side Scatter Area (SSC-A) plot and gated on to exclude debris. (B) Single cell moieties were obtained from the 
population by first plotting FSC-A against Forward Scatter Height (FSC-H)  to exclude doublet cells, followed by further 
doublets excluded by plotting this population on a SSC-A against Side Scatter Width (SSC-W) axis. (C) The population 
of singlets was plotted on an axis with the bandpass filter for the CD45 marker against SSC-A. This determined the 
leukocyte (CD45+) population from other events obtained. The relative cell numbers for specific hematopoietic cell 




For in vivo neutrophil apoptosis peritoneal exudates were analysed immediately post 
collection. For ex vivo neutrophil apoptosis 1ml peritoneal exudate was spun (5 mins 
@ 400g, RT) in a microcentrifuge, supernatant was collected (and stored at -80°C) for 
cytokine analysis. Pelleted cells were resuspended in RPMI – 1640 Medium + 0.5% 
BSA (1ml) and plated into 12-well cell culture plates. Plates were incubated in a 
humidified chamber in 5% CO2 at 37°C for 20 hours, after which 200µl cell suspension 
was plated into a 96-well U-bottomed plate. Cells were pelleted, Fc block added, and 
a wash performed (as described above). 
 
In both in vivo and ex vivo analyses an antibody to Ly6G, a marker expressed on 
murine neutrophils, was added, cells were resuspended and covered and incubated 
(30 mins, on ice). Cells were washed twice, pelleted, and the supernatant discarded 
followed by the addition of AnnexinV and Zombie (NIR or Aqua) or Propidium Iodide 
(PI) in (50µl per well) AnnexinV binding buffer. Cells were resuspended, covered and 
incubated (15 mins, at room temperature (RT)). After incubation 150µl AnnexinV 
binding buffer was added to each well and well contents were transferred to FACS 
tubes. Cells were analysed immediately by flow cytometry. 
 
Apoptosis of neutrophils was determined by first gating Ly6G positive cells, and then 
analysing the AnnexinV/Zombie or AnnexinV/PI staining by quadrant gating on the 
viable, early apoptotic, late apoptotic and necrotic populations. The gating strategy 































Figure 8. Zymosan induced peritonitis neutrophil gating strategy. 
(A) Murine leukocytes collected from peritoneal lavage were displayed on a Forward Scatter Area (FSC-A) against 
Side Scatter Area (SSC-A) plot and gated on to exclude debris. (B) Single cell moieties were obtained from the 
population by first plotting FSC-A against Forward Scatter Height (FSC-H)  to exclude doublet cells, followed by 
further doublet exclusion by plotting this population on a SSC-A against Side Scatter Width (SSC-W) axis. (C) The 
population of singlets was plotted on an axis with the bandpass filter for the Ly6G marker against SSC-A. This 
determined the neutrophil (Ly6G+) population from other events obtained. The subsequent percentages of neutrophil 




For efferocytosis a standard protocol for fixation followed by permeabilisation of cells 
was used. Firstly, an antibody to surface F4/80, an antigen expressed at high levels 
on peritoneal macrophage populations, was added, cells were resuspended, covered 
and incubated (30 mins, on ice). Following incubation cells were washed, pelleted, and 
the supernatant discarded, twice. Cells were resuspended in fixation buffer (200µl), 
covered and incubated (30 mins, at RT). Cells were pelleted, and the supernatant 
discarded. Permeabilisation buffer (200µl) was added in place of FACS buffer and the 
wash cycle performed twice. Secondly anti-Ly6G diluted in permeabilisation buffer 
(50µl) was added and cells were incubated (30 mins, at RT). The wash cycle was then 
performed three times. Finally, the cells were resuspended in FACS buffer (200µl) and 
transferred into FACS tubes for analysis. Efferocytosis was determined by gating on 
the macrophage specific surface biomarker (F4/80) followed by assessing this 
population for cells positive for the neutrophil specific biomarker (Ly6G), with the 









































Figure 9. Zymosan induced peritonitis efferocytosis gating strategy. 
(A) Murine leukocytes collected from peritoneal lavage were displayed on a Forward Scatter Area (FSC-A) against 
Side Scatter Area (SSC-A) plot and gated on to exclude debris. (B) Single cell moieties were obtained from the 
population by first plotting FSC-A against Forward Scatter Height (FSC-H)  to exclude doublet cells, followed by further 
doublet exclusion by plotting this population on a SSC-A against Side Scatter Width (SSC-W) axis. (C) The population 
of singlets was plotted on an axis with the bandpass filter for the Ly6G antibody on the x-axis against F4/80 on the y-
axis. This determined the neutrophil only (Ly6G+), macrophage only (F4/80+) populations as well as the population of 




2.2.3.5. Inflammatory Mediator Analysis 
 
Peritoneal exudate (1ml) was centrifuged (5 mins @ 400g, RT) and supernatant was 
collected and stored at -80°C. The supernatant samples from peritoneal lavages 
obtained 2h post zymosan were sent to Labospace (LaboSpace Ltd. Milan, Italy). 
Levels of analytes (see table 5) were measured using a custom designed mouse 





Table 5: Inflammatory mediators analysed in peritoneal exudate. 
Cytokine Class Production Target Cell (Interaction) 
Functions Detection Range (pg/ml) 
GM-CSF Cytokine (growth factor) 
Macrophages, T 
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IL-6 Cytokine (pro-inflammatory)  
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of leukocyte 
recruitment. 
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KC (CXCL1) Chemokine Induced by inflammatory 
cytokines (IL-1, 
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cancer. 
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0 – 1020 
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2.2.3.6. Bone Marrow Derived Macrophage Skewing 
 
Peritonitis was elicited in Gal-1 KO and WT mice by administration of 1mg of zymosan 
(in 500µl DPBS-/-) by i.p. injection at 0h and mice were sacrificed at 2h post zymosan. 
Following peritoneal lavage, the right hind limb of each mouse was collected into falcon 
tubes containing RPMI – 1640 + 2% FBS + 1% P/S and stored on ice.  
 
Bone marrow cells were collected from the femur of WT and Gal-1 KO mice following 
2h of inflammatory stimulation. Cells flushed from the bone were plated and 
differentiated into bone marrow derived macrophages (BMDMs) before being 
stimulated with macrophage skewing cytokines (Narayan et al., 2017; Rhys et al., 
2018; Wang et al., 2020), as displayed in figure 10. Stimulated cells were collected 
and stained with a panel of fluorescently conjugated antibodies to key macrophage 
biomarkers (MerTK, CD36, CD206, MHC-II and CD86). Samples were analysed by 
flow cytometry to determine if phenotypic differences existed between WT and Gal-1 




Figure 10. Schematic time course for differentiation and skewing of bone marrow derived macrophages.  
Mice (WT or Gal-1 KO) were sacrificed 2h post zymosan (1mg in 500µl PBS) and the right hind limb collected. Bone 
marrow was extracted from the femur, plated, differentiated to macrophage for 6 days and then stimulated with M1 
(10ng/ml LPS + 20ng/ml IFN-γ) / M2 (20ng/ml IL-4) to polarise macrophages for 3 days. Macrophage phenotyping 
was performed by flow cytometry to detect surface presentation of MerTK, CD36, CD206, MHC-II and CD86. 
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To free the femur from the rest of the limb the muscle was first cut away from the lower 
extremity, next, whilst ensuring not to break the femur head, the acetabulum was 
carefully dislocated from the hip joint. Ligaments attaching the femur and tibia were 
then snipped with scissors and the bones detached from one another by a gentle twist 
and pull action. Any remaining muscle was cleaned off the femur using a piece of 
gauze.  
 
To harvest the cells both ends were cut from the bone and the bevel of a 23-gauge 
needle attached to a 5ml syringe inserted into the bone marrow shaft. DPBS-/- + 1% 
P/S was slowly passed through the bone. Whilst flushing the needle head was used 
to gently scrape the inner surface of the bone to maximise cell recovery and flushing 
was performed until bone was clear. Bone marrow was passed through a 70μm cell 
strainer and collected in a 50ml falcon. The collected bone marrow was then 
transferred to a 15ml falcon and pelleted by centrifugation (10mins @ 425g). 
 
Following centrifugation, the supernatant was discarded, and the pelleted cells 
resuspended in 10ml culture media (RPMI 1640 + 20% FBS + 1% P/S + 10ng/ml mM-
CSF) and plated in 10cm cell culture plates. Plates were incubated at 37˚C, 5% CO2 
for 6 days allowing cells to differentiate into macrophages.  
 
After 6 days of cell culture, BMDM were detached from the 10cm culture plate and 
replated into a 24-well cell culture plate for skewing. The media was aspirated, and 
the 10cm culture plates washed with DPBS-/-. Macrophages were then incubated at 
37°C in 5% CO2 for 20 minutes with (3ml per plate) pre-warmed (37°C) accutase + 
0.5mM EDTA. Following incubation to detach the cells the bottom of the plate was 
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gently swept with a cell scraper and a 3ml pasteur pipette was used to flush the 
accutase solution around the plate several times to loosen any macrophages that may 
have remained attached. Cells in solution were then collected in a (15ml) falcon tube 
and detachment of macrophages from the plate confirmed by microscopy. Any 
remaining cells were collected by flushing the plate several additional times with 
DPBS-/- (3ml). Falcon tubes were topped up to 15ml with DPBS-/- and macrophages 
were pelleted by centrifugation (10 mins @ 425g, RT). 
 
Following centrifugation, macrophages were resuspended in 1ml media (RPMI – 1640 
Medium + 20% FBS + 1% P/S). BMDM cultured from each mouse were then divided 
into 3 wells of a 24-well cell culture plate (300μl per well) to skew to M0, M1, and M2 
phenotypes. For M0 no stimulant was added. For M1 (classical/pro-inflammatory) 
skewing macrophages were stimulated with 10ng/ml LPS and 20ng/ml IFN-γ whilst 
M2 (alternative / non-inflammatory) skewing of macrophages was performed by the 
addition of 20ng/ml IL-4. Macrophages were incubated in their stimulatory media at 
37˚C in 5% CO2 for 3 days.  
 
After 3 days the cultured BMDM were detached as described above. Cells were 
resuspended in FACS buffer (200μl) and plated into a 96-well U-bottomed plate for 
staining for flow cytometric analysis. For detecting expression of macrophage 
phenotypic markers, a panel of (MerTK, CD36, CD206, MHC-II, CD86 and F4/80) 
fluorescently conjugated antibodies was used.  Antibodies were added to wells at 
working dilution (see table 3) in (50μl) mouse Fc block (diluted 1:5 in FACS buffer), 
cells were resuspended in the solution, covered and incubated (30 mins, on ice). Cells 
were then washed twice with FACS buffer, pelleted by centrifugation, and the 
120 
 
supernatant discarded before finally being resuspended in FACS buffer (100µl), 
transferred into FACS tubes and fixed by the addition of 4% PFA solution (25µl). 
Samples were acquired (on an LSR Fortessa) and data was analysed by selecting the 
single cell populations, followed by F4/80+ and measuring the MFI for each of the 
antibody conjugated fluorochromes 
 
2.2.3.7. Peripheral Blood Profiling 
 
Peripheral blood was collected from mice and profiled across time in the delayed 
resolving model of peritonitis (as described in section 2.2.3.2). Briefly peritonitis was 
elicited by administering 10mg zymosan by i.p. injection at the 0h time point. WT mice 
were administered hrGal-1 (10µg) or vehicle (200µl DPBS+/+) only control daily from 
24h post-zymosan. At 72h and 120h post-zymosan blood was retrieved by cardiac 
puncture (as described in section 2.2.4.5.), withdrawn into a 1ml syringe and 
immediately transferred to 1.3ml EDTA Micro tubes.  
 
Whole blood (50µl) was ran on the ProCyte DX Haematolgy Analyser (IDEXX) as per 
manufacturer’s guidelines. The Analyser combines flow cytometry, optical 
fluorescence and laminar flow impedance to provide a comprehensive complete blood 




Table 6. ProCyte DX Haematolgy Analyser whole blood parameters. 
  
Parameter Description
RBC Total number of erythrocytes
HCT Hematocrit value: erythrocyte ratio of total blood volume
HGB Hemoglobin concentration
MCV Mean erythrocyte volume in total sample
MCH Mean haemoglobin volume per red clood cell (RBC) count
MCHC Mean haemogobin concentration of erythocytes. 
RDW The degree of variation in size of the erythrocyte population
%RETIC Reticulocyte percent
RETIC Reticulocyte count











PLT Total number of platelets
MPV Mean platelet volume 




2.2.4. K/BxN Serum Transfer Arthritis 
 
An inflammatory polyarthritis was induced in mice by i.p. injection of K/BxN serum. 
Arthritogenic serum was produced in-house from KRN/NOD mice as previously 
described (Kouskoff et al., 1996). The KRN/NOD colony was established from 
crossing KRN mice, which are heterozygous for the transgenic T cell receptor (TCR) 
KRN with NOD (non-obese diabetic; ShiLtJ) mice. Offspring (K/BxN) develop a 
spontaneous arthritis upon weaning and possess arthritogenic antibodies in their 
bloodstream (Kouskoff et al., 1996; Christensen et al., 2016). Consequently, serum 
isolated from these mice can induce disease in recipient animals. Arthritis was induced 
using a dosing strategy and volume of serum that elicits visible disease onset 




K/BxN serum transfer Arthritis was performed with Gal-1 KO mice and WT 
counterparts or with WT mice administered hrGal-1 (3µg) to assess the effects of both 
endogenous and exogenous Gal-1. Mice aged 10-12 weeks on a C57BL/6 background 
received two doses  of K/BxN serum, the initial dose was given on day zero and the 
subsequent on day two, for each dose serum was diluted 1:1 with DPBS-/- and 200µl 
administered by i.p. injection. 
 
2.2.4.2. Disease Profile 
 
Mice were assessed daily for weight loss and oedema and clinically scored for arthritis. 
Paw oedema was measured by use of a digital plethysmometer, which involved 
immersing the mouse paw into the water where a sensor notes a pressure change, 
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outputting the volume displacement measured with 0.01 ml resolution. Both hind paws 
were measured, and a mean value calculated. Clinical scoring for each paw was 
measured on a semi-quantitative scale. The ankle/wrist, pad and digits of all four limbs 
were assessed and a score was given to each of these three factors. Features of the 
appendages that were visibly swollen received a score of one whilst those that 
appeared normal/healthy were scored with a zero. From these scores a total value 
(maximum 12) for each mouse was then calculated, the scoring system used is shown 
in figure 11. 
 
To determine if endogenous Gal-1 has a role in this neutrophil driven model two 
separate experiments were performed. To obtain an idea of the full disease profile, 
where mice were monitored for 40 days and remission indices were calculated. Values 
indicated the time points when mice reached the maximum magnitude of arthritis 
(Tmax), when 50% of the maximum was reached (T50) and the resolution interval (Ri) 
determined as the time from Tmax to T50. A second experiment was performed for a 
duration of four days, a period determined based on the divergence previously seen 
between the two genotypes at this time and thus of interest to analyse the cellular 
infiltrate in both genotypes at that point. 
 
To explore whether exogenous hrGal-1 would influence neutrophil driven arthritis. WT 
mice were treated with hrGal-1 (3μg) or vehicle (20μl DPBS+/+) by intraplantar injection 
using a MicroFine syringe with 30-gauge needle. Mice were treated from day 3, when 
disease was established, and every alternate day thereafter before being sacrificed at 




Figure 11. K/BxN serum transfer induced arthritis clinical scoring. 
Digits, pads and ankle and wrist joints of mice given K/BxN serum were clinically assessed for swelling throughout 
the duration of the model. Digits of the upper (A) and lower (B) paws were given a score of one for inflamed digits, as 
indicated by black arrows. The wrist joint and pad of the upper limb (C) and ankle joint and foot pad of the lower limb 
(D) were also given a score of one for each independently swollen feature. All features were compared with the upper 







2.2.4.3. Isolation of Cells from Arthritic Paws and Analysis by Flow  
  Cytometry 
 
The effects of Gal-1 on cellular infiltrate into the paw was assessed for both the 
endogenous and exogenous protein due to the divergence in the role of the protein 
depending on its source. The role of endogenous Gal-1 on the cellular milieu within 
the inflamed paw was assessed at 4 days post K/BxN serum injection, a timepoint 
when inflammation is well established, but disease severity is still increasing.  
Exogenous Gal-1 was administered post disease establishment to assess its anti-
inflammatory/pro-resolving potential. As such, the cellular content of inflamed paws 
was assessed at 11 days post K/BxN serum injection, when inflammation in the joint 
is typically beginning to cease and resolve. In both cases mice were sacrificed at the 
specified time points and hind paws were collected and placed in ice-cold RPMI – 
1640 Medium prior to processing. Cells from the hind paws were isolated by 
performing a digestion protocol. 
 
Firstly, the sock of hair around the ankle was removed followed by the rest of the skin. 
Dissection scissors were used to cut from the top of the ankle down to the tip of the 
middle digit, the layer of skin was then pulled back and removed by use of mechanical 
force and dissection tweezers. Further dissection of the paw was performed by 
carefully cutting between the digits for the length of the paw, ensuring not to break or 
damage the bones. 
 
A digestion buffer was prepared by dissolving collagenase D (0.5ng/ml) and DNAse 
(40ng/ml) in RPMI – 1640 Medium, 15ml of this was then added to Erlenmeyer flasks. 
The dissected paws were each placed into their own flask along with a small metal 
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stirring bar and the flasks were covered. A first digestion cycle was then performed, 
whereby flasks were incubated at 37°C for 30 minutes on a magnetic stirrer set to a 
medium speed. The digestion solution was passed through a 70µm cell strainer and 
collected into 50ml falcon tubes containing 2ml FBS and kept on ice. A second 
digestion cycle, identical to the first, was performed with 15ml of fresh digestion buffer 
added to the dissected paws in the flasks. The digestion solution was again passed 
through a 70µm cell strainer and combined with the solution from the first round of 
digestion. The cell solution was spun (10 mins @ 425g, RT) and the supernatant 
discarded, and pelleted cells resuspended in 500µl RPMI – 1640 Medium. Cells were 
then transferred into a 96-well U-bottom plate for staining for flow cytometry analysis. 
 
After resuspension the cells isolated from the paw digestion were plated, 200µl per 
well, and pelleted by centrifugation (30 secs @ 800g). The supernatant was discarded, 
cells were resuspended in Zombie (Aqua) in (100µl per well) DPBS-/- then covered and 
incubated (20 mins, on ice). Following incubation, cells were pelleted by centrifugation 
and the supernatant discarded. To perform a wash, FACS buffer (100µl per well) was 
added and cells were resuspended then spun (30 secs @ 800g), this step was then 
repeated to wash once more. Fc block diluted 1:5 in FACS buffer (50µl per well) was 
added, cells were resuspended, covered and incubated (15 mins, on ice). After 
incubation, cells were washed again, pelleted by centrifugation and the supernatant 
discarded.  
 
For identifying immune cells a panel of (CD11b, CD45, CD64, F4/80, Ly6C, Ly6G, 
MHC-II and 7/4) fluorescently conjugated antibodies at working dilution in FACS buffer 
(see table 3) was added (100µl per well), cells were resuspended, covered and 
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incubated (30 mins, on ice). Cells were washed twice with FACS buffer, pelleted by 
centrifugation, and the supernatant discarded before finally being resuspended in 
FACS buffer (200µl) and transferred into FACS tubes. 
 
The panel of antibodies used for this staining includes some that are conjugated to 
fluorochromes that are tandem dyes. For this reason, extra precautions were taken 
when staining to ensure that the stability of the tandem is preserved. These dyes are 
considered less stable than single molecule fluorochromes due to their potential for 
degradation or decoupling which results in loss of emission from the acceptor and 
increased emission from the donor. Some tandem dyes are susceptible to cell-
mediated damage due to cell metabolism; hence staining was performed on ice. An 
additional risk to these fluorochromes is fixation. It is recommended that cells (if they 
must be fixed) are fixed for only for a short period of time due to the risk of over fixing. 
Therefore, the addition of 4% PFA (50µl), that would normally be used to fix stained 
cells, was omitted from the protocol when staining with this panel. Consequently, 
samples were run on an analyser (LSR Fortessa) immediately after staining. 
 
The fluorescently conjugated antibodies specific to the different biomarkers present 
on the surface of the cell were used to determine subsets of leukocytes (CD45+). 
Specifically, populations of neutrophils (CD64-Ly6G+) and macrophages (Ly6G-
F4/80+) were reviewed. The gating strategy used for the analysis firstly gated on single 
cell moieties, followed by live cells by exclusion of Zombie positive cells. 
Hematopoietic cells were then selected as the CD45+ population, which was then 
used as the parent population for gating on the CD11b+ myeloid cells. The myeloid 




2.2.4.4. Histological Staining and Analysis 
 
Histological staining and analysis were performed for both the 4 day and 40 day 
experimental arthritis for WT and Gal-1 KO mice. A hind limb joint was removed from 
each mouse and processed to enable histological analysis (see section 2.4.2.). Briefly, 
joints were fixed in neutral buffered formalin (NBF) and decalcified in 10% EDTA in 
DPBS-/- before being trimmed down, embedded in paraffin blocks, sectioned and 
transferred to slides. 
  
Haematoxylin and Eosin (H&E) staining was performed on deparaffinized sections to 
assess cell and tissue morphology and distribution including cellular infiltrate and 
pannus formation. Stained sections were viewed using standard light microscopy 
(EVOS™ XL Core Imaging System) and images were taken using the 4X objective. 
The resulting images from the H&E stain were analysed to assess the joints for 
severity of arthritis, scoring on a scale of zero to three by assessing the bones, 
cartilage, synovium, level of infiltrate (pannus formation) and overall joint architecture 
(including thickness of synovium). The analysis was performed blindly against a 
predetermined scoring system, with a scale from 0-3.  A score of zero was given to 
normal non-arthritic joints displaying normal architecture, with no signs of infiltration or 
damage. A score of one indicated the joint to be mildly arthritic where synovitis could 
be observed in the absence of damage. Joints that maintained their architecture but 
still showed moderate levels of arthritis including synovitis and damage were given a 
score of two. A top score of three was determined as severely arthritic where there 




2.2.4.5. Blood Collection 
 
Cardiac punctures, a technique suitable for collecting a large and good quality sample 
of blood from mice, were performed four days post initiation of disease. Isoflurane was 
used to deeply anaesthetise mice and blood samples were taken from the heart which 
was accessed via the left side of the chest or from underneath by going through the 
diaphragm. Blood was withdrawn slowly, to prevent the heart collapsing, using a 25-
gauge needle and collected into 1ml syringes.  Here syringes were prefilled with 100µl 
of 100U/ml heparin diluted in saline (ddH2O + 0.9% NaCl) as an anti-coagulant. In all 
cases this method was performed as a terminal procedure. 
  
2.2.4.6. Inflammatory Mediator Analysis 
 
Blood samples (0.5-1ml) were spun (10 mins @ 6000g, RT) and plasma was collected 
and stored at -80°C. The plasma samples from cardiac punctures were sent to 
Labospace (LaboSpace Ltd. Milan, Italy) and levels of analytes (see table 7) were 





Table 7. Inflammatory mediators analysed in plasma from blood. 
 
Cytokine Class Production Target 
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Efferocytosis was assessed by injecting fluorescently labelled apoptotic neutrophils 
(2.5 x 106 cells) into the peritoneal cavity of mice, allowing time for the macrophage to 
ingest the apoptotic cells and then collecting the cells from the peritoneal cavity for 
analysis. Efferocytosis was performed with Gal-1 KO mice and WT counterparts, both 
on a C57BL/6 background. 
 
This model was performed a number of times, the age of mice varied from 8-15 weeks 
across a number of experiments however in all cases the two genotypes were both 
age and sex matched for each individual experiment that was performed. Mice were 
injected with CFSE labelled apoptotic human neutrophils and efferocytosis was 
assessed following two time points (either 30 or 60 minutes) post injection.  
  
2.2.5.2. Preparation and Injection of Neutrophils 
 
Human neutrophils were isolated from the peripheral blood of healthy donors by 
double density centrifugation (as detailed in section 2.3.1.1). Isolated neutrophils were 
counted and resuspended (to 4 x 106 cells/ml) in RPMI – 1640 Medium for staining 
with CFSE. Resuspended cells were added to 50ml falcon tubes (10ml per tube) and 
CFSE (10µl dissolved in anhydrous DMSO at 5mM) was added at a final concentration 
of 5µM. Falcon tubes were wrapped in aluminium foil (to protect from light exposure) 




Following incubation fluorescence was quenched by addition of an equal volume 
(10ml) of FBS and the solution mixed by gently inverting the falcon tube several times. 
The cell solution was spun (10 mins @ 425g, RT), the supernatant discarded, and 
pelleted cells resuspended in 1ml RPMI – 1640 Medium. A washing step was then 
performed by topping up the cell solution to 10ml with RPMI – 1640 Medium, pelleting 
the cells by centrifugation (10 mins @ 425g, RT) and discarding the supernatant. 
CFSE labelled neutrophils were then counted, resuspended (to 4 x 106 cells/ml) in 
RPMI – 1640 Medium + 0.5% BSA and transferred in to a T25 culture flask. The flask 
was then placed upright (to minimise adherence to the surface) and incubated in a 
humidified chamber in 5% CO2 at 37°C for 20 hours to allow for neutrophils to undergo 
apoptosis. 
 
After incubation CFSE labelled neutrophils were collected from the culture flask and 
the cell solution was spun (10 mins @ 425g, RT), the supernatant discarded, and 
pelleted cells resuspended in 1ml DPBS-/- and counted. Apoptotic CFSE labelled 
neutrophils were resuspended (to 5 x 106 cells/ml) in DPBS-/- and the cell solution was 
kept covered. 
 
Administration to mice followed shortly after, 2.5 x 106 cells in 500µl DPBS-/- was 
delivered into the peritoneal cavity of mice by i.p. injection using a 0.5ml insulin syringe 
with 27-gauge needle. After 30 or 60 minutes, mice were sacrificed, and peritoneal 





2.2.5.3. Analysis by Flow Cytometry 
 
The peritoneal exudate retrieved was analysed by flow cytometry for efferocytosis. 
Prior to staining cells with surface antibodies, the cells from the peritoneal exudate 
were pelleted by centrifugation (5 mins @ 800g, RT), resuspended in 1ml FACS buffer 
and 200µl was plated into a 96-well U-bottom plate. Steps to pellet the cells, incubate 
in Fc block, wash cells, stain with antibodies and fix were then performed (as described 
in section 2.2.3.3). 
 
The fluorescently conjugated antibodies used for the staining included a marker for 
murine hematopoietic cells (CD45), a murine macrophage marker (F4/80) and a 
human neutrophil marker (CD66b). Antibodies were added at working dilution (see 
table 1) in (50µl) FACS buffer. Samples were run on a flow cytometry cell analyser 
(LSR Fortessa). 
 
To assess levels of efferocytosis the following gating strategy was applied, firstly 
debris was gated out, followed by selection of mouse haematopoietic cells using the 
CD45+ population. From this population cells expressing the human neutrophil marker 
CD66b, which is constitutively expressed on neutrophils independent of cell location, 
activation or disease state (Lakschevitz et al., 2016), were gated out by selecting the 
CD66b- population, to exclude macrophages with neutrophils attached to their surface. 
Murine macrophages were then gated on by selecting the F4/80+ population and the 




2.3. In vitro Methods 
 
2.3.1. Human Blood Leukocytes 
 
Human leukocytes were isolated from the peripheral blood of healthy volunteers using 
double density centrifugation. All donors gave informed consent and all work was 
performed under ethical approval (QMREC2014.61) granted by the QMUL Research 
Ethics Committee. 
 
Collected blood was handled quickly to prevent coagulation and steadily to avoid 
activation of the cells, likewise solutions that mix with the blood were warmed to 37°C 
prior to use. 
 
2.3.1.1. Neutrophil Isolation 
 
Blood was drawn from the median cubital vein using a 21-gauge butterfly needle and 
collected into a 60ml syringe. Blood was gently expelled from the syringe into a sterile 
pot containing an anti-coagulant. Specifically, 3.2% (w/v) sodium citrate (dissolved in 
dH2O) was used at a 1:10 ratio of anti-coagulant to blood volume. The pot was slowly 
tilted several times to disperse the anti-coagulant throughout the blood sample and 
RPMI – 1640 Medium was added (in equal volume to blood). 
 
The diluted blood (6ml per 15ml falcon tube) was then gently layered above a double 
density Histopaque layer. To create the double density Histopaque layer two solutions 
(composing of polysucrose and sodium diatrizoate) adjusted to specific densities 
(1.077 g/ml and 1.119 g/ml) were layered one above the other. Firstly Histopaque – 
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1119 (3ml) was added to the bottom of (15ml) falcon tubes, above which Histopaque 
– 1077 (3ml) was carefully added to create two separate layers. The blood and 
Histopaque was then spun (30 mins @ 400g, RT). Following the spin, separate layers 
of leukocytes, plasma and Histopaque were visibly formed (figure 12). 
 
Following centrifugation (30 mins @ 400g, RT) the neutrophil layer was collected from 
each of the tubes, transferred to new (15ml) falcon tubes and RPMI – 1640 Medium 
was added (in equal volume - 6ml of each). The blood and media were then spun (15 
mins @ 425g, RT) and the supernatant discarded. The remaining red blood cells were 
then lysed using ice cold water (7.5ml) and falcon tubes were gently inverted (10 
seconds). To return solution to an isotonic balance 3.6% (w/v) sodium chloride 
(dissolved in dH2O) was added at a 1:3 ratio of salt solution to cell solution. The 
solution was then spun (10 mins @ 425g, RT), the supernatant was discarded and 
remaining pelleted neutrophils were resuspended in RPMI – 1640 Medium (1ml) and 
counted using Turk’s Solution. The neutrophil suspension was added to Turk’s 
Solution (10µl to 990µl respectively) to give a final dilution of 1:100 and cells were 
counted on a Neubauer counting chamber (as described in section 2.2.3.3). Following 
the count neutrophils were resuspended in media (type and volume dependant on 





Figure 12. Leukocyte separation using double density centrifugation. 
Whole blood was layered above two different density histopaque solutions (1.077g/ml and 1.119g/ml). Following 
centrifugation leukocyte subsets separate out according to their density and the density of the solutions. Plasma cells, 
mononuclear cells, polymorphonuclear cells and erythrocytes form individual layers, as shown, due to their respective 




2.3.1.2. Monocyte Isolation   
 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy cones. Cones 
were obtained in collaboration with a hospital-based phlebotomy facility and were 
produced from blood drawn from healthy donors. The cone, also known as a 
Leukocyte reduction system chamber (LRSC) is the fraction of blood leftover following 
platelet collection. The platelet rich fraction obtained from centrifugation of whole blood 
(450ml) will also contain leukocytes, which are then filtered out by leukoreduction and 
collected into an LRSC. The LRSC will contain a high density of leukocytes with a low 
concentration of neutrophils (relative to both the PBMC population and proportion 
present in peripheral blood). 
 
Each buffy cone contained 20ml of blood which was collected into a 50ml falcon tube. 
The cone was pointed upwards and the tubing coming from the tip was cut, the open 
end was put into the falcon and the cone inverted so that blood drained into the falcon. 
The tubing attached to the other broader end was cut and a 21-gauge needle inserted. 
A 30ml syringe containing 20ml DPBS-/- was attached to the needle and flushed 
through the cone. The syringe was then refilled with air and the cone was flushed to 
release any remaining liquid. The blood (diluted 1:1 with DPBS-/-) was then gently 
layered above 10ml Histopaque – 1077 in new 50ml falcon tube. The blood and 
Histopaque was then spun (30 mins @ 400g, RT) to separate out layers of leukocyte 
subsets from plasma.  
 
Following centrifugation, the PBMC layer was collected from the tube, transferred to a 
new (50ml) falcon tube and DPBS-/- (to 50ml) was added. The diluted PBMCs were 
then spun (10 mins @ 425g, RT) and the supernatant discarded.  
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2.3.1.3. Monocyte Derived Macrophages 
 
PBMC were isolated from a buffy cone (as in section 2.3.1.2.), following the final 
centrifugation the pelleted PBMC were resuspended in DPBS+/+ (15ml) and counted 
using Turk’s Solution (as described in section 2.2.3.3). PBMC were then resuspended 
to 30 x 106/ml in DPBS+/+ and plated into 10cm bacteriological dishes, 1ml cells added 
to 6ml DPBS+/+ to give a final concentration of 30 x 106 cells in 7ml DPBS+/+ per plate.  
 
The plate was then incubated in a humidified chamber with 5% CO2 at 37°C for one 
hour to allow monocytes to adhere to the plate. Adherence was confirmed using 
standard light microscopy and the solution aspirated. Cells were then washed three 
times with DPBS-/- (5ml per plate added, swirled around the plate, and aspirated) and 
then recovered with RPMI – 1640 Medium + 20% FBS + 50ng/ml hrM-CSF + 1% P/S. 
The plate was then incubated in a humidified chamber in 5% CO2 at 37°C for six days 
(with media refreshed on day 3) to allow for monocytes to differentiate to 
macrophages. 
 
To detach macrophages from the plate, culture medium was aspirated, and plates 
were washed with DPBS-/- (as described above). Warmed (37°C) accutase + 0.5mM 
EDTA (3ml) was overlaid and cells were incubated in a humidified chamber in 5% CO2 
at 37°C for 20 minutes to allow macrophages to detach. After the incubation period a 
cell scraper was gently swept across the bottom of the plate to detach the cells and 
the plate flushed several times with the accutase solution using a 3ml pasteur pipette. 
The cells in solution were then collected, added to a (15ml) falcon tube and the plate 
checked under a light microscope to confirm detachment of macrophage from the 
bottom of the plate. DPBS-/- (3ml) was then added to the plate and used to flush around 
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the outsides several times to collect any remaining cells. Falcon tubes were topped up 
to 15ml with DPBS-/-, spun (5 mins @ 425g, RT) and the supernatant discarded leaving 
the pelleted macrophages.   
         
2.3.2. Neutrophil Apoptosis 
  
Neutrophils isolated from human peripheral blood (as in section 2.3.1.1.) were treated 
with hrGal-1 (0.03, 0.1, 0.3 and 1μM) ± human recombinant Granulocyte Macrophage 
Colony Stimulating Factor (GM-CSF, 50ng/ml), which is known to delay neutrophil 
apoptosis (Colotta et al., 1992). In additional assays, instead of GM-CSF, neutrophils 
were treated with serum amyloid A (SAA, 10µg/ml), an apolipoprotein in plasma 
likewise reported to delay the spontaneous apoptosis of neutrophils (Christenson et 
al., 2008). 
  
Neutrophils were incubated for 20 hours and levels of apoptosis were primarily 
determined by AnnexinV (AnxV) binding and Propidium Iodide (PI) staining using flow 
cytometry. Samples were also stained with 3,3′-dihexyloxacarbocyanine iodide 
(DiOC6), a lipophilic dye that is selective for the mitochondria of live cells and cytospins 
of viable (0h) and apoptotic (20h) cells performed, to provide accompanying methods 
for the quantification of apoptosis. 
 
To determine whether Gal-1 influences initial PS exposure neutrophils isolated from 
human peripheral blood were also assessed by AnxV/PI staining at 1h and 4h (± GM-




Neutrophils were resuspended (2 x 106 cells/ml) in RPMI – 1640 Medium + L-glutamine 
(L-glut, 2mM) + 5% autologous serum. Autologous serum was collected from 
neutrophil donors by transferring blood into 1.1ml Z-Gel Micro tubes containing a gel 
matrix specialised for serum separation. Tubes were spun (10 mins @ 10000g, RT) 
and as a result the blood cells pelleted below the gel matrix and the serum remained 
above. The serum was collected from the tubes and placed on ice until required for 
media preparation. 
 
Neutrophils were then transferred in to a 96-well u-bottom plate (200µl per well) and 
treated as described above. The plates were then incubated in a humidified chamber 
in 5% CO2 at 37°C for 20 hours to allow for neutrophils to undergo apoptosis.  
 
2.3.2.1. AnxV/PI  
 
After incubation cells were pelleted by centrifugation (30 secs @ 800g), the 
supernatant was discarded, and pelleted cells stained for AnxV/PI. AnxV binds to PS 
on the neutrophil extracellular membrane, whereas PI is a membrane permeable dye 
able to enter the cell when there is a loss of outer membrane integrity.   
 
AnnexinV/PI in AnnexinV binding buffer (50µl) was added to each well. Cells were 
resuspended, covered and incubated (15 mins, RT). AnnexinV binding buffer (150µl) 
was then added to each well and the contents transferred to FACS tubes. Cells were 
analysed by flow cytometry immediately after staining. Apoptosis of neutrophils was 
determined by analysing the AnnexinV/PI staining of single cells by quadrant gating 


































Figure 13. In vitro neutrophil apoptosis gating strategy. 
(A) Human neutrophils isolated from peripheral blood were displayed on a Forward Scatter Area (FSC-A) against Side 
Scatter Area (SSC-A) plot and gated on to exclude debris. (B) Single cell moieties were obtained from the population 
by first plotting FSC-A against Forward Scatter Height (FSC-H)  to exclude doublet cells, followed by further doublet 
exclusion by plotting this population on a SSC-A against Side Scatter Width (SSC-W) axis. (C) Neutrophils that were 
single stained for either AnnexinV (AnxV) or Propidium Iodide (PI) were used to apply gating. (D) The population of 
singlets was plotted on an axis with the bandpass filter for AnxV against PI. The subsequent percentages of neutrophil 




2.3.2.2. Nuclear Morphology 
 
Cytospins were prepared by centrifuging (30 secs @ 800g) the incubated plate and 
resuspending the pelleted cells in DPBS-/- (100µl). Samples (50µl) were then added to 
a cytospin chamber and cells were spun for 3 mins @ 200g. Slides were removed and 
left to air dry prior to staining.  
 
Once dry cells were fixed with methanol, left to air dry and then stained using Kwik-
Diff Staining System. Specifically, neutrophils were exposed to solution 2 for three 
minutes, after which it was then tipped off the slide. Solution 3 was then pipetted on 
and left for five seconds, followed by a wash, whereby distilled water was pipetted on 
and immediately tipped off several times until running off the slide clear. Slides were 
left to air dry and a coverslip applied using Entellan mounting medium. Once dry, 
stained slides were visualised under light microscopy using the 60x objective.  
 
To provide differential cell counts 200 cells were counted on each cytospin and 
apoptotic neutrophils, determined morphologically by the condensed nuclei as shown 




  Figure 14. Neutrophil nuclear morphology. 
Cytospins of human neutrophils isolated from peripheral blood were stained using Kwik-Diff Staining System and 
visualised under light microscopy using the 60x objective. Nuclear morphology was assessed to determine cell viability. 
Neutrophils were considered viable, indicated by the green arrows, when a multi-lobular nucleus was present whereas 





After incubation cells were pelleted by centrifugation (30 secs @ 800g), the 
supernatant was discarded and pelleted cells stained for DiOC6, a lipophilic dye that 
stains the organelle membranes within live cells. The cell permeant dye has 
particularly high specificity for the mitochondrial membrane and thus can be used to 
determine the depletion of mitochondrial membrane potential that occurs as cells 
undergo apoptosis. 
 
For DiOC6 staining a working concentration of 40nM of dye was added to cells. This 
was prepared from a 4µM stock solution of DiOC6 (dissolved in EtOH) that was further 
diluted (1:100) in RPMI – 1640 Medium. Pelleted cells were then resuspended in the 
diluted dye (200µl per well), covered and incubated in a humidified chamber in 5% 
CO2 at 37°C for 30 minutes. After this the plate was spun (30 secs @ 800g), 
supernatant was discarded and pelleted cells were washed in FACS buffer (100µl), 
the washing steps were then repeated. Finally, the cells were resuspended in FACS 
buffer (200µl), transferred to FACS tubes and analysed immediately by flow cytometry. 
Apoptosis of neutrophils was determined by analysing the DiOC6 staining of single 
cells, by gating on the viable (DiOC6 high) population of cells. 
 
2.3.2.4. Signalling Pathways 
 
Intracellular signalling pathways known to be involved in neutrophil apoptosis were 
investigated by Western blot (see section 2.4.4.). Neutrophils ± hrGal-1 (1μM) ± GM-
CSF (50ng/ml) were incubated at 37˚C (in a water bath) for 1, 5 and 15 mins prior to 
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being immunoblotted for the phosphorylated forms of AKT, ERK and p38 MAPK as 
well as their respective totals. 
 
For this assay neutrophils were isolated from human peripheral blood (as in section 
2.3.1.1.) with the omission of the red cell lysis step to reduce neutrophil activation and 
resuspended to 2 x 106 neutrophils in 150µl RPMI – 1640. Following stimulations 
neutrophils were lysed with 50µl hot Western blot loading buffer (LDS + DTT, 95˚C) 
and a standard Western blot protocol followed (see section 2.4.4.). 
 
2.3.3. Neutrophil AnnexinA1 Expression 
 
Annexin A1 (AnxA1) is an endogenous protein that exerts anti-inflammatory and pro-
resolving effects over many cellular events, thus limiting the extent of the inflammatory 
response. Contained within neutrophil gelatinase granules, endogenous AnxA1 is 
rapidly translocated to the cell surface upon activation (Perretti and D’Acquisto, 2009), 
furthermore it can override pro-survival signals to induce neutrophil apoptosis (El Kebir 
et al., 2008).  
 
This assay set out to determine if incubation of neutrophils ± GM-CSF ± hrGal-1 
modulates the levels of cellular AnxA1 during apoptosis. Neutrophils isolated from 
human peripheral blood (as in section 2.3.1.1.) were diluted in culture media (2 x 106 
cells/ml in RPMI 1640 + L-Glut + 5% autologous serum) treated with hrGal-1 (1μM) ± 
GM-CSF (50ng/ml) in a 96-well u-bottom plate (200µl per well) and incubated at 37°C 
5% CO2 for 4h or 20h. After incubation cells were pelleted by centrifugation (30 secs 
@ 800g) and the culture media was collected. Neutrophils were then resuspended in 
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FACS buffer and samples divided equally between two 96-well u-bottom plates, to 
assess surface and total staining.  
 
 2.3.3.1. Surface Expression 
 
Neutrophils were stained for surface AnxA1 using an unconjugated mouse anti-
human AnxA1 primary antibody diluted with blocking immunoglobulins (1:1 in FACS 
buffer, 50µl per well) and incubated (30mins, on ice). Neutrophils were then pelleted 
by centrifugation (30 secs at 800g) and the supernatant discarded. Cells were 
washed twice in FACS buffer (200µl) and a fluorescently conjugated anti-Mouse 
secondary antibody was added, and cells incubated (30 mins, on ice). Finally, cells 
were washed twice in FACS buffer and stained neutrophils were collected (in 200µl 
FACS buffer per well), transferred to FACS tubes and fixed with (50µl) 4% PFA. 
Samples were acquired (on an LSR Fortessa), the single cell populations were 
selected and their MFI of the conjugated secondary to the AnxA1 primary antibody 
was assessed. 
 
 2.3.3.2. Total Expression 
 
Total neutrophil AnxA1 was assessed using a standard protocol for fixation followed 
by permeabilisation of cells. Pelleted neutrophils were resuspended in (200µl) Fixation 
buffer and incubated (30 mins, at RT). Cells were then pelleted by centrifugation and 
the supernatant discarded followed by two wash cycles with permeabilisation buffer 
(200µl). An unconjugated mouse anti-human AnxA1 primary antibody was added in 
permeabilisation buffer (50µl per well) and cells were incubated (30 mins, at RT). After 
incubation two wash cycles with permeabilisation buffer (200µl) were performed. An 
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anti-Mouse secondary antibody conjugated with a fluorochrome was added (50µl per 
well) in permeabilisation buffer and cells were incubated (30 mins, RT). Incubation 
was followed by three wash cycles with permeabilisation buffer (200µl) after which 
cells were resuspended in FACS buffer (200µl) and transferred into FACS tubes. 
Samples were acquired and analysed as above (in section 2.3.4.1). 
 
 2.3.3.3. Release 
 
To detect release of AnxA1 from neutrophils, cell free culture media was collected after 
4h and 20h incubation and analysed by Western blot (see section 2.4.4.). Following 
incubation cells were pelleted by centrifugation and the cell culture media was 
collected in to Eppendorfs. A subsequent centrifugation (5min @ 400g) was performed 
to ensure media was free from cells or cellular debris. Loading buffer (LDS + DTT, see 
section 2.4.4.1.) was diluted 1:4 with the collected supernatant (5μl buffer to 15μl 
media) and samples were incubated at 95˚C on a heat block for 5 minutes. Prepared 
samples were then stored at -20˚C prior to loading 10μl and following a standard 
Western blot protocol (see section 2.4.4.2. onwards). 
 
2.3.4. Neutrophil Galectin-1 Expression & Binding 
 
Extracellular Gal-1, exogenously bound and/or endogenously expressed, was 
detected on neutrophils using flow cytometry. This assay was performed to determine 
the relative levels of Gal-1 on the surface of neutrophil as they move through the 
process of apoptosis. Likewise it was also used to establish if the Gal-1 detected on 
the surface was coming from the addition of the exogenous protein binding to the cell 
or if it originated intracellularly and if its exposure at the cell surface was modulated as 
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a consequence of undergoing apoptosis. Whether the exogenous Gal-1 had a higher 
affinity for binding the viable or apoptotic neutrophils was also addressed as was 
whether the bound Gal-1 would again dissociate from the cell surface in the presence 
of a competitive binding sugar. 
 
Neutrophils isolated from human peripheral blood (as in section 2.3.1.1.) were diluted 
in culture media (2 x 106 cells/ml in RPMI 1640 + L-Glut + 5% autologous serum) 
treated ± hrGal-1 (1μM) ± GM-CSF (50ng/ml) in a 96-well u-bottom plate (200µl per 
well) and incubated at 37°C, 5% CO2. Surface Gal-1 was assessed after 1h, 4h and 
20h incubation. Serum free incubations and addition of lactose (30mM) were also 
included as further controls in some assays. 
 
Following the incubation period neutrophils were pelleted by centrifugation (30 secs 
@ 800g), the supernatant was discarded, and cells surface stained for Gal-1 using an 
unconjugated primary antibody to human Gal-1 followed by a conjugated secondary 
to the antibody host. The anti-hGal-1 primary was diluted to working concentration 
(table 1) in FACS buffer with blocking immunoglobulins (1:1), 50μl was added to each 
well and neutrophils were resuspended and incubated (30mins, on ice). Neutrophils 
were then spun, and the supernatant discarded followed by two washes with (200μl) 
FACS buffer. Cells were then resuspended in FACS buffer (50µl per well) containing 
fluorescently conjugated anti-Goat secondary antibody and incubated (30 mins, on 
ice). Cells were then washed twice in FACS buffer before being resuspended in 
(200µl) FACS buffer, transferred to FACS tubes and fixed with (50µl) 4% PFA. 
Following sample acquisition, data was analysed by selecting the single cell 
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populations and measuring the MFI of the conjugated secondary to the hGal-1 primary 
antibody. 
 
2.3.5. Neutrophil Galectin Receptor Expression & Binding 
 
Galectins bind specific transmembrane glycoproteins expressed on nucleated 
haematopoietic cells. Assessment of receptor expression on neutrophils was 
performed ± GM-CSF to investigate whether the galectin binding glycoproteins on the 
cell surface, were modified in response to this pro-survival cytokine. In this set up 
neutrophils were also incubated ± hrGal-1 to determine if there was any alteration to 
the binding capacity of Gal-1. 
 
Neutrophils isolated from human peripheral blood (as in section 2.3.1.1.) were diluted 
in culture media (1 x 106 cells/ml in RPMI 1640 + L-Glut + 5% autologous serum) 
treated with hrGal-1 (0.03μM, 0.1μM, 0.3μM and 1μM) ± GM-CSF (50ng/ml) in a 96-
well u-bottom plate (200µl per well) and incubated at 37°C for 4 hours. Neutrophils 
were then pelleted by centrifugation (30 secs @ 800g), the supernatant discarded and 
then surface stained for CD43, CD44 and CD45, three known Galectin receptors 
(reviewed in (Rabinovich et al., 2002)). 
 
Cells were resuspended in 40µl per well mix of fluorescently conjugated antibodies to 
CD43 and CD45 and an unconjugated primary antibody for CD44. Antibodies were 
diluted to working dilution (table 3) in FACS buffer with blocking immunoglobulins (1:1) 
and incubated (1h, on ice). Neutrophils were then washed three times in FACS buffer 
followed by incubation (30 mins, on ice) with 40µl per well fluorescently conjugated 
anti-rat secondary. Cells were then washed three times, resuspended in 200µl FACS 
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buffer and fixed with 50µl 4% PFA. Galectin receptor levels were determined by 






Efferocytosis was assessed by overlaying human neutrophils (2 x 106 or 5 x 106 cells 
in 1ml) on human macrophages (1 x 106 cells/well), allowing time (1h) for the 
macrophage to phagocytose the cells and then collecting the cells from the well for 
analysis by flow cytometry. 
 
The protocol was used to assess whether neutrophils undergoing apoptosis ± hrGal-
1 (1μM) ± GM-CSF (50ng/ml) would be efferocytosed any differently as a result of 
either agent. The assay was also performed with two different macrophage:neutrophil 
ratios for consideration of macrophage efferocytic satiation. Furthermore, the addition 
of hrGal-1 (1μM) to both viable and apoptotic neutrophils (1h) prior to and during their 
addition to macrophages was used to determine whether Gal-1 served as an opsonin.  
 
2.3.6.2. Preparation of Macrophage  
 
Monocytes were isolated from buffy cones (as in section 2.3.1.2.) and differentiated 
to macrophage (as in section 2.3.1.3). Following centrifugation macrophages were 
counted and diluted to 1 x 106/ml in media (RPMI – 1640 Medium + 20% FBS + 1% 
P/S), plated (1ml per well) in a 6-well cell culture plate and incubated overnight at 
37°C with 5% CO2.   
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2.3.6.3. Preparation and Incubation of Neutrophils 
 
Neutrophils were isolated from human peripheral blood (as in section 2.3.1.1.) and 
assayed in one of the following ways: 
• Cultured in media (RPMI 1640 + L-Glut + 5% autologous serum) ± hrGal-1 
(1μM) ± GM-CSF (50ng/ml) and incubated (at 37°C 5% CO2) overnight. 
Apoptotic cells were then collected, counted and resuspended to either 2 x 106 
cells/ml or 5 x 106 cells/ml in media (RPMI 1640 +1% FCS). 
• Cultured in media (RPMI 1640 + L-Glut + 5% autologous serum) and incubated 
(at 37°C 5% CO2) overnight. Apoptotic cells were then collected, counted and 
resuspended to 2 x 106 cells/ml (RPMI 1640 +1% FCS) ± 1μM hrGal-1. 
Apoptotic cells were incubated (at 37°C, 5% CO2) for a further hour prior to 
overlay on macrophages. 
• Freshly isolated neutrophils resuspended to 2 x 106 cells/ml were incubated (at 
37°C, 5% CO2) for 1h in media (RPMI 1640 +1% FCS) ± 1μM hrGal-1 prior to 
overlay on macrophages. 
 
2.3.6.4. Analysis by Flow Cytometry. 
 
Following the 1h co-incubation of neutrophils and macrophages media was aspirated, 
and the wells were washed with DPBS-/-. Macrophages were collected using accutase 
+ 0.5mM EDTA (1ml) as described previously (see section 2.3.1.3).  
 
Pelleted cells were resuspended in FACS buffer (500μl) and 200µl was plated into a 
96-well U-bottomed plate. For staining a standard protocol for fixation followed by 
permeabilisation of cells was used as described previously (see section 2.3.3.2). Cells 
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were stained for the human neutrophil and macrophage biomarkers, CD66b and CD86 
respectively. Samples were run on a Flow cytometer (LSR Fortessa) and efferocytosis 
was confirmed as cells double positive for both the macrophage and neutrophil specific 
biomarkers. The MFI of the anti-CD66b antibody was used to compare the relative 
quantity of neutrophils engulfed by individual macrophages.  
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2.4. Supporting Protocols 
          
2.4.1. Flow Cytometry 
 
 Flow cytometry is a high throughput laser-based method used for the purposes of 
counting, sorting and profiling cells (and other particles). It is used extensively and is 
a common approach for whole blood analysis, isolation and characterisation of rare 
populations and immunophenotyping, as well as for assessing cell cycle and cell 
viability.  
    
2.4.1.1. The Flow Cytometer 
 
The flow cytometer consists of three core systems: fluidics, optics and electronics and 
has the ability to analyse thousands of particles per second. The fluidics system is 
responsible for the hydrodynamic focusing and includes the flow cell, the site where 
the sample and sheath fluid are injected and combined to ensure the entities in the 
sample are carried in single file. The sample then reaches the laser intercept which 
precedes the optic system within the machine. Multiple sources, filters and detectors 
of light make up the optic system, where laser beams of various wavelengths are used 
to screen the sample, if these provoke ‘excitation’ of elements within the sample then 
‘emission’ of light follows.  
 
2.4.1.2. Acquiring Sample Populations  
 
Forward light scatter (FSC), side light scatter (SSC) and fluorescence are the key 
parameters detected and measured by the machine, with each providing distinct 
information. Particle size can be understood using the FSC parameter as larger 
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entities will produce more forward scattered light. As opposed to FSC, which is light 
that continues to travel in the same direction as its original path regardless of making 
contact, SSC is the light that is refracted in different directions following contact and 
can be used to discern the complexity of the entity. Specifically, SSC provides 
information on granularity whereby a positive correlation links the two.  
 
Populations can often be separated based on FSC and SSC alone, however it is often 
more robust a method to do so using protein expression. The most common approach 
to this involves staining with fluorescently conjugated antibodies specific to cell surface 
antigens. A blocking step, with recombinant Fc protein, is used to reduce false positive 
(non-specific) results and high fluorescent background that can result from 




Fluorescence compensation is required when there is spectral overlap between 
fluorophores which occurs when, in addition to falling within its selected filter, there is 
also a ‘spill over’ of fluorescein into other filters/channels. Each individual fluorophore 
will emit photons of multiple energies and wavelengths, as a result, many of the 
fluorophores used in flow cytometry will have some degree of overlapping emission 
spectra and moreover emission from a single fluorophore will be measured by multiple 
detectors. To address the measurement of the photons of one fluorophore in multiple 
detectors, the spill over from the primary signal into a secondary channel must be 




Compensation is a mathematical method aimed at ensuring that erroneous 
contributions of fluorochromes don't affect the distribution of the data. Single stained 
samples are used to reveal the amount of spectral overlap, thus by running a positively 
stained single sample for each fluorochrome the amount of spill over is revealed. The 
values obtained can be combined and mathematically converted into a compensation 
matrix (Bagwell and Adams, 1993).  
 
Most often it is considered best practice to use automatic compensation, provided by 
either a package on the flow cytometer itself or preferably by third-party software, due 
to the complexity of the methodology.  
 
2.4.1.4. Compensation Samples 
 
Compensation beads is often an advantageous approach to obtain the required 
samples. Although cells can in many cases be used successfully as compensation 
controls, risks such as low antigen expression or cell number can result in the staining 
not being bright enough and/or not acquiring enough events.  
 
In the current study, compensation controls have been prepared using compensation 
beads, specifically UltraComp eBeads™, which compose a mix of positive and 
negative beads. Within the suspension the positive beads are reactive to hamster, 
mouse and rat antibodies and provide a positively stained population, the negative 
beads are non-reactive and will not bind antibody, thus serving as a negative (un-




To prepare compensation samples using the beads Eppendorf tubes containing 20𝜇l 
of beads and 100𝜇l FACS buffer are prepared for each of the antibodies, 1𝜇l of an 
antibody is added in singular to each of the tubes and the solution gently vortexed. 
The antibody and bead solution are then incubated in the dark at room temperature 
for 20 minutes. Following incubation an additional 1ml of FACS buffer was added to 
the tubes which were then spun (5 mins @ 500g, RT) in a micro-centrifuge.  FACS 
buffer was aspirated and the pelleted beads resuspended in (250µl) fresh FACS 
buffer. Samples were then stored at 4°C before being ran on a flow cytometry cell 





2.4.2.1. Fixation with Neutral Buffered Formalin 
 
A hind leg from each mouse was collected into a solution of 10% NBF (10% 
formaldehyde (w/v), 0.4% sodium phosphate monobasic (w/v) and 0.65% sodium 
phosphate dibasic (w/v) dissolved in ddH2O and equilibrated to pH 7.4), a solution 
considered to be more effective than other simple formalin mixtures. The phosphate 
salts present in NBF offer a protective effect for erythrocytes during the fixation 
process and the formation of formalin pigment is prevented by the neutral pH of the 
solution. 
 
The fixative volume was approximately 20 times the volume of the tissue being fixed, 
samples were kept sedentary in solution for 48 hours (at room temperature). Tissues 
must have sufficient time in fixation solution to allow for the chemical reactions required 
for crosslinking to occur. Crosslinking is essential to provide the cellular and fibrous 
elements protection from damage that may be caused using decalcifying agents and 
dehydrating ethanol in later steps. 
 
2.4.2.2. Decalcification with Ethylenediaminetetraacetic Acid 
 
Following fixation, the samples were then placed in a solution of 10% EDTA (w/v) pH 
7.4. The EDTA acts as a chelating agent, facilitating the formation of two or more 
coordinate bonds between a multiple bonded ligand and a single atom, after being 
bound by EDTA, calcium ions will remain in solution, but reactivity is diminished. 
Routinely refreshing the EDTA is essential for the continual removal of calcium ions, 
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consequently the solution was changed 1-2 times per week continuously until the 
tissue samples had thoroughly decalcified. The process was performed at room 
temperature and was aided by standing the samples in solution on a shaker to provide 
gentle agitation. Thorough decalcification was determined by physically testing the 
pliability of the joint. Firstly, feeling the specimen for remaining calcified areas followed 
by gentle manipulation and secondly by piercing the bone with a fine needle. The bone 
bending without resistance and the needle penetrating the bone indicated the end 
point of the process. 
  
2.4.2.3. Paraffin Embedding and Sectioning 
 
After the decalcification process the leg was sectioned further. Separating the ankle 
and knee joint segments from each other, the ankle section was then cut through the 
sagittal central plane. The result of this was a roughly cube shaped section of the knee 
joint as well as two equal sections containing the ankle joint (figure 15). 
 
The prepared samples were placed in individual cassettes, remaining acid was 
washed out by overnight storage in ddH2O, following which cassettes were put in to 
70% EtOH and sent for paraffin infiltration. This procedure dehydrates the tissue 
through a series of graded ethanol baths to displace the water, before being infiltrated 
with wax in a tissue processor (Leica). The tissue samples were then embedded into 
moulds using hot paraffin wax and the resulting blocks left to cool and harden on a 
cold plate (-4°C), solidified blocks were then removed from their moulds. These went 
on to be trimmed and sectioned on the microtome (Leica) to a thickness of 5μm and 





Figure 15. Procedure for sectioning of decalcified joint.  
The procedural steps (1-6) taken to section the decalcified joint are displayed. Six cuts are made along different planes 
of the joint. The section that results is a roughly cube shaped knee joint section as well as two equal sections containing 




2.4.2.4. Haematoxylin and Eosin Staining 
 
Before staining, dried slides were placed on a slide heater at 65°C to soften the wax, 
samples were then deparaffinised using Histo-ClearⓇ, into which slides were 
submerged for two incubations of five minutes each. Sections were rehydrated by 
passing them through alcohols of depreciating concentrations, from anhydrous EtOH 
to 95%, before being exposed to distilled water, with five-minute incubations in each 
solution. The specimens being stained for H&E were exposed to Haematoxylin for five 
minutes, followed by five minutes rinsing in running tap water and then Eosin Y solution 
for two minutes. After the dye samples were again rinsed for five minutes in running 
tap water before being dehydrated using a series of increasing concentrations of 
alcohols. Slides were exposed to solutions of 70%, 90% and 100% EtOH and spent a 
period of five minutes in each solution. Finally, samples were cleared by two 
submersions in Histo-ClearⓇ for 5 mins each, left to air dry and a coverslip applied 
using the xylene based mounting medium Entellan. 
 
Stained H&E slides exhibit blue nuclei and pink cytoplasm, this results from the ionic 
bonding between ions of opposite charges, one fixed in the tissue and the other in the 
dye. Haematoxylin is positively charged (cationic) and will bind to negatively charged 
elements including nucleic acids in the nucleus. Eosin is negatively charged (anionic) 
and will react with positively charged tissue components, including amino groups in 





The genotype of mice from the Gal-1 KO colony was confirmed using a standard 
polymerase chain reaction (PCR) method. A technique that amplifies the required DNA 
sequence generating many copies from a small amount of the original DNA 
segment/gene. The amplified DNA was then separated by electrophoresis alongside 
a molecular weight marker, which can subsequently be used to determine the base 
pair (bp) number. Due to the use of sequence specific primers the selected strands of 
DNA are different lengths for WT and Gal-1 KO mice, therefore presence or absence 
of DNA fragments of specific bp length can be used to verify the genotype of the mice. 
 
The REDExtract-N-Amp Tissue PCR Kit (containing Tissue Preparation Solution, 
Extraction Solution, Neutralising solution and REDExtract-N-Amp PCR Reaction Mix) 
was used to extract genomic DNA from mouse tails and amplify by PCR. The DNA is 
extracted by incubating the tissue sample with a mixture of the Extraction Solution and 
the Tissue Preparation Solution. Following addition of Neutralization Solution B, the 
extracted DNA is combined with primers and the REDExtract-N-Amp PCR Reaction 
Mix (a 2X reaction mixture containing buffer, salts, dNTPs, Taq polymerase, REDTaq 
dye, and JumpStart Taq antibody) and is ready for PCR. 
 
2.4.3.1. DNA Extraction from Tissue 
 
Genomic DNA was extracted from tail clippings (~0.5cm) taken from Gal-1 KO mice. 
Each tissue sample was placed in an Eppendorf tube into which Extraction solution 
(50µL) with Tissue Preparation solution (12.5µL) was added and the tubes vortexed. 
The tissue was then incubated in the solution for 10 mins at RT followed by a 
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subsequent incubation of three mins at 95°C. In order to halt the reaction 
Neutralization solution (50µL) was added followed by vortexing of the tubes and tail 
clippings removed. Prepared DNA solution from tissue extraction is ready to use 
immediately (alternatively storage at 4°C will maintain its stability for ~ six months).  
 
2.4.3.2. Primer Selection 
 
A combination of three primers are required to bind to the relevant sequences on 
single-stranded DNA for performing the PCR to copy those sequences. The name and 
specific nucleic acid sequence of each of these primers is shown in table 8.  
 
Table 8. Primers used for genotyping Gal-1 KO mice.  
 
 
2.4.3.3. Gene Extraction and Amplification 
 
A mastermix of reagents required for the PCR was prepared from REDExtract-N-Amp, 
the three primers and RNAse free water. The required volumes per sample, shown in 
table 9, were multiplied by the number of DNA samples to calculate the total volumes 
needed of each reagent, these volumes were then combined for the mastermix. The 
mastermix (10µl) was added to PCR tubes containing the DNA solution (2µl) to give a 
total volume of 12µl per tube. Negative and positive control samples were also 
prepared using RNAse free water and DNA from a known Gal-1 KO mouse in place 
of the DNA solutions obtained from the tissue extractions. The PCR tubes of sample 
Primer Primer Type Primer Sequence (5' -> 3')
oIMR6918 Common AAA CTT CAG CCG GGA GAA AGG
oIMR6919 Wild Type Forward GAC CCC ATC CCT ACA CCC CAG
oIMR8306 Mutant Forward CTA TCA GGA CAT AGC GTT GG
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were placed in the PCR machine and thermal cycling was carried out as per 
manufacturer's guidelines (see table 10). 
  




Table 10. Thermal cycling protocol for genotyping Gal-1 KO mice.  
 
 
2.4.3.4. DNA Separation 
 
Following the PCR cycle gel electrophoresis was performed on the samples to 
separate the DNA. First a 1.5% agarose was prepared by dissolving agarose powder 
in Tris-acetate EDTA (TAE) buffer with 2µL Gel Red nucleic acid stain added to the 
solution to allow visualisation of the DNA. The set gel was positioned in an 
electrophoresis machine and the tank filled with TAE buffer. The amplified DNA 
(10µL), along with an equal volume of the positive control, negative control and 100bp 
DNA ladder, was then loaded into the wells.  
Reagent Volume (µl) per sample
REDExtract-N-Amp 6
DNA solution from tissue extraction 2
Common primer (100µM) 0.12
Wild-type primer(100µM) 0.12
Mutant primer (100µM) 0.12
RNAse free water 3.64
Total 12
Step Temp. (°C) Time Note
1 94 3 min  -
2 94 30 sec
3 65 1 min
4 72 1 min
5 72 2 min  -
6 10  - hold
Repeat 





Due to DNA being negatively charged, samples will run through the gel in a negative 
to positive direction when a current is applied and DNA of shorter bp length will travel 
more easily than those of longer bp length. A constant voltage (100V) was passed 
through the gel until the DNA samples had migrated far enough that the dye front of 
the lanes had approached the end of the gel.  
 
To visualise the end product size of the samples a UV light box was used. The 
Ethidium Bromide channel was selected, and the exposure time calculated using the 
auto-exposure function although generally exposure to ultraviolet illumination for 
100ms was the most appropriate. The illuminated bands of the bp ladder were then 
used as markers to determine the bp length of the bands of DNA from the samples. In 
this case expected results would be a band indicating DNA of ~390bp for a WT mouse 




2.4.4. Western Blotting 
 
Western blotting is a well-established technique for detection and analysis of proteins. 
Proteins are separated according to their molecular weight by gel electrophoresis and 
then undergo electrophoretic transfer to immobilise them at their correct molecular 
weight on a membrane. Primary antibodies bind to the immobilised protein resulting in 
formation of a protein:antibody complex. A secondary enzyme conjugated antibody 
specific for the primary is added and results in the formation of a 
protein:antibody:antibody:enzyme complex proportional to the amount of protein on 
the membrane. On addition of the appropriate substrate the enzyme acts to catalyse 
the reaction resulting in the emission of light and the signal is captured and quantified. 
 
Western blots were performed using the NuPAGE® Bis-Tris Electrophoresis System 
(Invitrogen). The system operates at a neutral pH which in partnership with the pre-
cast, discontinuous SDS-PAGE gels supports the stability of both proteins and gel 
matrix during electrophoresis. 
 
2.4.4.1. Sample Preparation 
 
Cell lysate samples were prepared from 2 x 106 neutrophils in 150µl volume in a 1.5ml 
Eppendorf. Loading buffer was prepared from LDS sample buffer (4X) + DTT (1:100) 
and heated to 95°C on a heat block. The LDS sample buffer is specifically suited to 
prepare protein samples to run with Bis-Tris gels. The sample buffer contains lithium 
dodecyl sulphate and has a slightly alkaline pH which improves activity of the reducing 
agent, DTT, in cleaving disulphide bonds between cysteine residues and thus 
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linearising the protein. The Coomassie G250 in the buffer migrates in closely with the 
ions providing a sharp dye front.  
 
Immediately after the stimulation period, 50µl hot loading buffer was added to 
neutrophil samples and quickly resuspended before placing in an Eppendorf on the 
heat block and boiling at 95°C for 5 mins to lyse the samples. Boiled samples were 
then passed, 10 times, through a 23-gauge needle using a 1ml syringe to shear the 
DNA and decrease viscosity. Prepared Western blot samples were then stored at -
20°C prior to their loading in the gel. 
 
2.4.4.2. Denaturing Gel Electrophoresis 
 
Gel electrophoresis was performed using a NuPAGE® Novex® Pre-Cast Bis-Tris 12 
well 10% acrylamide gel and NuPAGE® MOPS SDS Running Buffer in an XCell 
SureLock™ Mini-Cell unit. The running buffer, specifically suited for detection of mid-
sized proteins on the NuPAGE® Bis-Tris Gels, is a 20X stock solution and was 
prepared by diluting 25ml stock with 475ml dH2O. To set up the tank the electrode 
assembly was placed into the tank unit. The 10cm gel cassette was then placed in the 
tank, flush with the electrode unit and orientated so that the well side of the gel cassette 
faces inwards towards the buffer core and locked in place with the gel tension wedge. 
The inner buffer chamber between the two gels was then filled to just above the wells 
with approximately 200ml running buffer and left for several minutes to check the 
tightness of the seal. Following confirmation of no leakage the outer chamber of the 




An appropriate molecular weight marker was loaded (5μl) in to the first well of the gel, 
followed by the prepared samples (20μl). The inner buffer chamber was then filled to 
the top with loading buffer. The voltage was set to 80V for the first ~15mins of running, 
until the sample had passed through the stacking gel, and then increased to 120V for 
~75mins to run the samples to the bottom of the gel.  
 
The electric field applied will have separated proteins by their molecular weight, shape 
and intrinsic charge. The anion detergents in the loading buffer and running buffer 
(LDS and SDS respectively) will bind to the protein by disrupting the hydrogen bonds 
holding it in its native form such that it becomes linearised. The denatured structure, 
with its polypeptide backbone surrounded by hydrophobic tails provides an overall 
negative charge.  The constant ratio of detergent to protein binding outcomes a 
uniform mass to charge ratio far more significant than the mass/charge of the protein 
itself thus allowing it to migrate effectively through the gel when a current is applied, 
with the smallest proteins travelling furthest. Once gel electrophoresis was complete, 
as indicated by the sample dye front reaching the end of the gel, the current was 




Following the running of the gel the separated proteins were electro-transferred on to 
a membrane using a wet transfer technique.  
 
The gel cassette was removed from the electrophoresis tank and opened by 
separating the three bonded sides of the two plates and the shorter back plate carefully 
lifted off. The stacking gel at the top of the gel was removed and the gel, attached to 
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the front plate was immersed in transfer buffer (25mM Tris base, 190mM glycine, 10% 
ethanol, pH 8.3) in the assembly tray.  
 
The blotting cassette was placed black side down in the assembly tray (aside the gel) 
and the ‘sandwich’ was constructed by building upwards. All layers were of a size 
larger than the gel but smaller than the blotting cassette and were submerged in 
transfer buffer prior to their addition. First a thin sponge was sat on the blotting 
cassette, followed by two layers of filter paper. The gel (with the marker on the right) 
was then carefully 'slid’ off its front plate on to the filter paper, ensuring no air bubbles 
were trapped between the layers. The PVDF membrane was activated by immersion 
in 100% methanol (~30secs) prior to transfer buffer and then placed on top of the gel. 
Two further layers of filter paper and a piece of sponge followed, after which a roller 
was used to remove any air bubbles that may have got trapped between the layers 
and the cassette closed.  
 
The filled cassette was then inserted into the transfer tank with black side of the 
cassette to black side of tank so that the membrane is closer than the gel to the anode 
(+). In this way the negatively charged proteins will migrate with the current from the 
gel towards the positive charge via the membrane, where they will become 
immobilised and fixed. The electro transfer was run at 80V for 90mins. After 90mins, 
the current was stopped, the electrodes were disconnected, and the blotting cassette 




2.4.4.4. Blocking and Antibody Probing 
 
The membrane was removed from the sandwich and incubated with a blocking 
solution. To prevent non-specific antibody binding the spaces not already occupied by 
proteins must be blocked by an agent with greater affinity for the membrane than the 
antibodies. Here the blocking step was performed using 5% non-fat milk diluted in 
TBS-T (Tris buffered saline (TBS) (150nM sodium chloride, 2mM Tris base, pH7.4) 
containing 0.1% Tween) which was incubated with the membrane for 1 hour on a plate 
rocker (RT). 
 
Antibody probing in Western blots most often involves using a non-labelled primary 
antibody against the target protein and a species specific labelled secondary antibody. 
In this way the signal is amplified, and the sensitivity of the assay increased. Following 
the blocking step membranes were incubated with the target specific primary antibody 
(for dilution and buffer see table 4) overnight on a plate rocker (4°C). After the 
incubation period the membrane was washed three times in TBS-T for 10 mins on a 
plate rocker (RT). The HRP conjugated secondary antibody (see table 4) was then 
added and incubated with the membrane for 1 hour on a plate rocker (RT). Following 
incubation, the membrane was washed three times in TBS-T for 10 mins on a plate 
rocker (RT). 
 
2.4.4.5 Detection and Imaging 
 
Detection was performed using an enzyme-based chemiluminescent system, a 
method which requires the addition of a reagent that emits light when it reacts with the 
enzyme (HRP) conjugated to the secondary antibody. The HRP enzyme catalyses the 
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oxidation of luminol in the presence of peroxide, a reaction which results in the 
emission of light.  
 
The chemiluminescent substrate (Immobilon forte western HRP substrate) was 
incubated briefly (~1min) with the membrane and excess substrate was drained off. 
The membrane was placed protein side up in an X-ray film developing cassette and 
transferred to the dark room. A sheet of X-ray film was placed on top of the membrane 
and the cassette was closed as film was exposed (see table 4). Following the exposure 
period films were removed from the cassette and fed through a developer machine 
which contained both the developing and fixing solutions. 
 
2.4.4.6. Analysis  
 
Densitometry was performed using ImageJ software analysis to provide a value for 
each band. For quantifying phosphorylation of signalling proteins, the value for the 
phospho-protein was divided by value of the total protein on an individual sample 
basis. Normalisation was not performed for Western blots detecting protein levels in 
cell free culture media. 
170 
 
2.5. Statistical Analysis 
  
Data are expressed as mean ± SEM. Comparisons were analysed for statistical 
significance. GraphPad Prism (v7 or v8) software was used for all analyses and a 
P≤0.05 was considered as statistically significant. 
  
For zymosan peritonitis data each individual time point (2, 6, 24, and 48h, where 
applicable) leukocyte numbers, apoptosis (percentage of neutrophils in each 
quadrant), efferocytosis (both percentage and enumeration of cells), plasma cytokine 
concentrations, BMDM (each phenotype for each marker) and peripheral blood counts 
were analysed using an unpaired t test. Leukocyte numbers profiled across time were 
analysed using a two-way repeated measures ANOVA with Sidak’s multiple 
comparisons test.  
 
For K/BxN serum transfer arthritis the histology of the joint (microscopic scoring), 
lymphocyte numbers and plasma cytokine concentrations were analysed using an 
unpaired t test. Arthritic scoring indices (macroscopic scoring, paw oedema and weight 
loss) were analysed using a two-way repeated measures ANOVA with Sidak’s multiple 
comparisons test. 
  
For human neutrophil assays (including each time point for Western blot) data was 
analysed using a paired t test or a one-way ANOVA with Tukey’s multiple comparison 
as appropriate dependent on the number of groups.  
 
For efferocytosis assays data was analysed using a paired t test or a one-way ANOVA 
with Tukey’s multiple comparison as appropriate dependent on the number of groups.  
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Chapter 3: Results  
 
3.1. The Role of Endogenous Gal-1 in Acute Self-Resolving Inflammation. 
 
To assess the role of endogenous Gal-1, a model of zymosan-induced peritonitis was 
performed in Gal-1 KO mice and their wild-type counterparts. Leukocyte trafficking, 
apoptosis and clearance were assessed at 2, 6, 24 and 48h post zymosan injection.  
 
3.1.1. Leukocyte Trafficking 
 
As shown in figure 16A there was a sharp and significant increase in leukocyte influx 
into the peritoneal cavities of wild-type mice from 2h (17.59 x 106 ± 0.51 x 106) to 6h 
(35.01 x 106 ± 6.32 x 106) followed by a decline at 24h (15.50 x 106 ± 0.54 x 106). A 
biphasic response was observed with a second increase in total leukocyte number at 
48h (26.72 x 106 ± 2.28 x 106). Leukocyte recruitment in Gal-1 KO mice mirrored that 
observed in their WT counterparts in terms of the temporal nature of the response, 
however significantly more leukocytes migrated into the peritoneal cavities of Gal-1 
KO mice when compared to WT at the 6h time point (41.33 x 106 ± 3.43 x 106 vs 28.69 
x 106 ± 0.78 x 106 p = 0.009). 
 
Further analysis of leukocyte subtypes identified neutrophils as the predominant cell 
type during the initiation phase from 2h onwards, with a decline in number observed 
at 24h (figure 16B). Whilst this trend was observed in both genotypes significantly 
more neutrophils (7/4+Ly6Ghigh) trafficked to the peritoneal cavity of Gal-1 KO mice, 
compared to WT at the 6h time point (30.27 x 106 ± 1.70 x 106 vs 20.14 x 106 ± 0.60 x 




Monocyte (7/4+Ly6G-) numbers displayed a bell shaped trend (figure 16C) with low 
numbers at 2h, a respective rise at 6 and 24h followed by a decline at 48h (1.25 x 106 
± 0.10 x 106) in WT mice. No difference was observed between genotypes. 
 
Eosinophil (Siglec F+) numbers rose sharply at 48h post zymosan in both genotypes 
(figure 16D), however, no differences in eosinophil number were observed at any of 
the observed time-points between genotypes.  
 
In WT mice, macrophage (F4/80+) numbers increased with time from 2h to 6h, remain 
unchanged at 24h before rising sharply at 48h (figure 16E). At early time points there 
was no significant difference between macrophage numbers in the cavities of Gal-1 
KO mice compared to WT, however significantly more macrophages were present in 
Gal-1 KO mice at 48h (20.98 x 106 ± 1.02 x 106 vs 17.86 x 106 ± 1.13 x 106 for WT, p 
= 0.011, figure 16E). Macrophage phenotype was also assessed. There were no 
significant differences between genotypes in the number of mature macrophages 
(F4/80+CD11bhigh), however significantly more resolving macrophages 
(F4/80+CD11blow) were present within the cavities of Gal-1 KO mice at 48h compared 
to their WT counterparts (11.89 x 106 ± 0.84 x 106 vs 9.08 x 106 ± 0.89 x 106, P = 










  Figure 16. Leukocyte recruitment is enhanced in Gal-1 KO mice. 
Mice received zymosan (1mg i.p.) and peritoneal lavage was performed at 2h, 6h, 24h and 48h. Total cell counts were 
performed (A) and the number of neutrophils (7/4+Ly6G+) (B), inflammatory monocytes (7/4+Ly6G-) (C),  eosinophils 
(Siglec F+) (D), macrophages (F4/80+) (E), mature macrophages (F4/80+CD11bhigh) (F) and resolving macrophages 
(F4/80+CD11blow) (G) were identified by flow cytometry. Representative flow cytometry plots are shown for each 
subset. Statistical analysis was performed using a two-way ANOVA with Sidak’s multiple comparisons test, results are 




3.1.2. Neutrophil Apoptosis  
 
Neutrophils (Ly6G+ cells) that were collected from the peritoneal cavity were assessed 
for apoptosis using Annexin V (AnxV) and the viability dye Zombie NIR (figure 17A). 
At 2h post zymosan most neutrophils from within the cavity were viable (AnxV-NIR-; 
78.79% ± 0.49%. figure 17B) with the majority of the remaining neutrophils being early 
apoptotic (AnxV+NIR-; 16.25% ± 0.21%). Very few neutrophils were late apoptotic 
(AnxV+NIR+) or necrotic (AnxV-NIR+; 3.89% ± 0.12% or 1.08% ± 0.17% respectively). 
No significant differences in the percentage of apoptotic neutrophils were observed 
between WT and Gal-1 KO mice. At 6h post-zymosan (figure 17C), the majority of 
neutrophils (72.25% ± 0.45%) were early apoptotic with few cells in late apoptosis 
(3.09% ± 0.92%) or necrosis (0.07% ± 0.04%). Again, there were no significant 
differences between cell states of WT and Gal-1 KO mice. At 24h post zymosan the 
remaining neutrophils were mainly viable (72.36% ± 5.41%) with some early apoptotic 
(22.70% ± 4.32%) and late apoptotic cells detectable (4.56% ± 0.90%, figure 17D). As 
observed at earlier time-points there were no significant differences between WT and 
Gal-1 KO cells. When assessed 48h after administration of zymosan, neutrophils were 
predominantly viable (69.96% ± 2.72%). Again, no differences were observed between 











  Figure 17. In vivo neutrophil apoptosis is not effected by the absence of Gal-1. 
Mice received zymosan (1mg i.p.) and peritoneal lavage was performed at 2h, 6h, 24h and 48h. Flow cytometry was 
used to select the neutrophil (Ly6G+) population, which was further assessed by AnxV binding and Zombie (NIR) 
staining. A quadrant gating strategy was applied to determine (A) viable (AnxV-NIR-), early apoptotic (AnxV+NIR-), late 
apoptotic (AnxV+NIR+) and necrotic (AnxV-NIR+) neutrophil populations. Results for the percentages of the neutrophil 
populations within each of the quadrants is shown for 2h (B), 6h (C), 24h (D) and 48h (E). Statistical analysis was 
performed using an unpaired t-test for each quadrant at each time point with results displayed showing the mean ± 




As apoptotic neutrophils are rapidly cleared from the peritoneum in vivo, cells from 
peritoneal exudates were collected and incubated overnight to assess ex vivo 
apoptosis. Analysis of neutrophil apoptosis ex vivo was performed at 2, 6, 24 and 48h 
post injection of zymosan using AnxV and Zombie NIR (figure 18A).  
 
Neutrophils from the peritoneal exudate of WT mice collected 2h post zymosan and 
assessed for apoptosis following overnight incubation were predominantly apoptotic 
with a large population of late apoptotic (66.77% ± 1.1%) and a smaller population of 
early apoptotic (27.84% ± 0.84%) cells observed. A small viable population of 
neutrophils were detectable (5.19% ± 0.34%) as well as a negligible population of cells 
shown to be necrotic (0.214% ± 0.05%) (figure 18B). There were no significant 
differences between genotypes in any of the populations of neutrophils. 
 
When neutrophils were collected from the peritoneal cavity at 6h post zymosan 
injection and incubated ex vivo, the majority of cells were early apoptotic (63.21% ± 
3.54%; figure 18C) with a considerable population of late apoptotic cells (27.05% ± 
4.55%). Neutrophils from Gal-1 KO mice were further along the apoptotic pathway 
than cells from WT mice, with significantly higher numbers of late apoptotic neutrophils 
in cultures from Gal-1 KO mice compared to WT (31.6% ± 3.35% vs 22.5% ± 1.39%; 
p = 0.003).  
 
No significant differences in apoptosis were observed between genotypes when 
neutrophils were harvested from the peritoneal cavity at either 24 or 48h post-zymosan 
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  Figure 18. Gal-1 KO neutrophils from peak inflammation display enhanced apoptosis ex vivo. 
Mice received zymosan (1mg i.p.) and peritoneal lavage was performed at 2h, 6h, 24h and 48h. Cells from 1ml of 
peritoneal exudate were resuspended in RPMI + 0.5% BSA and incubated for 20h. Flow cytometry was used to select 
the neutrophil (Ly6G+) population, which was further assessed by AnxV binding and Zombie (NIR) staining. A quadrant 
gating strategy (A) was applied to determine viable (AnxV-NIR-), early apoptotic (AnxV+NIR-), late apoptotic 
(AnxV+NIR+) and necrotic (AnxV-NIR+) neutrophil populations. Results for the percentages of the neutrophil population 
within each of the quadrants is shown for 2h (B), 6h (C), 24h (D) and 48h (E). Statistical analysis was performed using 
an unpaired t-test for each quadrant at each time point with results displayed showing the mean ± SEM, in all cases 




3.1.3. Neutrophil Clearance 
 
At 24h, significantly more macrophages had efferocytosed neutrophils in Gal-1 KO 
mice compared to WT (5.14% ± 0.36% vs 3.92% ± 0.26%; p = 0.011, figure 19A). 
However, further analysis indicated a significantly lower MFI in the Ly6G channel of 
Gal-1 KO macrophages indicating that fewer neutrophils had been efferocytosed per 
macrophage compared to WT (0.86 x104 ± 0.14 x104 vs 1.27 x104 ± 0.13 x104; p = 
0.009; figure 19B). At 48h there were no significant difference in either parameter 

























































































Figure 19. In vivo efferocytosis is modulated in the absence of endogenous Gal-1.  
Mice received zymosan (1mg i.p.) and peritoneal lavage was performed at 24h and 48h. Cell surface staining for 
macrophages (F4/80+) was followed by fixation, permeabilisation and neutrophil (Ly6G+) staining. A quadrant gating 
strategy was applied to determine the percentage of cells positive for efferocytosis (F4/80+Ly6G+) with representative 
plots for both genotypes inlaid. Results for the percentage of cells positive for efferocytosis at 24h (A) and 48h (C) are 
displayed with the mean for both genotypes. The median fluorescence intensity (MFI) for the neutrophil (Ly6G+) 
staining of double positive (F4/80+Ly6G+) cells was also analysed to compare the relative amount of neutrophils within 
macrophages at 24h (B) and 48h (D) and representative MFI values shown. Statistical analysis was performed using 




3.1.4. Inflammatory Mediator Profile 
 
Peritoneal lavage fluid was collected at 2h post zymosan and cell free exudates 
analysed by Luminex (Labospace Ltd. Milan) for levels of key inflammatory proteins. 
This data revealed a trend towards increased levels of chemokines CCL2 (MCP-1), 
CCL3 (MIP-1α) and CXCL1 (KC) (shown in figures 20A-C), the pro-inflammatory 
cytokine TNF-α (figures 20D) and the growth factor granulocyte macrophage colony 
stimulating factor (GM-CSF) (figures 20G) with roles in cell survival and trafficking 
were all elevated in Gal-1 KO mice. Significantly elevated levels of IL-6 (figure 20F) 
and VEGF (figure 20H) were detected in the lavage fluid of Gal-1 KO mice compared 
















































































































































  Figure 20. Inflammatory mediators are increased in Gal-1 KO mice  
The supernatant was collected from 1ml of peritoneal exudate (2h zymosan peritonitis) and concentrations of analytes 
measured by luminex. Levels of chemokines (A) CCL2 (MCP-1), (B) CCL3 (MIP-1-α) and (C) CXCL-1 (KC) and 
inflammatory cytokines (D) TNF-α, (E) IL-1β and (F) IL-6 are shown for both genotypes, as well as the growth factors 
(G) GM-CSF and (H) VEGF. Statistical analysis was performed using an unpaired t-test and significant results 




3.1.5. Macrophage Phenotype Skewing 
 
Bone Marrow Derived Macrophages (BMDM) from WT and Gal-1 KO mice were 
skewed using cytokines and endotoxin and macrophage M1 markers (CD86 and 
MHC-II) and M2 markers (CD206, CD36 and MerTK) were analysed. Macrophages 
from Gal-1 KO mice had significantly lower CD86 (p = 0.003) and significantly higher 
CD206 (p = 0.017) on the MO and M2 populations compared to WT mice, indicative 
or a more M2-like phenotype (figure 21A & B). Additionally, Gal-1 KO macrophages 
had higher surface expression of the scavenger receptors CD36 (figure 21C) and 
MerTK (figure 21D) compared to WT, indicative of an M2-like phenotype. Somewhat 
surprisingly, MHC-II expression, which is associated with M1-like macrophages was 
also slightly higher on Gal-1 KO macrophages when compared to WT cells (as shown 















































































*P = 0.017 *P = 0.007
Figure 21. Bone Marrow Derived Macrophages from Gal-1 KO mice exhibit a more M2-like phenotype. 
Mice (WT or Gal-1 KO) were sacrificed 2h post zymosan (1mg i.p.) and bone marrow cells were collected from the 
femur and differentiated to macrophages. BMDM were skewed with M1 (10ng/ml LPS + 20ng/ml IFNγ) / M2 (20ng/ml 
IL-4) mediators for 3 days. Macrophage phenotyping was performed by flow cytometry to detect surface expression 
of CD86 (A), CD206 (B), CD36 (C), MerTK (D) and MHC-II (E). Statistical analysis was performed using an unpaired 




3.2. The Effect of Exogenous Gal-1 on the Resolution of Acute Inflammation. 
 
Given the enhanced neutrophil recruitment observed in Gal-1 KO mice, whether 
exogenous human recombinant Gal-1 can modulate neutrophil trafficking and 
clearance to drive inflammatory resolution was next assessed. To this end, hrGal-1 
was administered either during the recruitment phase at 2h post-zymosan (and lavage 
performed at 6h), or at the peak; 8h post-zymosan (and lavage performed at 24 and 
48h).  
 
3.2.1. Leukocyte Trafficking 
 
Administration of hrGal-1 (10ug) at 2h post zymosan had no significant effect on 
leukocyte recruitment to the peritoneum as assessed at 6h post zymosan (figure 22A-
G). 
 
To assess resolution hrGal-1 was administered at peak (8h) and lavage performed at 
24h and 48h post zymosan. Administration of hrGal-1 at this time-point resulted in 
significantly fewer leukocytes being recovered 16h later (24h time point) compared to 
those recovered from vehicle treated mice (figure 23A). As shown in figures 23B-G 
further analysis of the individual leukocyte subtypes indicated that there was a trend 
towards an all-round decrease in the numbers of all leukocyte subsets analysed in the 
cavities of mice treated with hrGal-1. Significant reductions in the numbers of 
neutrophils (7/4+Ly6G+; figure 23B), eosinophils (SiglecF+; figure 23D) and resolving 
macrophages (F4/80+CD11blow; figure 23G) were observed. At the 48h timepoint 
significantly fewer leukocytes were recovered from the peritoneal cavities of mice 
treated with hrGal-1 compared to vehicle treated mice (7.05 x 106 ± 1.28 x 106 vs 12.90 
189 
 
x 106 ± 2.50 x 106; p< 0.037, table 11). Further analysis of leukocyte subtypes indicated 
a trend towards decreased neutrophils numbers and significantly fewer monocytes 
(7/4+Ly6G-), total macrophages (F4/80+) and mature macrophages (F4/80+CD11bhigh) 



































































































































































  Figure 22. Administration of exogenous Gal-1 during the early phase of neutrophil infiltration does not 
modulate leukocyte recruitment. 
Mice received zymosan (1mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/-) 2h later during the 
early phase of neutrophil infiltration. Peritoneal lavage was performed at 6h and cells from the exudate were counted 
to enumerate total cells (CD45+) (A). Neutrophils (7/4+Ly6G+) (B), inflammatory monocytes (7/4+Ly6G-) (C), 
eosinophils (Siglec F+) (D), macrophages (F4/80+) (E), mature macrophages (F4/80+CD11bhigh) (F) and resolving 
macrophages (F4/80+CD11blow) (G) were determined using flow cytometry. Statistical analysis was performed using 
an unpaired t-test with results displayed showing the mean ± SEM, in all cases significant results are considered as P 
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Table 11. Leukocyte numbers at 48h following exogenous Gal-1 during the peak. 
  
Figure 23. Exogenous Gal-1 administraton during the peak of inflammation promotes neutrophil clearance.  
Mice received zymosan (1mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) 8h later during 
the peak of neutrophil infiltration. Peritoneal lavage was performed at 24h Cells from the exudate were counted to 
enumerate total cells (CD45+) (A) and neutrophils (7/4+Ly6G+) (B), inflammatory monocytes (7/4+Ly6G-) (C), 
eosinophils (Siglec F+) (D), macrophages (F4/80+) (E), mature macrophages (F4/80+CD11bhigh) (F) and resolving 
macrophages (F4/80+CD11blow) (G) were determined using flow cytometry.  Representative flow cytometry gating plots 
are inset for each subset. Statistical analysis was performed using a two-way ANOVA with Sidak’s multiple 




In order to quantitate the pro-resolving actions of Gal-1, resolution indices were 
calculated. These are widely utilized to identify mediators that stimulate, as well as 
those that disrupt or delay resolution (Bannenberg et al., 2005; Schwab et al., 2007; 
Navarro-Xavier et al., 2010). Figure 24 shows remission indices in response to 
exogenous Gal-1 based on the neutrophil counts for hrGal-1 treated mice compared 
to those receiving vehicle. Values calculated indicate the maximum neutrophil number 
(Tmax), when 50% of this maximum was reached (T50) and the resolution interval (Ri; 
time from Tmax to T50). Treatment with hrGal-1 reduced the resolution interval from 39h 
observed in vehicle treated mice to 14h (figure 24) indicating that neutrophils are 
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Figure 24. Exogenous Gal-1 reduced the resolution interval. 
Mice received zymosan (1mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) 8h later during 
the peak of neutrophil infiltration. Peritoneal lavage was performed at 8h for baseline and subsequently at 24h and 
48h. Total cell counts were performed, and flow cytometry was used to quantify neutrophils (7/4+Ly6G+). Remission 
indices were calculated to indicate when mice reached the maximum neutrophil number (Tmax), when 50% of this 




3.2.2. Neutrophil Apoptosis  
 
Analysis of in vivo neutrophil apoptosis was performed at 6h (with hrGal-1 given at 
2h), as well as at 24 and 48h (with hrGal-1 given at 8h) post injection of zymosan with 
AnxV and Zombie NIR (figure 25A).  
 
At the 6h time point (figure 25B), neutrophils were predominantly viable (78.92% ± 
1.70%) with most others being either early apoptotic (16.32% ± 1.17%), late apoptotic 
(4.57% ± 0.56%) or necrotic (0.19% ± 0.01%). Significantly fewer viable cells were 
evident at the 6h time point in mice treated with hrGal-1 when compared to vehicle 
(77.21% ± 1.3% vs 80.62% ± 1.51%; p= 0.049), with a trend for increased early and 
late apoptotic neutrophils with hrGal-1 treatment.  
 
At 24h post zymosan significantly fewer viable cells were detected within the peritoneal 
cavities of mice treated with hrGal-1 compared to vehicle (65.48% ± 3.97% vs 75.9% 
± 2.34%; p = 0.018; figure 25C) and a significant increase in the percentage of early 
apoptotic neutrophils (AnxV+/PI–) was observed. In contrast, 48h after administration 
of zymosan significantly more viable cells were observed in the peritoneal cavities of 
mice that received hrGal-1 compared to vehicle (figure 25D; 79.00% ± 0.061% vs 
53.46% ± 7.83%; p = 0.0001).  
 
The percentage of late apoptotic cells was minimal in both genotypes at all time points 
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  Figure 25. Exogenous Gal-1 accelerated neutrophil apoptosis in vivo. 
Mice received zymosan (1mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) 8h later during 
the peak of neutrophil infiltration. Peritoneal lavage was performed at 8h for baseline and subsequently at 24h and 
48h. Flow cytometry was used to select the neutrophil (Ly6G+) population, which was further assessed for AnxV 
binding and Zombie (NIR) staining. Quadrant gating (A) was applied to determine viable (AnxV-NIR-), early apoptotic 
(AnxV+NIR-), late apoptotic (AnxV+NIR+) and necrotic (AnxV-NIR+) neutrophil populations. Results for the 
percentages of the neutrophil population within each of the quadrants is shown at 6h (B) when hrGal-1 was 
administered during neutrophil recruitment (at 2h) and at 24h (C) and 48h (D) post when hrGal-1 administration 
followed the peak in neutrophil number (at 8h).  Statistical analysis was performed using an unpaired T-test for each 
quadrant at each time point with results displayed showing the mean ± SEM, in all cases significant results are 




In addition to analysis of neutrophils taken directly from the peritoneal cavity to assess 
in vivo apoptosis cells from peritoneal exudate were also incubated overnight to 
assess ex vivo apoptosis. Analysis of ex vivo neutrophil apoptosis was performed at 
6h, having received vehicle or hrGal-1 at 2h post injection of zymosan (figure 26A & 
B). 
 
Neutrophils that were collected from the peritoneal cavity, incubated overnight and 
then assessed for apoptosis, were in the majority early apoptotic (62.53% ± 6.89%), 
as shown in figure 26B. A considerable population were late apoptotic (27.24% ± 
10.52%) and a modest population of viable cells was also present (10.20% ± 3.65%). 
A very small percentage of neutrophils were necrotic (0.12% ± 0.08%). Gal-1-treated 
mice had a significantly lower percentage of viable neutrophils (6.54% ± 0.47%) 
compared to those from vehicle controls (13.85% ± 2.01%) as well as a significantly 
lower percentage of early apoptotic cells (55.64% ± 1.47% vs. 69.42% ± 0.89%). 
Correspondingly, there was a significantly higher percentage of late apoptotic 
neutrophils in Gal-1 treated mice (37.76% ± 1.67% vs. 16.72% ± 1.49%) suggesting 
that they had progressed further into the process of apoptosis.  
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Figure 26. Exogenous Gal-1 treatment enhanced neutrophil apoptosis ex vivo. 
Peritonitis was initiated with zymosan (1mg i.p.) and mice were treated with hrGal-1 (10µg) or vehicle (200µl DPBS-/-
) at 2h and peritoneal lavage performed at 6h. Peritoneal exudate (1mL) cells were resuspended in RPMI + 0.5% BSA 
and incubated overnight (20h). Flow cytometry was used to select the neutrophil (Ly6G+) population, which was further 
assessed for AnxV binding and Zombie (NIR) staining. Quadrant gating (A) was applied to determine viable (AnxV-
NIR-), early apoptotic (AnxV+NIR-), late apoptotic (AnxV+NIR+) and necrotic (AnxV-NIR+) neutrophil populations. 
Representative plots are displayed for veh (left) and hrGal-1 (right) treated mice (A). Representative plots for each 
treatment indicating the percentages of the neutrophil populations within each of the quadrants is shown (B). Statistical 
analysis was performed using an unpaired t-test for each quadrant with results displayed showing the mean ± SEM, 




3.2.3. Neutrophil Clearance 
 
Administration of Gal-1 at either 2h or 8h post-zymosan did not modulate efferocytosis 
at either the 6h or 24 and 48h timepoints respectively (figure 27).  
 
In addition to analysing peritoneal neutrophils for their levels of apoptosis engulfment 
of these cells by macrophages was also investigated. Following fixation and 
permeabilisation of peritoneal cells macrophages containing neutrophils 
(F4/80+Ly6G+) were selected to assess in vivo efferocytosis. Analysis of efferocytosis 
was performed at 6h (figure 27A & B), having received vehicle or hrGal-1 at 2h post 
injection of zymosan. Here data showed a subtle trend towards a decrease in the 
percentage of peritoneal cells involved in the process of efferocytosis following 
treatment with hrGal-1, however the relative number of neutrophils per macrophage 
was slightly more in response to treatment with hrGal-1. Fewer macrophage ingesting 
more neutrophils each suggests that there would be no overall difference in cell 
clearance at this early timepoint 
 
When efferocytosis was assessed at 24h (figure 27C & D) and 48h (figure 27E & F) 
post zymosan after treatment with hrGal-1 or vehicle at 8h, the MFI values were 
considerably higher compared to the 6h timepoint (figure 27B), indicating that there 
were a greater number of neutrophils contained within macrophages at the latter 
timepoints (figure 27D & F), with peak numbers seen at the 24h timepoint. However, 
despite the notable change in relative MFI values across time, there were no 
differences between genotypes nor were there any differences in percentage of 







  Figure 27. In vivo efferocytosis is not modulated by exogenous Gal-1. 
Mice received zymosan (1mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/-) at 2h and 
peritoneal lavage performed at 6h (hrGal-1 at 2h), 24h and 48h (hrGal-1 at 8h). Cell surface staining for macrophages 
(F4/80+) was followed by fixation, permeabilisation and neutrophil (Ly6G+) staining. Quadrant gating was applied to 
determine the percentage of cells positive for efferocytosis (F4/80+Ly6G+), representative plots inlaid above for both 
vehicle and hrGal-1 treated mice. Results show the individual and mean values for the percentage of cells positive for 
efferocytosis at 6h (A), 24h (C) and 48h (E). The median fluorescence intensity (MFI) for neutrophil (Ly6G+) staining 
of the cells positive for efferocytosis (F4/80+Ly6G+) at 6h (B), 24h (D) and 48h (F) are also shown with representative 
MFI value plots above. Statistical analysis was performed using an unpaired t-test at each time point and in all cases 




3.2.4. Migration to the Lymph Node. 
 
Neutrophil (Ly6G+) numbers and lymphocyte (CD3+CD4+ and CD3+CD8+) subtypes 
within the inguinal lymph node were investigated at 24 and 48h post zymosan following 
treatment with hrGal-1 (or vehicle) at 8h. No changes in the percentages of neutrophils 
(figure 28A & B), helper (CD4+) T cells (figures 28C & D) and cytotoxic (CD8+) T cells 
























































































































Figure 28. Exogenous Gal-1 had no effect on the percentage of neutrophils and lymphocytes within the lymph 
node. 
Mice received zymosan (1mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/-) 8h later during 
the peak of neutrophil infiltration. Inguinal, axillary, mesenteric and popliteal lymph nodes were collected at 24h and 
48h. Cells were isolated using a cell strainer and flow cytometry was used to analyse the cell populations. Positive 
populations were determined using antibodies specific to neutrophils (Ly6G+) and cytotoxic (CD8+) and helper (CD4+) 
subsets of T cells (CD3+). Results show percentages of neutrophils (A,B), helper T cells (C,D) and cytotoxic T cells 
(E,F) at 24h and 48h. Statistical analysis was performed using an unpaired t-test for each time point with results 
displayed additionally showing the mean of each treatment group, in all cases significant results are considered as P 




3.3. The Effect of Exogenous Gal-1 in a Model of Delayed Resolving
 Inflammation. 
 
To determine whether Gal-1 influences neutrophil trafficking, clearance or both in a 
high dose zymosan model (10mg) where resolution of the inflammatory response is 
comparatively delayed compared to the acute disease profile with 1mg zymosan 
described until now, hrGal-1 was administered daily from peak neutrophil influx at 24h 
post-zymosan and peritoneal cavities lavaged at 72 and 120h.  
 
3.3.1. Leukocyte Trafficking 
 
Results from administering hrGal-1 treatment daily from 24h post high dose zymosan 
showed no significant differences in leukocyte recruitment to the peritoneal cavity of 
any leukocyte subtype at either 72h or 120h (figure 29A-G). The data shows a notable 
trend towards fewer macrophages (most prominent for the mature (F4/80+CD11bhigh; 










































































































































































































  Figure 29. Exogenous Gal-1 had no effect on leukocyte numbers in a high-dose zymosan peritonitis model.  
Mice received zymosan (10mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) daily from 24h 
(peak of neutrophil infiltration). Peritoneal lavage was performed at 24h for baseline and subsequently at 72h and 
120h. Cells from the exudate were counted to enumerate total cells (CD45+) (A) and neutrophils (7/4+Ly6G+) (B), 
inflammatory monocytes (7/4+Ly6G-) (C), eosinophils (Siglec F+) (D), macrophages (F4/80+) (E), mature macrophages 
(F4/80+CD11bhigh) (F) and resolving macrophages (F4/80+CD11blow) (G) were determined using flow cytometry. 
Representative flow cytometry gating plots are inset for each subset. Statistical analysis was performed using a two-
way ANOVA with Sidak’s multiple comparisons test, results display the mean ± SEM, in all cases significant results 
are considered as P < 0.05. n=4-6. 
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3.3.2. Neutrophil Apoptosis 
 
Analysis of in vivo neutrophil apoptosis was performed at 24h (for comparison), as well 
as at 72 and 120h (with hrGal-1 given daily from 24h) post injection of high dose 
zymosan. At the 24h time point (figure 30A), neutrophils were predominantly viable 
(83.75% ± 2.06%) with smaller proportions early apoptotic (10.42% ± 1.41%), late 
apoptotic (5.35% ± 0.64%) or necrotic (0.47% ± 0.23%). Neutrophils obtained at 
subsequent time points were also primarily viable, with the highest percentage viability 
seen at 72h (90.71% ± 0.75). Treatment with hrGal-1 did not modulate levels of 
apoptosis seen at this time-point (figure 30B). At 120h post zymosan (figure 30C) there 
was a significantly higher percentage of viable cells within the population of neutrophils 
retrieved from the cavities of mice treated with hrGal-1 compared to vehicle (88.47% 
± 0.98% vs 84.32% ± 1.43%; p = 0.0362). Correspondingly fewer early apoptotic cells 
were present within the cavities of hrGal-1 treated mice (3.80% ± 0.35% vs 5.73% ± 

















































































  Figure 30. Exogenous Gal-1 treatment in the high-dose zymosan peritonitis model resulted in fewer apoptotic 
neutrophils during the late phase of the inflammatory response.   
Mice received zymosan (10mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) daily from 24h 
(peak of neutrophil infiltration). Peritoneal lavage was performed at 24h for baseline and subsequently at 72h and 
120h. Flow cytometry was used to select the neutrophil (Ly6G+) population, which was further assessed by AnxV 
binding and Propidium Iodide (PI) staining. Quadrant gating was applied to determine viable (AnxV-PI-), early apoptotic 
(AnxV+PI-), late apoptotic (AnxV+PI+) and necrotic (AnxV-PI+) neutrophil populations. Results for the percentages of 
the neutrophil population within each of the quadrants is shown at 24h (A), 72h (B) and 120h (C). Statistical analysis 
was performed using an unpaired t-test for each quadrant at each time point with results displayed showing the mean 




3.3.3. Neutrophil Clearance 
 
The daily administration of hrGal-1 following high dose zymosan did not modulate 
efferocytosis when detected at 72 or 120h post inflammogen (figure 31A-F). 
 
Following fixation and permeabilisation of peritoneal cells, macrophages containing 
neutrophils (F4/80+Ly6G+) were selected to assess in vivo efferocytosis. When 
assessed at 72h (figure 31C & D) post high dose zymosan, with either hrGal-1 or 
vehicle administered daily from 24h onwards, the percentage of double positive 
(F4/80+Ly6G+) cells was notably higher compared to both the earlier 24h timepoint 
(figure 31A & B) and the latter 120h timepoint (figure 31E & F). This data indicates that 
there was a greater percentage of macrophages having engulfed neutrophils at this 
time point, whereas similar lower percentages were detected at 24h and 120h.   
 
Despite the notable change across time, there were no differences detected in 
response to treatment with hrGal-1. Interestingly, the peritoneal macrophage 
population was consistent for their Ly6G MFI levels across all assessed timepoints 
regardless of whether they had received treatment with hrGal-1 or not. This would 
suggest that efferocytosis was a constant process within the peritoneal cavity, and that 
in an attempt to counteract the increase in neutrophil numbers, seen as a result of the 


































































































































Figure 31. Exogenous Gal-1 did not modulate efferocytosis in the high dose zymosan peritonitis model. 
Mice received zymosan (10mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) daily from 24h 
(peak of neutrophil infiltration). Peritoneal lavage was performed at 24h for baseline and subsequently at 72h and 
120h. Cell surface staining for macrophage (F4/80+) was followed by fixation, permeabilisation and neutrophil (Ly6G+) 
staining. Quadrant gating was applied to determine the percentage of cells positive for efferocytosis (F4/80+Ly6G+). 
Results show the individual and mean values for the percentage of cells positive for efferocytosis at 24h (A), 72h (C) 
and 120h (E). The mean fluorescence intensity (MFI) for neutrophil (Ly6G+) staining of the double positive 
(F4/80+Ly6G+) cells at 24h (B), 72h (D) and 120h (F) are also shown. Statistical analysis was performed using an 




3.3.4. Peripheral blood Leukocyte Profile 
 
The peripheral blood was collected from mice at 72h and 120h post high dose 
zymosan (10mg) and profiled for 27 parameters (see table 6). There were no 
significant differences detected at either time point in mice administered hrGal-1 
(10µg) compared to vehicle only.  
 
However, the data from 72h displays a recognisable bias towards an increased 
myeloid cell population in the peripheral blood of hrGal-1 treated mice, resulting in an 
overall increase in white blood cell (WBC) counts (figure 32A). As shown in figure 32B 
platelet counts were also increased in response to hrGal-1 treatment. In line with the 
overall increase in WBC counts populations of myeloid cells including neutrophils, 
monocytes and eosinophils were increased in both number and percentage as shown 
in figures 32C-H, Conversely, a decreased population of lymphoid cells (figures 32I & 
J) was seen the peripheral blood of hrGal-1 treated mice. 
 
Interestingly, data from 120h shows the inverse, the WBC count, as shown in figure 
33A, was lower in mice having received hrGal-1. However, there was no effect on 
platelet counts at 120h (figure 33B). In support of the decreased WBCs, lower numbers 
of all myeloid subsets (figures 33C-H) as well as a subtle decrease in lymphoid cell 
number (figures 33I & J) were detected in the peripheral blood of hrGal-1 treated mice. 
 
No alterations in red blood cell counts or parameters were seen in response to hrGal-






































































































































































































Figure 32. Exogenous Gal-1 increased peripheral white blood cell and platelet counts during the early 
resolution phase of the high dose zymosan peritonitis model. 
Mice received zymosan (10mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) daily from 24h 
(peak of neutrophil infiltration). Blood was collected at 72h post zymosan injection. Whole blood (50µl) was ran on 
the ProCyte DX Haematolgy Analyser (IDEXX) and analysed for while blood cell (WBC) (A) and platelets (B). As 
well as neutrophil (C, D), monocyte (E, F), eosinophils (G, H) and lymphocyte (I, J) numbers and percentage 
respectively. Statistical analysis was performed using an unpaired t-test and results considered as significant when 











































































































































































































  Figure 33. Exogenous Gal-1 resulted in a trend towards decreased peripheral white blood cell counts during 
the resolution phase of the high dose zymosan peritonitis model. 
Mice received zymosan (10mg i.p.) and were administered hrGal-1 (10µg) or vehicle (200µl DPBS-/- ) daily from 24h 
(peak of neutrophil infiltration). Blood was collected at 120h post zymosan injection. Whole blood (50µl) was ran on 
the ProCyte DX Haematolgy Analyser (IDEXX) and analysed for while blood cell (WBC) (A) and platelets (B).  As 
well as neutrophil (C, D), monocyte (E, F), eosinophils (G, H) and lymphocyte (I, J) numbers and percentage 
respectively. Statistical analysis was performed using an unpaired t-test and results considered as significant when 




3.4. The Role of Endogenous Gal-1 in Inflammatory Arthritis. 
 
The role of endogenous Gal-1 was next explored in the K/BxN model of inflammatory 
arthritis by comparing WT and Gal-1 KO mice. Mice were injected with arthritogenic 
K/BxN serum on days 0 and 2 and monitored daily for clinical signs of arthritis and 
weight loss as well as paw swelling by water displacement plethysmometry. 
 
3.4.1. Oedema Formation 
 
The immediate vasoactive response was measured as a change in paw thickness 
using calipers prior to and thirty minutes post injection with K/BxN serum (day 0). This 
initial response was significantly heightened in Gal-1 KO mice (0.28mm ± 0.01mm vs 






















* *P  =  0 .0 1 0
W T
KO
Figure 34. Initial oedema response is heightened in Gal-1 KO mice. 
WT and Gal-1 KO mice received arthritogenic K/BxN serum (by i.p. injection) and paw swelling was measured using 
callipers. Fast response paw oedema was assessed 30 mins following serum. Statistical analysis was performed using 
a Two-way RM ANOVA with results displayed showing the mean ± SEM, in all cases significant results are considered 




3.4.2. Disease Severity 
 
Administration of K/BxN serum triggered a rapid and robust onset of arthritis. The 
initiation phase (first 4 days) was less severe in Gal-1 KO mice compared to their WT 
counterparts. At day three there was significant divergence in scores between 
genotypes (P = 0.0018), which was maintained at day four when Gal-1 KO (6.41± 
0.34) scored significantly less than WT (8.67± 0.64) mice (P = 0.0003). Figure 35A 
displays the clinical scores for the mice and the overall difference between genotypes 
(P = 0.0087). 
 
Hind paw oedema was significantly increased in WT mice compared to Gal-1 KO mice 
and reached significance at day 3 (figure 35B). Overall, across the four-day duration, 
hind paw oedema is significantly lower in Gal-1 KO mice compared to WT mice (P = 
0.0189).  
 
WT mice lost significantly more weight compared to Gal-1 KO mice (P = 0.0042; figure 
35C). Gal-1 KO mice also took longer to succumb to disease than WT mice with 100% 
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Figure 35. Early arthritis is less severe in Gal-1 KO mice. 
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2. 
Disease severity was clinically assessed for 4 days post-induction by clinical scoring (A), paw oedema by water 
displacement plethysmometry (B) and weight loss (C). Incidence of disease (D) was also recorded. Statistical analysis 
was performed using a Two-way RM ANOVA with results displayed showing the mean ± SEM, in all cases significant 




3.4.3. Microscopic Injury 
 
Microscopic assessment of joint histology indicated significantly more inflammation in 
WT mice compared to Gal-1 KO displaying increased leukocyte infiltration and 








































Figure 36. Cellular infiltrate during the initiation phase of arthritis is less severe in Gal-1 KO mice.  
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2, 
disease progressed for four days and knee joints were collected for histology. H&E stained sections were analysed 
and scored blindly. Stained sections were scored on a scale of zero to three by assessing level of infiltrate and 
thickness of the synovium (A). Representative images for WT (B) and KO (C) show scores of 3 and 0 respectively. 
Statistical analysis was performed using an unpaired t-test with results showing the mean for each genotype, 
significant results are considered as P < 0.05. n=6-7.  




3.4.4. Neutrophil Infiltration 
 
In addition to histological scoring, arthritic paws were also enzymatically digested to 
further analyse the cellular infiltrate by flow cytometry. At day 4, leukocyte infiltration 
was assessed within the arthritic paws, with around 10% of CD45 positive cells 
identified as neutrophils (Ly6G positive). There was no significant difference in the 
percentage of neutrophils found to have infiltrated the paws of WT mice compared to 


































Figure 37. Neutrophil infiltrate into the paws during early arthritis was not affected by the absence of Gal-1. 
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p) on days 0 and 2, 
disease progressed for four days and hind paws were collected and tissue digested. Cellular infiltrate was assessed 
by flow cytometry and percentage of neutrophils (CD11bhigh Ly6G+) was calculated from the CD45+ cells. Statistical 
analysis was performed using an unpaired t-test with results showing the mean for each genotype. Results considered 




3.4.5. Profile of Draining Lymph Nodes 
 
Cells isolated from the draining (popliteal) lymph nodes of Gal-1 KO and WT mice 
were assessed for relative percentages of T cell subsets. Cytotoxic (CD8+) T cells 
were significantly higher in the draining lymph nodes of WT (40.43% ± 0.82%) mice 
compared to Gal-1 KO (27.00% ± 1.70%) as shown in figure 38A (P = 0.0021). 
However, figure 38B indicates that there was no difference between genotypes with 
regards to helper (CD4+) T cells (WT = 50.73% ± 0.91% and Gal-1 KO = 53.6% ± 
3.85%). The CD4+ population was further characterised, and significant differences 
were seen in the number of naïve (CD62L+CD44-) and effector (CD62L-CD44-) T cells, 
with representative flow cytometry plots for both WT and Gal-1 KO mice (figures 38C 
& D). The percentage of naïve T cells was significantly lower in Gal-1 KO compared 
to WT mice (13.91% ± 5.83% vs 44.03% ± 6.75%; P = 0.0279; figure 38E). In contrast, 
the percentage of effector T cells was significantly enhanced in Gal-1 KO compared 
to WT (77.37% ± 3.67% vs 47.17% ± 5.41%; P = 0.0099, figure 38G) mice. No 
differences were observed between genotypes in the percentage of memory (CD62L-

























** P = 0.002




















































* P = 0.028































































































  Figure 38. T cell populations are altered in the draining lymph node from arthritic joints of Gal-1 KO mice.  
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2, 
disease progressed for four days and popliteal lymph nodes were collected to assess cellular infiltrate. Cells were 
isolated from lymph nodes and flow cytometry was used to analyse the cell populations. Percentages of T cell (CD3+) 
subsets were determined as cytotoxic (CD8+) (A) and helper (CD4+) (B) T cells. Representative plots for both WT (C) 
and Gal-1 KO (D) show how expression of cell adhesion molecules (CD44 and CD62L) can further distinguish CD4+ 
T cells into naïve (CD62L+CD44-) (E), effector (CD62L-CD44-) (F) and memory (CD62L-CD44+) (G) subsets. Statistical 
analysis was performed using an unpaired t-test with results showing the mean for each genotype. Results are 




3.4.6. Inflammatory Mediator Profile 
 
Peripheral blood was taken from WT and Gal-1 KO mice on day 4. Serum was 
separated from whole blood, collected, and analysed by Luminex (Labospace Ltd. 
Milan) for levels of key inflammatory mediators. CXCL (KC) (figure 39A) and 
leukotriene B4 (LTB4) levels (figure 39B) were measured by ELISA in serum of WT 
and Gal-1 KO mice. No significant differences were observed for either mediator 
between genotypes. IL-1β, IL-6, CCL2 (MCP-1) and TNF-α were also analysed, 
however results showed that levels were below the detectable range for the assay.
  
Figure 39. The absence of Gal-1 had no effect on levels of inflammatory mediators in early arthritis. 
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2, 
disease progressed for four days and inflammatory mediator levels within the plasma were assessed. Plasma was 
separated from blood obtained by cardiac puncture and concentrations of CXCL1 (KC) (A) and Leukotriene B4 (LTB4) 
(B) were measured by ELISA. Statistical analysis was performed using an unpaired t-test with results showing the 




3.4.7. Resolution of Inflammatory Arthritis 
 
A full disease profile for K/BxN serum transfer induced arthritis, was obtained for Gal-
1 KO mice and WT mice to assess resolution. The initial development of arthritis was 
slower in Gal-1 KO than WT mice as indicated by the delay to reach peak disease 
(figure 40A) verifying the results observed in the previous 4 day experiment. A 
significant delay in disease resolution was observed for Gal-1 KO mice compared to 
their WT counterparts (figure 40A). Paw oedema was significantly lower in Gal-1 KO 
mice over the entire course of the disease (figure 40B). In line with the more rapid 
disease development observed in WT mice, they also lost significantly more weight 
during the first 4 days of observation (WT = 7.63% ± 1.28%, KO = 0.47% ± 1.04%; p 
= 0.0004, figure 40C). Following an approximate 5% loss in body weight during peak 
arthritis, Gal-1 KO mice then maintained weight over the course of remission whereas 
WT mice began to regain weight, a result seen from day 25 onwards (figure 40C). No 






Figure 40. Gal-1 KO mice display an altered arthritis profile. 
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2. 
Disease severity was clinically assessed for 40 days post-induction by clinical scoring (A), paw oedema (B) and weight 
loss (C). Incidence of disease (D) was also recorded. Statistical analysis was performed using a Two-way RM ANOVA 
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3.4.7.1. Remission Indices 
 
Remission indices were calculated following the 40 days of observation, as displayed 
in figure 41. Values indicate the time points when mice reached the maximum 
magnitude of arthritis (Tmax), when 50% of the maximum was reached (T50) and the 
resolution interval (Ri) determined as the time from Tmax to T50. Results for the two 
genotypes, show a delay in Tmax for the Gal-1 KO mice compared to their WT 
counterparts (19 days and 17 days, respectively) as well as a delay in T50 (WT = 29 
days and KO = 35 days). Consequently the Ri value was increased in Gal-1 KO (16 
days) compared to WT (12 days) mice, indicating that time to peak disease is 
lengthened in Gal-1 KO mice compared to WT and Gal-1 KO mice take longer to 
resolve again, resulting in their disease remission being a longer and slower process 
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Figure 41. Maximum magnitude and resolution of arthritis were delayed in Gal-1 KO mice. 
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2. Mice 
were scored clinically for 40 days post-induction, and each swollen feature (wrist and ankle and respective pads and 
digits) was given a score of one, with a maximum score of 12 per mouse. Remission indices were calculated to indicate 
the time points when mice reached the maximum magnitude of arthritis (Tmax), when 50% of the maximum was reached 
(T50) and the resolution interval (Ri) the time from Tmax to T50. n=7-8. 
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3.4.8. Joint Histology 
 
The resolution outcome was assessed in the previously inflamed joints from WT and 
Gal-1 KO mice in remission from arthritis. Microscopic damage was low in both 
genotypes at day 40 as would be expected. No significant differences were observed 



































Figure 42. The absence of Gal-1 did not modulate the outcome of arthritis remission as assessed 
microscopically.  
Arthritis was induced in WT and Gal-1 KO mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2. 
Disease progressed for forty days after which knee joints were collected for histology. H&E stained sections were 
analysed and scored blindly. Stained sections were scored on a scale of zero to three by assessing level of infiltrate 
and thickness of the synovium (A). Representative images for WT (B) and KO (C) show scores of 0.5 and 0 
respectively. Statistical analysis was performed using an unpaired t-test with results showing the mean for each 
genotype, in all cases significant results are considered as P < 0.05. n=6.  




3.5. The Effect of Exogenous Gal-1 in the Resolution of Inflammatory Arthritis. 
 
To explore the effect of exogenous hrGal-1 the K/BxN model of inflammatory arthritis 
was performed on WT mice administered hrGal-1 (3μg) or vehicle (20μl DPBS+/+) by 
intraplantar injection (figure 43). Mice were treated on alternate days from established 
disease on day 3 and sacrificed during peak (day 7) or resolving (day 11) arthritis. 
 
3.5.1. Disease Severity 
 
Intraplantar treatment with hrGal-1 had no effect on either clinical score (figure 43A) 
or oedema (figure 43B). 
  
 








































































hrGal-1 (3µg intraplantar) hrGal-1 (3µg intraplantar)
Figure 43. Intraplantar administration of Gal-1 had no effect on arthritis in the hind paw.   
Arthritis was induced in WT mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2. Mice were then 
treated with hrGal-1 (3μg) or vehicle (20μl DPBS+/+) by intraplantar injection on days 3, 5, 7 and 9. The effect of hrGal-
1 was measured against contralateral vehicle control for clinical score (A) and hind paw oedema (B) and recorded as 
the difference from baseline (day 3). Statistical analysis was performed using a Two-way mixed effects ANOVA with 
results displayed showing the mean ± SEM, in all cases significant results are considered as P < 0.05. n=13 (days 0-





3.5.2. Leukocyte Infiltration 
 
During the resolving phase (day 11) there was no significant differences in any of the 
leukocyte subsets that had infiltrated hrGal-1 treated paws compared to vehicle 
controls as assessed by flow cytometry (figure 44A-D). However, data revealed a 
subtle trend towards a decreased percentage of neutrophils (figure 44A) and 




















































































Figure 44. Intraplantar administration of Gal-1 had no significant effect on leukocyte infiltration. 
Arthritis was induced in WT mice by injection of arthritogenic (K/BxN) serum (i.p.) on days 0 and 2. Mice were treated 
with hrGal-1 (3μg) or vehicle (20μl DPBS+/+) by intraplantar injection on days 3, 5, 7 and 9. Disease progressed for 11 
days and hind paws were collected and tissue digested. Cellular infiltrate was assessed by flow cytometry and 
percentage of neutrophils (Ly6G+) (A), monocytes (Ly6C+) (B), macrophages (F4/80+) (C) and eosinophils (SiglecF+) 
(D) were calculated from the CD45+ cells. Statistical analysis was performed using a paired t-test with results showing 




3.6. The Role of Endogenous Gal-1 in Efferocytosis. 
 
Efferocytosis was assessed by injecting fluorescently (CFSE) labelled apoptotic 
human neutrophils (2.5 x 106 cells) into the peritoneal cavity of WT and Gal-1 KO mice. 
After 30 or 60 mins cells were collected from the cavity by peritoneal lavage and 
analysed by flow cytometry (figure 45). 
 
Results, as shown in figure 45A revealed that Gal-1 KO mice had a significantly lower 
percentage of (F4/80+) macrophages (26.75% ± 2.5%) within the peritoneum 
compared to WT mice (41.43% ± 1.78%). This relatively decreased percentage of 
macrophages in Gal-1 KO mice did not confer a difference between genotypes in the 
percentage of macrophages positive for CFSE at either time point (figure 45B & C). 
Expectedly, there was an increase in percentages of macrophages CFSE+ from 30 
mins (figure 45B) to 60 mins (figure 45C)   
 
Assessment of the CFSE median fluorescence intensity (MFI) of the efferocytic 
(F4/80+CFSE+) population of cells showed that there was no difference between 
genotypes following a 30 min period of efferocytosis (figure 45D)  indicating a similar 
number of apoptotic cells had been engulfed per macrophage for each genotype. 
Following 60 minutes of efferocytosis (figure 45E) Gal-1 KO mice were shown to have 
ingested more apoptotic neutrophils than their WT counterparts (6810 ± 480 vs 5730 
± 400), however this increase was not significant.  
 
The percentage of CFSE+ apoptotic neutrophils remaining in the cavity was also 
analysed at both time points. When assessed as a percentage of the whole CFSE+ 
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population the results were comparable between genotypes, with an expected decline 
in percentage of free CFSE+ apoptotic neutrophils at 60 mins (22.93% ± 0.69%) (figure 
45G) compared to 30 mins (38.48% ± 5%) (figure 45F). However, a limitation of these 
values is that the percentage is relative to the other cells in the cavity, therefore actual 









































































































































































  Figure 45. In the absence of Gal-1 the percentage of macrophages were decreased following efferocytosis 
with no significant impact on apoptotic cell engulfment. 
CFSE labelled apoptotic neutrophils (2.5 x 106 cells) were injected into the peritoneal cavity of Gal-1 KO and WT mice. 
After 30 or 60 mins cells were collected from the cavity by peritoneal lavage and stained with antibodies to detect 
murine hematopoietic cells (CD45), murine macrophages (F4/80) and human neutrophils (CD66b). The CD45+ 
peritoneal exudate was assessed for percentage of macrophages (F4/80+) with representative flow cytometry plots 
displayed (A) and the macrophage population analysed for percentage CFSE+ after 30 mins (B) and 60 mins (C). The 
CFSE median fluorescence intensity was determined for the double positive efferocytic population (F4/80+CFSE+) 
following 30 mins (D) and 60 mins (E). The CFSE+ population was gated from the whole cell population and the 
percentage of free CFSE+ apoptotic neutrophils remaining within the cavity after 30 mins (F) or 60 mins (G) was 
determined as those F4/80-. Statistical analysis was performed using an unpaired t-test with results considered 




3.7. The Effect of Gal-1 on Apoptosis of Human Neutrophils in vitro.  
 
Neutrophils isolated from human peripheral blood were treated ± hrGal-1 (0.03, 0.1, 
0.3 and 1μM) ± GM-CSF (50ng/ml) or SAA (10µg/ml). Neutrophils were incubated 
overnight and levels of apoptosis were primarily determined by AnxV/PI using flow 
cytometry. Apoptosis was also quantified by mitochondrial membrane potential using 
DiOC6 staining and by morphology from cytospins. Additionally, phosphorylation of 
intracellular signalling proteins AKT, ERK and p38 MAPK, involved in the neutrophil 
apoptosis pathway, were also investigated by Western blot. Neutrophil release of 
AnxA1 was also detected by Western blot and expression analysed by flow cytometry. 
Early PS exposure on neutrophils in response to hrGal-1 was also assessed by 




Human PMN were isolated and incubated overnight to assess the impact of hrGal-1 
on spontaneous apoptosis. Treatment with hrGal-1 alone did not modulate the level of 
late apoptosis in human neutrophils. As expected GM-CSF significantly reduced the 
spontaneous apoptosis of neutrophils. Treatment with hrGal-1 in addition to GM-CSF 
reversed the protective effect of GM-CSF resulting in significantly increased levels of 
apoptosis (figure 46A & B). Results for the other stages of neutrophil apoptosis are 
summarised in table 12 as percentages (mean ± SEM) of the neutrophil populations 
found within each of the cell viability quadrants. The significant differences in late 





















GM-CSF (50ng/ml) + hrGal-1 (1µM)
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Figure 46. Gal-1 induces apoptosis of GM-CSF stimulated human neutrophils.  
Neutrophils isolated from human peripheral blood were incubated (20h) in RPMI + 5% autologous serum ± GM-CSF 
(50ng/ml) ± hrGal-1 (0.03, 0.1, 0.3 or 1μM). Levels of neutrophil apoptosis were assessed by flow cytometry using 
AnxV and Propidium Iodide (PI). A quadrant gating strategy was applied to determine viable (AnxV-PI-), early apoptotic 
(AnxV+PI-), late apoptotic (AnxV+PI+) and necrotic (AnxV-PI+) neutrophil populations. The percentage of double positive 
(AnxV+PI+) neutrophils is shown for each treatment as the mean ± SEM (A) together with representative flow plots (B). 
Statistical analysis was performed using a one-way ANOVA and in all cases results are considered significant when 
P < 0.05. * = significant difference between control and GM-CSF (50ng/ml) treatment. # = significant difference 





SAA (10µg/ml) was also used as an alternative pro-survival factor to GM-CSF, and the 
results revealed a similar trend. The proportion of neutrophils undergoing spontaneous 
apoptosis with SAA was reversed by addition of hrGal-1 (figure 47A & B), however, 
the results were not statistically significant. Again, results for the other stages of 
neutrophil apoptosis are summarised in table 13. Although statistical significance was 
not reached for the data, there is a clear trend for increased AnxV+PI+ late apoptotic 
percentages in SAA treated neutrophils co-incubated with hrGal-1 (18.73% ± 0.73% 
vs 32.87% ± 9.72%). As expected, the percentage of the population deemed as viable 
showed the inverse with decreased AnxV-PI- cells seen in response to addition of 
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Table 13. Gal-1 induces apoptosis of SAA stimulated human neutrophils.  




SAA (10µg/ml) + hrGal-1 (1µM)
Viable Early Apoptotic Late Apoptotic Necrotic









32.87 ±  9.72
0.15 ± 0.02
0.09 ± 0.02
0.42 ±  0.09
0.09 ±  0.02
29.53 ±  3.47
Figure 47. Gal-1 induces apoptosis of SAA stimulated human neutrophils.  
Neutrophils were isolated from the peripheral blood of healthy volunteers and incubated (20h) in RPMI – 1640 Medium 
+ L-glutamine + 5% autologous serum ± SAA (10µg/ml) ± hrGal-1 (0.03, 0.1, 0.3 or 1μM). Levels of neutrophil apoptosis 
were assessed by flow cytometry using AnxV and Propidium Iodide (PI). A quadrant gating strategy was applied to 
determine viable (AnxV-PI-), early apoptotic (AnxV+PI-), late apoptotic (AnxV+PI+) and necrotic (AnxV-PI+) neutrophil 
populations. The percentage of double positive (AnxV+PI+) neutrophils is shown for each treatment as the mean ± 
SEM (A) with representative flow plots (B). Statistical analysis was performed using a one-way ANOVA and in all 




3.7.2. Nuclear Morphology 
 
For confirmation of apoptosis it is best practise to use more than one method of 
assessment. Here, AnxV/PI results were validated using cytospins to assess 
neutrophil morphology.  
 
Cytospins were prepared for apoptotic neutrophils ± GM-CSF (50ng/ml) or SAA 
(10µg/ml) ± hrGal-1 (1µM) and stained with Kwik-Diff. From each cytospin 200 cells 
were counted and apoptotic neutrophils expressed as a percentage of the total 
neutrophil count. In line with the results obtained from the flow cytometry analysis 
morphological assessment of the nuclei revealed a decreased percentage of 
apoptosis in neutrophils treated with GM-CSF compared to untreated cells (30.14% ± 
3.47% vs 56.21% ± 6.20%). This pro-survival was reversed by the addition of hrGal-
1, which increased the percentage of apoptotic neutrophils (45.36% ± 5.48%), as 
displayed in figure 48 and table 14. 
 
When SAA was used as the pro-survival factor in place of GM-CSF a similar trend was 
observed. As shown in figure 49, SAA significantly decreased the percentage of 
apoptotic neutrophils compared to control (25.50% ± 10.10% vs 59.63% ± 9.75%), an 








































Figure 48. Gal-1 reverses GM-CSF elicited survival of human neutrophils.  
Neutrophils isolated from human peripheral blood were incubated (20h) in RPMI – 1640 Medium + L-glut + 5% 
autologous serum ± GM-CSF (50ng/ml) ± hrGal-1 (1μM). Levels of neutrophil apoptosis were assessed by nuclear 
morphology using light microscopy. 200 cells were counted for each sample and apoptotic neutrophils expressed as 
a percentage. Cumulative data are shown as the mean ± SEM  (A). Representative images are shown for each 
condition (B), with viable neutrophils indicated with a green spot. Statistical analysis was performed using a one-way 








hrGal-1 (1µM) ± 2.40
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Figure 49. Gal-1 reverses SAA elicited survival of human neutrophils.  
Neutrophils were isolated from the peripheral blood of healthy volunteers and incubated (20h) in RPMI – 1640 
Medium + L-glut + 5% autologous serum ± SAA (10µg/ml) ± hrGal-1 (1μM). Levels of neutrophil apoptosis were 
assessed by nuclear morphology using light microspcopy. 200 cells were counted for each sample and apoptotic 
neutrophils expressed as a percentage. Cumulative data are shown as the mean ± SEM (A). Representative images 
are shown for each condition (B), with viable neutrophils indicated with a green spot. Statistical analysis was 








hrGal-1 (1µM) ± 5.32
SAA (10µg/ml) ± 10.10













Besides PS exposure another early event as neutrophils undergo apoptosis is the 
disruption to mitochondrial membrane potential thus apoptosis was also assessed by 
DiOC6, a lipophilic dye that is selective for the mitochondria of live cells. Viable cells 
are DiOC6 high due to their density of lipids in their intact mitochondrial membrane, 
whereas apoptotic cells with their loss of membrane integrity stain with a relatively 
lower intensity. In this manner levels of apoptosis of neutrophils ± GM-CSF (50ng/ml) 
± hrGal-1 (1µM) was determined by gating on the viable (DiOC6 high) population of 
cells.  
 
Results in table 16 are expressed as a percentage of the total single cell population ± 
SEM and displayed in figure 50. Apoptotic neutrophils had the lowest DiOC6 staining 
and thus the least viable cells (25.82% ± 4.61%). Interestingly hrGal-1 treated 
neutrophils and GM-CSF treated neutrophils had an increased percentage of DiOC6 
positive cells (35.66% ± 7.42% and 40.73% ± 5.67% respectively) compared to control. 
Neutrophils that had been co-treated with both hrGal-1 and GM-CSF whilst undergoing 
spontaneous apoptosis had the highest population of DiOC6 positive cells (48.48% ± 
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Figure 50. Gal-1 has no significant effect on mitochondrial membrane potential during apoptosis.  
Neutrophils isolated from human peripheral blood were incubated (20h) in RPMI – 1640 Medium + L-glut + 5% 
autologous serum ± GM-CSF (50ng/ml) ± hrGal-1 (0.03, 0.1, 0.3 or 1μM). Mitochondrial membrane potential was 
assessed by DiOC6 staining and analysed by flow cytometry. DiOC6 positive neutrophils were gated from the single 
cell population and cumulative data is shown as the mean ± SEM (A) with representative flow plots (B) for each 
treatment. Statistical analysis was performed using a one-way ANOVA and in all cases results are considered 
significant when P < 0.05. n=9. 
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3.7.4. Intracellular Signalling  
 
Intracellular signalling pathways known to be involved in neutrophil apoptosis were 
investigated by Western blot. Results indicated that GM-CSF (50ng/ml) induced rapid 
phosphorylation of AKT within 1 minute. This response was mainly upheld at 5mins 
and reduced by 15mins, as displayed in figure 51A. HrGal-1 (1μM) in combination with 
GM-CSF shows a trend for decreased signalling at 1min whereas at 5mins and 15mins 
the phosphorylation of AKT was no different to GM-CSF only. The initial peak in GM-
CSF induced phosphorylation of AKT was blunted by hrGal-1, resulting in comparably 
increased phosphorylation occurring at 5mins. No detectable phosphorylation of AKT 
occurred in response to stimulation with hrGal-1 alone, with all samples remaining 
comparable to unstimulated neutrophils. 
 
Phosphorylation of p38 MAPK was also rapidly induced by GM-CSF at 1 min and 
remained relatively constant, as shown in figure 51B. The p38 MAPK signalling 
pathway was largely unchanged when neutrophils were co-treated with hrGal-1 in 
addition to GM-CSF. Neutrophils stimulated with hrGal-1 alone showed no significant 
signalling induction however phosphorylation of p38 MAPK was marginally enhanced 
at 15mins compared to unstimulated neutrophils.  
 
The induction of ERK phosphorylation by GM-CSF stimulation commenced after 1min, 
and continued to increase at 5mins and 15mins, as in figure 51C. The signal induction 
was initially delayed when neutrophils were co-stimulated with hrGal-1, before 
increasing with longer stimulation, with highest phosphorylation levels at 15mins. 
Treatment with hrGal-1 alone induced a very subtle signalling response in neutrophils 











Figure 51. Gal-1 delayed GM-CSF induced phosphorylation of signalling pathways. 
Neutrophils isolated from human peripheral blood were incubated (1min, 5min and 15mins) in RPMI Medium ± GM-
CSF (50ng/ml) ± hrGal-1 (1μM). Following stimulation cells were lysed in hot loading buffer, sheared with a syringe 
and blotted for phosphorylation of AKT (A), P38 (B) and ERK (C). Representative blots are inlaid. Densitometry 
analysis was performed to quantify protein in bands. Results are shown as a ratio of phosphorylated protein to total. 
Cumulative data is shown as the mean ± SEM. n=2. 
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3.7.5. Early Phosphatidylserine Exposure 
 
AnxV binding was used to detect initial PS exposure on neutrophils following 1h 
treatment with hrGal-1 (1μM). Results shown in figure 52, revealed that compared to 
control neutrophils, hrGal-1 (1h) caused significantly increased PS exposure on the 
neutrophil surface (22.30% ± 6.78% vs 36.17% ± 4.62%, p = 0. 0317).  
 
  
Figure 52. Gal-1 increases early phosphatidylserine exposure on the surface of neutrophils. 
Neutrophils isolated from human peripheral blood were suspended in RPMI + 5% autologous serum, hrGal-1 (1μM) 
was added to cells for 1h incubation and PS exposure was detected by AnxV staining and analysed by flow cytometry. 
Cumulative data for percentage of neutrophils AnxV+ is shown as the mean ± SEM (A) with representative flow plots 
for each treatment (B). Statistical analysis was performed using a paired t test and results are considered significant 
































Similarly, AnxV binding was used to detect initial PS exposure on neutrophils following 
4h (0.03, 0.1, 0.3 and 1μM) hrGal-1 ± hrGM-CSF (50ng/ml). After 4h neutrophils 
treated with hrGal-1 (1μM) still maintained increased PS exposure compared to 
unstimulated cells, this was not modified further by co-incubation with GM-CSF. As 
shown in figure 53 neutrophils incubated with GM-CSF had significantly increased 
phosphatidylserine externalisation in response to hrGal-1 (1μM) (AnxV+ %; 21.62% ± 






  Figure 53. Gal-1 maintains phosphatidylserine exposure on the surface of neutrophils. 
Neutrophils isolated from human peripheral blood were suspended in RPMI + 5% autologous serum. Cells were 
incubated for 4h ± GM-CSF (50ng/ml) ± hrGal-1 (0.03, 0.1, 0.3 or 1μM). Phosphatidylserine exposure was detected 
by AnxV staining and analysed by flow cytometry. Cumulative data for percentage of neutrophils AnxV+ is shown as 
the mean ± SEM (A) with representative flow plots for each treament (B). Statistical analysis was performed using a 




3.7.6. AnnexinA1 Expression 
 
Annexin A1 (AnxA1) is an endogenous protein that exerts anti-inflammatory and pro-
resolving effects. Endogenous AnxA1 is rapidly translocated to the neutrophil surface 
upon activation and can override pro-survival signals to induce neutrophil apoptosis.  
 
In this study surface and total AnxA1 levels were assessed on/in neutrophils at 0h and 
following incubations of 4h and 20h ± GM-CSF (50ng/ml) ± hrGal-1 (1µM). Results 
demonstrated no significant modulation in surface AnxA1 after 4h and 20h compared 
to levels expressed on freshly isolated cells. As displayed in figure 54A, stimulation 
with GM-CSF and/or hrGal-1 did not result in any notable modulation of surface AnxA1 
compared to control cells.  
 
Compared to surface expression, total AnxA1 levels were approximately 250-fold 
higher, indicating that the protein is predominantly intracellular. Total AnxA1 levels 
increased over time, with the highest expression of the protein detected at 20h (a time 
point where neutrophils are known to undergo spontaneous apoptosis). Results, 
shown in figure 54B, also revealed a trend towards reduced AnxA1 levels for 
neutrophils stimulated with GM-CSF, however this was not significant. Furthermore, 
data at 20h suggests that this reduction may be partially reversed by the co-incubation 
of cells with hrGal-1, whereas there was no notable effect revealed for hrGal-1 alone 
(similar to flow cytometry AnxV/PI data in section 3.3.1). 
 
To assess AnxA1 release from neutrophils, cell free culture media was collected after 
4h and 20h incubation and analysed by Western blot. Both the 4h and 20h time points 
showed the same trend, whereby GM-CSF markedly reduced neutrophil release of 
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AnxA1, as shown in figure 54C. Co-incubation with hrGal-1 reversed this effect, 
however the differences were less prominent at 4h compared to the 20h incubation. 
Notably, no AnxA1 was detected in the negative control which contained culture media 





Figure 54. Gal-1 reverses the effect of GM-CSF on AnxA1 release by apoptotic neutrophils. 
Neutrophils isolated from human peripheral blood were incubated in RPMI + 5% autologous serum ± hrGal-1 (1μM) ± 
GM-CSF (50ng/ml) for 4h and 20h. At 0h, 4h and 20h neutrophil surface (A) and total (B) AnxA1 was analysed by flow 
cytometry. Cell free culture media was assayed for AnxA1 by Western Blot (C), results shown for one representative 
donor (4h left hand side, 20h right hand side). Cumulative data are shown as the mean ± SEM. Statistical analysis 




3.8. Gal-1 Expression and Binding on Human Neutrophils. 
 
The relative level of Gal-1 on the surface of neutrophils as they undergo apoptosis 
was assessed to determine if it is modulated with the apoptotic process. Furthermore, 
if the Gal-1 detected on the surface was coming from the addition of the exogenous 
protein binding to the cell or if it originated intracellularly and if its exposure at the cell 
surface was modulated as a consequence of undergoing apoptosis was also 
investigated. Finally, whether exogenous Gal-1 had a higher affinity for binding to 
viable or apoptotic neutrophils was also addressed. In these assays extracellular Gal-
1, exogenously bound and/or endogenously expressed, was detected on neutrophils 
using flow cytometry.  
 
3.8.1. Viable Neutrophils 
 
Incubation of neutrophils with hrGal-1 (1μM) for 1h confirmed that Gal-1 binds to viable 
neutrophils, as indicated by significantly increased Gal-1 detected on the surface of 
neutrophils incubated with the exogenous protein (p = 0.0283, figure 55A). Inclusion 
of lactose (30mM), which is known to inhibit galectin binding, notably reduced surface 
Gal-1 (as shown in figure 55B), and therefore further verified that the initial increase 
was the result of exogenous protein binding to the neutrophil surface in a 






Figure 55. Gal-1 binds to the surface of viable neutrophils. 
Neutrophils isolated from human peripheral blood were suspended in RPMI + 5% autologous serum for 1h ± hrGal-1 
(1μM) (A) and co-incubated with lactose (30mM) (B). Surface Gal-1 levels were analysed by flow cytometry and 
cumulative data is shown as the mean ± SEM. Histogram and Gal-1 median fluorescence intensity values shown for 
a representative donor. Statistical analysis was performed using a paired t test with results considered significant when 




3.8.2. Exogenous Gal-1 during Neutrophil Apoptosis 
 
Neutrophils incubated for 20h in 5% autologous serum had similar levels of Gal-1 on 
their surface compared to viable neutrophils and therefore demonstrated that Gal-1 is 
not increased on the surface of unstimulated apoptotic neutrophils in comparison to 
viable cells, as shown in figure 56A. The addition of GM-CSF (50ng/ml) and/or hrGal-
1 (1μM) to the overnight incubation resulted in increased Gal-1 detected on the 
neutrophil surface, however this trend was not significant. Incubation with lactose 
(30mM) did not have any effect on the already bound/expressed levels of Gal-1 on 
apoptotic neutrophils (figure 56B) and therefore indicated that Gal-1 is not easily 
























Figure 56. Gal-1 on the surface of apoptotic neutrophils is not removed by lactose. 
Neutrophils isolated from human peripheral blood and incubated in RPMI 5% autologous serum ± GM-CSF (50ng/ml) 
± hrGal-1 (1μM) for 20h (A) and following 20h incubation, lactose (30mM) was added to apoptotic neutrophils for 1h 
(B). Surface Gal-1 levels were analysed by flow cytometry and cumulative data is shown as the mean ± SEM. Flow 




3.8.3. Apoptotic Neutrophils 
 
Incubation of apoptotic neutrophils with hrGal-1 (1μM) for 1h resulted in an increase 
in Gal-1 on the surface of the neutrophil population, as shown in figure 57A. When the 
whole neutrophil population was plotted as a histogram for Gal-1 MFI two distinct 
peaks were revealed, as in figure 57B. Both control neutrophils and hrGal-1 treated 
cells had a high MFI population that was comparably equal in height and distribution 
and did not shift in response to hrGal-1. Conversely the population which formed a 
peak with lower Gal-1 expression was shown to increase in levels of the protein in 
response to incubation with hrGal-1. On further assessment the population with high 
Gal-1 expression could be classified as late apoptotic based on the decreased forward 
and side scatter (indicative of cell shrinkage - a classic phenotype of apoptotic cells). 
The population with lower Gal-1 expression had a higher forward and side scatter 
when plotted and formed a tighter cloud of cells, typical of live neutrophils, as shown 
in plots in figure 57C. This data indicates that hrGal-1 does not bind to the surface of 
neutrophils undergoing the latter stages of apoptosis and thus committed to cell death. 
Furthermore, in this assay hrGal-1 maintains the ability to bind living neutrophils in the 
presence of apoptotic cells and any mediators they have released whilst undergoing 






Figure 57. Gal-1 does not bind to the surface of late apoptotic neutrophils. 
Neutrophils isolated from human peripheral blood were incubated in RPMI + 5% autologous serum for 20h. Following 
incubation hrGal-1 (1μM) was added to apoptotic neutrophils for 1h. Surface Gal-1 levels were analysed by flow 
cytometry and cumulative data is shown as the mean ± SEM (A). Histograms display Gal-1 MFI (left) and further 
indicate non apoptotic and late apoptotic cell populations (right) for a representative donor (B) also presented as FSC-


































3.9. Gal-1 Receptor Expression and Binding on Human Neutrophils. 
 
Assessment of galectin receptor expression on neutrophils was performed ± GM-CSF 
(50ng/ml). GM-CSF was not shown to modulate levels of the transmembrane 
glycoproteins CD43 (figure 58A) or CD44 (figure 58B). In this assay neutrophils were 
also incubated ± hrGal-1 (0.03μM, 0.1μM, 0.3μM and 1μM) in addition to GM-CSF. As 
shown in figures 58A and B there was no notable modulation to the capability of either 
the CD43 or CD44 antibodies to bind to the cell surface as a result of the addition of 
hrGal-1. In contrast, CD45 was markedly upregulated on the neutrophil surface in 
response to 4h incubation with the pro-survival cytokine, as shown in figure 58C. In 
addition, detection of CD45 using an anti-CD45 antibody was compromised by hrGal-
1, with a concentration dependent response seen, whereby an increase in hrGal-1 
resulted in the inverse level of anti-CD45 binding to the neutrophil. This was shown for 
neutrophils with and without GM-CSF (figure 58C) and suggested that hrGal-1 is 
binding to the CD45 on the cell surface and thus prohibiting antibody binding to the 





































































  Figure 58. The Gal-1 receptor CD45 was upregulated on neutrophils in response to GM-CSF. 
Neutrophils isolated from human peripheral were incubated (4h) in RPMI + 5% autologous serum ± GM-CSF (50ng/ml) 
± hrGal-1 (0.03, 0.1, 0.3 or 1μM). Expression of galectin receptors on the neutrophil surface were assessed by CD43 
(A), CD44 (B) and CD45 (C) antibody binding and analysed by flow cytometry. The median fluorescence intensity 
(MFI) for each receptor was determined from the single cell population of neutrophils. Cumulative data are shown as 
the mean ± SEM (left) with representative histograms (right). Statistical analysis was performed using a one-way 




3.10. The Effect of exogenous Gal-1 on Efferocytosis. 
 
Efferocytosis assays were performed to determine whether neutrophils undergoing 
apoptosis ± hrGal-1 (1μM) ± GM-CSF (50ng/ml) would be efferocytosed any differently 
as a result of either agent. Furthermore, the addition of hrGal-1 (1μM) to both viable 
and apoptotic neutrophils (1h) prior to and during their addition to macrophages was 
used to determine whether Gal-1 served as an opsonin. Efferocytosis was assessed 
by overlaying apoptotic human neutrophils on human macrophages for 1h and then 
analysing uptake by flow cytometry. For consideration of macrophage efferocytic 
satiation two different macrophages to apoptotic neutrophils ratios were assessed, by 
overlaying 2x106 or 5x106 neutrophils, yielding a ratio of 1:2 or 1:5 respectively.  
 
3.10.1. Exogenous Gal-1 during Neutrophil Apoptosis 
 
After 1h approximately 35% of macrophages had ingested an apoptotic neutrophil 
when they were plated at a ratio of 1:2.  Results indicated that there was no difference 
in phagocytic uptake of neutrophils by macrophages as a result of cells undergoing 
apoptosis in the presence ± hrGal-1 (1μM) ± GM-CSF (50ng/ml). The highest MFI 
values were observed with the co-treatment (figure 59B). As expected, when the ratio 
of apoptotic PMN to macrophages was increased, this resulted in an increased 
percentage of macrophages having ingested neutrophils (approximately 10-20% more 
macrophages) (figure 60A). When the baseline level of efferocytosis was increased 
the differences with Gal-1 treatment became less obvious, although the highest 
percentage of efferocytosis was observed with GM-CSF plus hrGal-1. Again, the 
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  Figure 59. Gal-1 addition to neutrophils undergoing apoptosis did not affect macrophage efferocytosis or 
satiation (I). 
Neutrophils were incubated (20h) in RPMI + 5% autologous serum ± GM-CSF (50ng/ml) ± hrGal-1 (1μM) to undergo 
apoptosis. Efferocytosis was assessed by overlaying apoptotic neutrophils (2 x 106) on macrophages (1 x 106) for 1h. 
Remaining neutrophils were washed away, and macrophages were collected. Cells were permeabilised, stained with 
an antibody against a human macrophage-specific marker (CD86) and a human neutrophil specific marker (CD66b) 
and analysed by flow cytometry.  The macrophage population was assessed for percentage CD66b+ (A) and the 
positive population assessed for CD66b fluorescence intensity and displayed as the median values (B) with 
representative plots for quadrant gating displayed (C). Statistical analysis was performed using a one-way ANOVA 
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Figure 60. Gal-1 addition to neutrophils undergoing apoptosis did not affect macrophage efferocytosis or 
satiation (II). 
Neutrophils were incubated (20h) in RPMI + 5% autologous serum ± GM-CSF (50ng/ml) ± hrGal-1 (1μM) to undergo 
apoptosis. Efferocytosis was assessed by overlaying apoptotic neutrophils (5 x 106) on macrophages (1 x 106) for 1h. 
Remaining neutrophils were washed away, and macrophages were collected. Cells were permeabilised, stained with 
an antibody against a human macrophage-specific marker (CD86) and a human neutrophil specific marker (CD66b) 
and analysed by flow cytometry.  The macrophage population was assessed for percentage CD66b+ (A) and the 
positive population assessed for CD66b fluorescence intensity and displayed as the median values (B) with 
representative plots for quadrant gating displayed (C). Statistical analysis was performed using a one-way ANOVA 




3.10.2. Exogenous Gal-1 as an Opsonin 
 
The addition of hrGal-1 (1μM) to both viable and apoptotic neutrophils (1h) prior to and 
during their incubation with macrophages was used to determine whether Gal-1 
served as an opsonin. Here, efferocytosis of neutrophils was not modulated by hrGal-
1 being added to apoptotic cells for 1h prior to and during their overlay on 
macrophages. These results showed that neither the percentage of macrophages 
containing neutrophils (figure 61A) or the relative number of cells ingested (figure 61B) 
was affected by addition of hrGal-1.  Likewise, viable neutrophils treated with hrGal-1 
before and during their co-incubation with macrophages revealed no significant effect 
on either macrophage percentage or MFI (figures 62A & B respectively) in response 
to the inclusion of hrGal-1 in the assay. These results suggest that Gal-1 does not act 





Figure 61. Gal-1 does not act as an opsonin for macrophage efferocytosis of apoptotic neutrophils. 
Efferocytosis was assessed by overlaying apoptotic neutrophils (2 x 106) on macrophage (1 x 106) for 1h ± hrGal-1 
(1µM). For apoptotic cells neutrophils were incubated in RPMI – 1640 Medium + L-glut + 5% autologous serum for 
20h, hrGal-1 was then added to apoptotic neutrophils 1h prior to overlaying on macrophage and maintained within the 
media during co-incubation. Remaining neutrophils were then washed away and macrophage collected. Cells were 
permeabilised and stained with antibodies against human macrophage (CD86) and human neutrophils (CD66b).  The 
macrophage population was analysed by flow cytometry for percentage CD66b+ (A) and the positive population 
assessed for CD66b fluorescence intensity and displayed as the median values (B) with representative plots for 
quadrant gating displayed (C). Statistical analysis was performed using a paired t test with results considered 






































































































































Figure 62. Gal-1 does not act as an opsonin for macrophage efferocytosis of viable neutrophils. 
Efferocytosis was assessed by overlaying viable neutrophils (2 x 106) on macrophage (1 x 106) for 1h ± hrGal-1 (1µM). 
HrGal-1 was added to neutrophils 1h prior to overlaying on macrophage and maintained within the media during co-
incubation. Remaining neutrophils were then washed away and macrophage collected. Cells were permeabilised and 
stained with antibodies against human macrophage (CD86) and human neutrophils (CD66b). The macrophage 
population was analysed by flow cytometry for percentage CD66b+ (A) and the positive population assessed for 
CD66b fluorescence intensity and displayed as the median values (B) with representative plots for quadrant gating 




Chapter 4: Discussion  
 
Considered to be predominantly endowed with anti-inflammatory actions Gal-1 targets 
various stages of the immune response. Its effects are varied depending on the target 
cell type and whether the actions are intracellular or extracellular. The promiscuous 
binding of Gal-1 also increases the complexity for defining the mechanisms of action; 
known receptors include CD43 and CD45 on T cells (Nguyen et al., 2001; Hernandez 
et al., 2006). Particularly pertinent to this project are its effects on leukocyte trafficking 
and apoptosis. Inhibition of T cell trafficking under both physiological and 
pathophysiological states, has been shown to be significantly inhibited in response to 
Gal-1 (Norling et al., 2008).  The ability of Gal-1 to induce the apoptosis of Th1 cells, 
as well as switch the immune response towards a Th2 phenotype, is thought to be 
central to its immunomodulatory functions (Rabinovich, Daly, et al., 1999). In this 
regard, the protective effects of Gal-1 have been evidenced in several models of auto-
immune disease, such as collagen-induced arthritis (Rabinovich, Daly, et al., 1999; 
Iqbal et al., 2013) and experimental autoimmune encephalomyelitis  (Offner et al., 
1990), with the former providing the first link between Gal-1 and RA .  
 
With regards to the innate immune system, administration of recombinant Gal-1 has 
been shown to reduce leukocyte trafficking in vivo (La et al., 2003) and to inhibit 
neutrophil-endothelial interactions in vitro (Cooper et al., 2008), whilst trafficking is 
enhanced in Gal-1 KO mice (Cooper et al., 2008). A suggested role in resolution of 
inflammation stemmed from its presence in resolving exudates (Chiang et al., 2008). 
Evidence for a role in neutrophil apoptosis and clearance is scant, with current 
literature suggesting that it may facilitate neutrophil clearance via a process termed 
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“preaperesis” whereby neutrophils are efferocytosed without undergoing apoptosis, 
but this has still to be definitively proven (Dias-Baruffi et al., 2003; Stowell et al., 2007, 
2009). Specifically, Gal-1 has been shown to induce the outer membrane exposure of 
the common death signal phosphatidylserine in neutrophils independently of apoptosis 
(Stowell et al., 2009). However findings from one study determined this response to 
be dependent on neutrophil phenotype, indicating that the phenomenon of PS 
exposure in the absence of apoptosis only occurs when cells are activated and the 
same effect is not seen on resting cells (Stowell et al., 2007). Furthermore, it was also 
shown to be reversible as phosphatidylserine exposure reverts inwards again after 
Gal-1 removal (Stowell et al., 2009), without altering cell viability.  
  
These studies point towards a relationship between Gal-1 and neutrophil behaviour, 
particularly with respect to cell trafficking and viability, which has the potential to be 
fundamentally relevant to neutrophil-driven pathologies. Rheumatoid Arthritis provides 
an example where perpetuation of disease results from the recurrent movement of 
neutrophils from the blood to the targeted site, in this case the arthritic joint. The 
continual influx of inflammatory stimulated neutrophils in combination with the 
enhanced lifespan afforded to these cells crucially supplement the progression of 
inflammation and causation of chronic disease. Yet the impact of Gal-1 on neutrophil-
driven pathologies is not well studied and remains poorly understood. Likewise, the 
roles of Gal-1 in the resolution of inflammation remains to be fully elucidated as well 
as whether the abilities of the protein to inhibit neutrophil recruitment and potentiate 
neutrophil clearance are responsible for mediating the anti-inflammatory properties 
demonstrated by Gal-1. Therefore, these aspects have been chosen for further 
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investigation and study by comprehensive examination of the role of Gal-1 on 





4.1. Gal-1 Modulates Neutrophil Numbers in a Model of Acute Inflammation. 
  
4.1.1. Neutrophil Recruitment is Enhanced in the Absence of Gal-1. 
 
Significantly more neutrophils trafficked to the peritoneal cavity of Gal-1 null mice, 
compared to their WT counterparts during acute low dose zymosan (6h time point), 
indicating that in acute inflammation, neutrophil trafficking is increased in the absence 
of Gal-1. This result is in line with findings in the literature, with enhanced neutrophil 
trafficking in the colon of Gal-1 KO mice in response to infection with C. rodentium 
(Curciarello et al., 2014). Leukocyte trafficking is also enhanced in the inflamed 
cremasters of Gal-1 KO mice in response to IL-1β (Cooper et al., 2008). 
 
It is well established that endogenous Gal-1 is expressed by endothelial cells and that 
this expression, as well as distribution, can be upregulated on the surface membrane 
by inflammatory cytokines (Baum, Pang, et al., 1995; Baum, Seilhamer, et al., 1995). 
It is therefore plausible that endogenous Gal-1 is produced by the endothelium to 
counter regulate neutrophil trafficking. More specifically that upregulation of Gal-1 on 
the endothelial cell surface occurs in response to stimulation by inflammatory 
cytokines as a mechanism of impeding recruitment and preventing an overzealous 
infiltration of leukocytes to sites of inflammation. This also holds true in the context of 
lymphocyte recruitment and trafficking of these cells along the activated endothelium  
(Norling et al., 2008). 
 
Along with increased neutrophil recruitment in Gal-1 KO mice significant increases in 
the pro-inflammatory cytokine IL-6 as well as the pro-angiogenic growth factor VEGF 
were also detected. IL-6 is a pleiotropic cytokine involved in the acute phase response 
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and in the context of zymosan peritonitis inhibition of this cytokine reduces the 
inflammatory response (Cuzzocrea et al., 1999). VEGF is also involved in the rapid 
recruitment of neutrophils in vivo (Massena et al., 2015), hence aligning with elevated 
levels in Gal-1 null mice. The chemokines CCL2 (MCP-1), CCL3 (MIP-1α) and CXCL1 
(KC), as well as the pro-inflammatory cytokine TNF-α and the growth factor GM-CSF 
also all revealed a trend towards increased levels in the absence of Gal-1, thus 
corroborating the heightened inflammatory response. The differences described 
above in the cytokine profile of Gal-1 KO mice compared to WT at 2h post zymosan 
suggest that a lack of Gal-1 may impact downstream signalling of TLR2 in 
macrophages.  
 
The augmented neutrophil response at the peak (6h) did not have a notable impact on 
recruitment of any other leukocyte subsets to the peritoneal cavity during peak 
infiltration. Although significantly more neutrophils were found within the peritoneal 
cavity of Gal-1 KO mice at 6h, this difference was lost at the 24h time-point suggesting 
that clearance might be faster in these mice.  
 
4.1.2. Gal-1 Null Macrophages Exhibit Alternative Activation and Augmented 
 Efferocytosis. 
 
To investigate the role of endogenous Gal-1 in neutrophil clearance, levels of 
apoptosis and efferocytosis were assessed from peritoneal exudates collected from 
multiple time points. As expected during the initiation of inflammation (2h) and 
resolving phase (24h and 48h), exudated neutrophils were predominantly viable, 
whereas at the peak (6h), the majority were early apoptotic, however there was no 
significant difference between genotypes. A trend towards increased early apoptotic 
285 
 
cells was detected at 24h in Gal-1 KO mice along with an increased percentage of 
efferocytic macrophages (F4/80+Ly6G+). However, these permeabilised 
macrophages had a lower Ly6G MFI suggesting they had ingested fewer neutrophils 
per macrophage than WT. Thus, whilst there were more macrophages clearing 
apoptotic neutrophils in Gal-1 KO mice the cumulative effect on clearance was likely 
similar between genotypes. It is feasible that the apoptotic/efferocytic process is faster 
or earlier in Gal-1 KO mice, or alternatively these results may simply be a reflection of 
the efficiency of the resolution process and the ability of the system to regain 
homeostasis. 
 
Following ingestion of apoptotic neutrophils, macrophages swiftly depart the 
inflammatory site making efferocytosis a tricky process to capture in vivo. Studying the 
cells ex vivo can provide an insight, which cannot be obtained using this in vivo model. 
Interestingly, when inflammatory macrophages collected from Gal-1 KO mice were 
cultured ex vivo the cells exhibited an enhanced phagocytic capacity (Barrionuevo et 
al., 2007), the same study also revealed significantly higher levels of MHC-II.  In 
support of this latter finding, bone marrow derived macrophages from Gal-1 KO mice 
showed elevated MHC-II expression on M1 as well as M2 cells. BMDM from Gal-1 KO 
mice were consistently more ‘M2’ like and displayed significantly higher CD206 and 
lower CD86 than WT cells. Levels of the scavenger receptors CD36 and MerTK, which 
promote efficient phagocytosis also showed a trend for increased expression on Gal-
1 null macrophages. These findings seem paradoxical when exogenous Gal-1 has 
been shown to promote macrophage conversion to a pro-resolving ‘M2’ phenotype 
(Rostoker et al., 2013) and thus further illustrate the divergent roles of intracellular 




It has already been established that macrophages are a major source of endogenous 
Gal-1 (Rabinovich et al., 1996, 1998). Resident peritoneal macrophages exhibit scant 
levels of Gal-1, however in vivo elicited-inflammatory macrophages and in vitro 
activated macrophages have far greater levels of Gal-1 with expression in the nuclei, 
secretory granules as well as adjacent to the granules within the cytoplasm (Correa et 
al., 2003). We demonstrated that Gal-1 was readily detected in peritoneal lavage fluid 
from mice undergoing zymosan peritonitis, with the highest levels at 48h. Our results 
corroborated published data; resident macrophages had very little Gal-1 expression 
whereas resolution phase macrophages (48h time point) had maximal expression 
(Law et al., 2020). These results implicate another cellular source for Gal-1 in the 
peritoneum under a non-inflamed state.  
 
Exogenous Gal-1 enhances macrophage infiltration into the resolving peritoneum (Gil 
et al., 2006; Malik et al., 2009). Thus, it was unexpected that increased numbers of 
macrophages were detected in the resolving (48h) cavity of Gal-1 null mice, 
specifically in the resolving (CD11blow) population of macrophages with no difference 
detected in numbers of mature (CD11bhigh) macrophages. Interestingly, endogenous 
Gal-1 has been shown to be selectively expressed by CD11bhigh macrophages and 
not by CD11blow macrophages (Rostoker et al., 2013). In the same study it was 
reported that exogenous Gal-1 directly promoted macrophage conversion from a 
CD11bhigh to a CD11blow phenotype and subsequent efferocytic satiation. This 
suggests that Gal-1 in the inflammatory milieu is important for active resolution of 
inflammation. It could be the case that Gal-1 presence in the inflammatory milieu, 
either via the release of endogenous Gal-1 from CD11bhigh macrophages or from the 
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addition of exogenous protein, has a role in promoting a more rapid conversion of 
macrophages to a CD11blow pro-resolving phenotype which subsequently reach 
efferocytic satiation quicker and thus will have departed from the resolving cavity 
earlier. If this theory were to be the case the higher number of resolving macrophages 
found within the cavity of Gal-1 null mice during the resolution phase could be 
explained by a delayed conversion to CD11blow cells. However, a full characterization 
of Gal-1 KO macrophage phenotype has not been performed and as such the exact 
role of endogenous Gal-1 in macrophages still requires full examination. 
 
Initially it was compelling to think that the increased number of macrophages detected 
in the Gal-1 KO mice at 48h was simply the direct response to the increased neutrophil 
infiltrate observed in these mice. However, further consideration of the data resulted 
in a revision of this hypothesis. Neutrophil numbers within the cavity were decreased 
at 24h, at which point they had also ceased to be increased in Gal-1 KO mice. There 
was also no increase in macrophages detected at 24h nor any suggestion of 
differences in efferocytosis at 48h. Taken together it seems highly unlikely that these 
CD11blow macrophages have been retained within the cavity because they are still 
required for the clearance of apoptotic neutrophils. 
 
Protocols to detect apoptosis and efferocytosis in the zymosan-induced peritonitis 
model have been optimised, however these events remain very difficult to capture in 
in vivo models. Exposure of phosphatidylserine (PS) on the neutrophil surface occurs 
as part of the initial stage of apoptosis (Denecker et al., 2000) and provides a rapid 
‘eat me’ signal to macrophages. Following their recognition of this signal macrophages 
are quick to respond and rapidly begin to engulf these PS exposing early apoptotic 
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cells. The percentage of cells that remain in the cavity following progression to late 
apoptosis are minimal. As such it was decided to assess neutrophil apoptosis ex vivo 
comparing genotypes. Significantly more apoptotic neutrophils were detected from 
peritoneal exudates collected at 6h from Gal-1 KO mice compared to WT. This 
suggests that apoptosis might progress faster in the absence of Gal-1, or it may be a 
reflection of increased neutrophil numbers within the peritoneal cavity at this time 
point. Regarding the latter there are a number of published studies supporting a 
positive correlation between cell density and spontaneous apoptosis and that this is 
the case for both adherent cells and cells cultured in suspension (Saeki et al., 1997; 
Qiao and Farrell, 1999). In this study cells from 1ml of lavage fluid collected from each 
mouse were resuspended in low serum media, plated and cultured overnight to 
undergo apoptosis. As cell number was not normalised, there would have been more 
neutrophils collected and plated from Gal-1 KO mice than WT, a difference which may 
well have impacted the rate of apoptosis and therefore could explain the significant 
increase in the ex vivo apoptosis of neutrophils from Gal-1 KO mice. In recognition of 
this discrepancy it would be pertinent to determine if apoptosis of viable neutrophils 
taken from Gal-1 KO mice would still progress quicker if peritoneal neutrophils were 
at the same cell density as WT cells. An additional important consideration regarding 
this ex vivo assay is the different levels of inflammatory mediators present in vivo within 
the peritoneal cavity of Gal-1 KO mice compared to WT. When measured during the 
early phase of the inflammatory response in this model Gal-1 KO mice were shown to 
have comparatively elevated levels of several inflammatory mediators, including GM-
CSF, known to influence neutrophil survival. Thus, it is worth considering that the loss 
of pro-survival signal, resulting from in vivo to ex vivo transition, was likely greater for 
Gal-1 KO cells and potentially impacted on their rate of spontaneous apoptosis. 
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4.1.3. Exogenous Gal-1 Reduces Neutrophil Number at the Inflammatory Site 
when Administered at the Peak of Inflammation. 
 
Both IL-1β and zymosan-induced peritonitis stimulate an acute immune response 
within a few hours post injection into the peritoneal cavity. The similarities between the 
models and previous findings seen in IL-1β induced peritonitis led to the hypothesis 
that neutrophil numbers within the peritoneal cavity would decrease in response to 
treatment with hrGal-1 in this in vivo model of zymosan induced peritonitis. However, 
despite that both studies assessed cellular infiltrate into the peritoneal cavity four hours 
post administration of hrGal-1 the same outcome was not reflected in this experimental 
setting. Indeed, it could be the case that the current study showed no significant 
modification of the leukocyte numbers in response to hrGal-1, when given early during 
the recruitment phase, due to the mechanistic differences between the models. In 
peritonitis induced by IL-1β there is direct activation of the endothelial cells whereas 
in the zymosan model the inflammogen is acting via toll like receptors (TLR) on 
macrophages. The mechanistic differences stimulating the inflammatory response in 
each of these in vivo models may be accountable for the differences seen in neutrophil 
trafficking and recruitment.  
 
The disparity between models may also be due to timing of administration of the 
recombinant protein or the dosing strategy utilised for the administration of hrGal-1 in 
this study. Previous in vitro studies demonstrating an inhibitory effect on neutrophil 
recruitment have involved pre-incubating neutrophils with hrGal-1 prior to use in an in 
vitro flow chamber model (Cooper et al., 2008). In the IL-1β–induced peritonitis model  
hrGal-1 was co-administered with the pro-inflammatory stimulant (La et al., 2003). 
Whereas in this current study, therapeutic administration of hrGal-1 was given two 
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hours post-stimuli, when the inflammatory response had already been initiated. In this 
case rapid recruitment of neutrophils towards the peritoneal cavity would have already 
taken place at the time of hrGal-1 treatment and thus might account for the lack of 
effect in this system. Future in vivo studies should consider the co-administration or 
prophylactic treatment with hrGal-1 in the Zymosan peritonitis model to verify that 
there is truly no difference in leukocyte and more specifically neutrophil recruitment in 
response to exogenous hrGal-1. 
 
Aside from the neutrophil population consideration should also be given to 
macrophages which have a key role in facilitating the inflammatory response. Few 
studies have investigated how Gal-1 may influence the role of macrophages in the 
initiation of the inflammatory response, with studies having focused primarily on 
macrophages during the resolution phase. In this scenario it has been indicated that 
Gal-1 promotes an anti-inflammatory pro-resolving phenotype in macrophages  
(Rostoker et al., 2013), a finding which will be elaborated on in a more relevant context 
later in this discussion.  
 
Although the literature is comparatively limited it is not unresearched and in vitro 
findings on Gal-1 treated macrophages showed inhibited arachidonic acid and PGE2 
secretion in response to LPS stimulation (Rabinovich et al., 2000). Furthermore, a 
study utilising activated peritoneal macrophages revealed that Gal-1 inhibits nitric 
oxide (NO) production and expression of inducible NO synthase (iNOS) in these cells 
instead favouring arginase activity (Correa et al., 2003). Taken together these findings 
indicate that Gal-1 promotes macrophage preference towards taking the alternative 
metabolic pathway consequently downregulating the classical metabolic pathway. In 
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addition, Gal-1 reduces macrophage production of pro-inflammatory cytokines 
including IL-1β, IL-6 and the chemokine MCP-1 (Correa et al., 2003; Kogawa et al., 
2011; Abebayehu et al., 2017). Consequently, it could be predicted that the pro-
inflammatory response following macrophages being stimulated with an inflammogen 
such as zymosan, may be dampened in the presence of Gal-1 however there was no 
evidence from the recruitment of leukocytes that this was the case in this study.  
 
Importantly, in this study neutrophil numbers in the peritoneal cavity were determined 
following exogenous Gal-1 administration during the peak of inflammation (at a time 
point that should not affect neutrophil recruitment) in order to assess neutrophil 
clearance. Administration of hrGal-1 at this time-point resulted in significantly fewer 
leukocytes being recovered 16h later (24h time point) compared to those recovered 
from vehicle treated mice. In vitro studies from Stowell et al describe the ability of Gal-
1 to induce exposure of the “eat me” signal PS on the surface of neutrophils (Stowell 
et al., 2007, 2009). Interestingly, PS exposure normally occurs as part of the early 
stages of apoptosis, however Gal-1 was not found to induce apoptosis in their studies, 
rather it was proposed that Gal-1-induced PS exposure is a mechanism to drive 
clearance of neutrophils in the absence of apoptosis. Here, increased numbers of PS 
exposing ‘early apoptotic’ neutrophils were detected within the peritoneal cavities of 
mice treated with hrGal-1. Whilst it was not possible to determine whether these cells 
progressed through the apoptotic process presumably due to the rapid clearance of 
PS expressing cells in vivo, we did uncover a pro-apoptotic role for Gal-1 when 





4.1.4. The Resolution Interval is Reduced by Exogenous Gal-1. 
 
Pro-resolving mediators are typically produced at the peak of the inflammatory 
response as they function to halt leukocyte infiltration and to promote active clearance 
of the cellular infiltrate thus allowing a return to homeostasis. Typically, 
proteins/peptides/lipids are administered at the peak of inflammation to assess their 
impact on the resolution interval, as pioneered by the Serhan laboratory (Bannenberg 
et al., 2005). When Gal-1 was administered at the 8h time point, the resolution interval 
was shortened from 39 to 14h, suggesting that Gal-1 has pro-resolving properties. As 
neutrophil numbers are highest when Gal-1 was administered this implies that it has 
an action on their clearance rather than neutrophil recruitment in this experimental 
setup.   
  
Analysis of the individual leukocyte subtypes indicated that there was a trend towards 
an all-round decrease in the numbers of all leukocyte subsets in hrGal-1 treated mice 
with significantly fewer macrophages found to be within the cavity of hrGal-1 treated 
mice. This data is in line with the increased macrophages present within the cavity in 
Gal-1 KO mice. Interestingly, the absence of the endogenous protein specifically 
altered resolving (CD11blow) macrophage numbers whereas the addition of the 
exogenous protein influenced primarily mature (CD11bhigh) macrophages with a lesser 
effect on resolving macrophages. The aforementioned study by Rostoker et al., 
demonstrating that exogenous Gal-1 promoted the conversion of macrophage 
phenotype from CD11bhigh to CD11blow (Rostoker et al., 2013), may provide an 
explanation for the data presented here. Specifically, if macrophages were converted 
from CD11bhigh in response to hrGal-1 it would account for fewer of these cells 
remaining in the system. The fact that there are not higher numbers of CD11b low 
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macrophages detected as a result of this is not unexpected given that these cells, with 
their pro-resolving phenotype, are swift in their response to PS exposing cells and 
following efferocytosis depart from the site. Of relevance to this current research it was 
also reported in the Rostoker et al., study that Gal-1 treatment in vivo promoted 
efferocytic satiation being reached more quickly in these CD11blow macrophages and 
thus a loss of their phagocytic capacity (Rostoker et al., 2013). This concept provides 
further support for the more rapid neutrophil engulfment by CD11blow macrophages 
and their subsequent departure as suggested by the data from the present in vivo 
study. Together these findings indicate that the endogenous and exogenous protein 
have disparate roles during the resolution of inflammation and that the capability of 
Gal-1 to facilitate actions on distinct macrophage populations may underline the 
proteins ability to resolve inflammation.   
 
When trying to develop a better understanding of the role of hrGal-1 in resolution and 
the mechanistic actions promoting cell clearance it is essential to also consider the 
neutrophil population. In this study neutrophils post-zymosan injection were further 
assessed for apoptosis. Most neutrophils were viable presumably as a result of the 
rapid clearance of any apoptotic cells. Importantly, significantly fewer viable cells were 
detected within the peritoneal cavities of mice treated with hrGal-1 and a significant 
increase in the percentage of early apoptotic neutrophils (AnxV+/PI-) was observed. 
The increase in PS positive cells in response to hrGal-1 detected in this model is 
corroborative with existing data in the literature. As previously mentioned, a study by 
Stowell et al., revealed that hrGal-1 induced PS exposure on the cell surface,  
furthermore it was also proposed that this occurs in the absence of apoptosis, a 
process termed as “preaperesis” as a mechanism to assist the progress of 
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efferocytosis (Dias-Baruffi et al., 2003; Stowell et al., 2007, 2009). However, the nature 
of this in vivo model with the rapid clearance of PS exposing cells made it impossible 
to determine if this were the case or if the PS positive neutrophils were in fact in early 
apoptosis and would be detectable as having progressed to late apoptosis in the 
absence of macrophages. 
 
Therefore, to further address the effect of exogenous Gal-1 on the apoptotic process, 
hrGal-1 was administered during the initial recruitment phase (2h) and peritoneal 
infiltrate collected during neutrophil peak (6h). Cells were then incubated in vitro in low 
serum media overnight to undergo apoptosis.  In this ex vivo setting it was found that 
neutrophil progression to late apoptosis (AnxV+PI+), as detected by positive PI 
staining indicating a loss of membrane integrity, was significantly increased following 
exposure to hrGal-1. In contrast to the results seen by Stowell et al. these findings 
indicate that hrGal-1 induced PS exposure is coupled with the progression of 
apoptosis. This discrepancy between the studies could be explained by the timing of 
cell assessment, amount/concentration of hrGal-1, cell type and/or activation state and 
will be discussed more elaborately in the context of the in vitro assays on human 
neutrophil survival performed as part of the scope of this thesis. 
 
4.1.5. Exogenous Gal-1 Showed no Effect on Delayed Self-resolving
 Inflammation. 
 
Curious to determine if Gal-1 restores resolution in a delayed self-resolving model of 
peritonitis, high dose (10mg) zymosan was utilised. Mice were sacrificed at 24h to 
obtain ‘baseline’ values and the remaining mice received either hrGal-1 (10μg) or 
vehicle only by daily i.p. injection. To profile the response across time mice were 
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sacrificed at 72h and 120h. There was no significant effect of hrGal-1 in this 
experiment.  
 
These results suggest that the protein may have to come into direct contact with the 
recruiting cell or endothelium to have an effect on inhibiting recruitment as seen in 
other models (La et al., 2003) or that is may have to be co-administered or given 
prophylactically to observe its effect on recruitment. 
  
Although disappointing that these results did not yield the same enhanced resolution 
profile in response to hrGal-1 as seen in the acute self-resolving model, there may still 
have been enhanced neutrophil apoptosis and the macrophage phenotype switching 
of the cells within the cavity. The administration of a higher dose of inflammogen 
results in prolonged recruitment of neutrophils to the peritoneal cavity in comparison 
to the acute model. This persistent emigration of new cells would ensure a constant 
supply of viable neutrophils and therefore it is plausible that any effect of hrGal-1 on 
inducing apoptosis and enhancing clearance of these short-lived cells may be masked 
by the excessive and persistent influx of new cells.  
  
In line with the above theory the percentage of viable neutrophils (from treated and 
non-treated mice) was higher in this system than in the acute model. In support of the 
potential enhanced clearance in response to hrGal-1 there was a reduced percentage 
of apoptotic neutrophils detected in the peritoneal cavity at 120h in hrGal-1 treated 
mice, as well as reduction in number of resolving macrophages, suggesting that 
apoptotic neutrophils have been cleared and that the efferocytic macrophages have 
departed the cavity. Furthermore, the data from 72h evidenced a subtle increase in 
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resolving macrophage numbers and apoptotic neutrophils in Gal-1 treated mice. More 
convincingly when assessed for efferocytosis the percentage of macrophages positive 
for neutrophils was higher in hrGal-1 treated mice at this time point.  
 
To summarise, it could be speculated that hrGal-1 still induces PS exposure on 
neutrophils resulting in enhanced clearance taking place between the 72h and 120h 
time point, yet this effect is masked by the stream of new viable neutrophils entering 
the cavity in replacement of their short lived predecessors and in an attempt to 
maintain control of this more severe inflammatory system.  
 
It would also be interesting to determine if there was any effect of endogenous Gal-1 
in this model by utilising the Gal-1 KO mice. However due to the heightened 
inflammatory response that was seen in the WT mice, it may not be a suitable 
experiment to perform in KO mice on the basis of their increased recruitment in the 




The divergence in the effects of exogenous, extracellular Gal-1 and the intracellular 
protein make it difficult to compare the effects seen in global knockout mice with 
studies that have utilised the recombinant protein. Furthermore, previous data from 
our laboratory suggest that compensatory mechanisms may exist in Gal-1 KO mice 
(Iqbal et al., 2011). None the less these findings confirm an anti-trafficking role for 
endogenous Gal-1 (figure 63A) and indicate a pro-apoptotic function for the 




The clearance of apoptotic cells is a fundamental process following cell damage, 
ageing and trafficking of leukocytes to an inflammatory site and hence is critical for the 
resolution of inflammation and preservation of self-tolerance. The reduction in the 
resolution interval in response to Gal-1 in this model provides further indication that 
the protein augments the transition from inflammation to resolution. Gal-1 
administration at the 8h time point reduced the resolution interval from 39h to 14h, 
suggesting that Gal-1 has pro-resolving properties that may be of therapeutic utility. 
 
Overall results from this in vivo model enhance our understanding of the role of Gal-1 
in resolution and shed light on the promising nature of this protein for the development 











Figure 63. A pro-resolving role for Gal-1 in acute inflammation. 
Mice received zymosan (1mg i.p.) to elicit an acute self-resolving inflammatory response and peritoneal lavage was 
performed to examine cellular infiltrate to the site of inflammation. During the early phase, the absence of endogenous 
Gal-1 resulted in increased neutrophil recruitment from the vasculature to the site of inflammation whereas 
administration of exogenous Gal-1 reduced the number of trafficked neutrophils (A). Administration of exogenous Gal-
1 during the peak of inflammation enhanced neutrophil apoptosis and thus reduced neutrophil numbers and shortened 
the resolution interval (B). Taken together these results indicate important pro-resolving actions for Gal-1 in the timely 
resolution of acute inflammation. [Created using BioRender illustrating tool.] 
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4.2. Gal-1 Influences the Disease Profile in a Model of Rheumatoid Arthritis. 
 
4.2.1. Disease Progression and Resolution are Augmented in Gal-1 Null Mice. 
 
In this current study Gal-1 KO mice developed arthritis at a slower rate, taking longer 
to reach the peak of their disease, as evidenced by clinical score, weight loss and 
oedema. WT mice lost significantly more weight and had significantly increased 
oedema compared to their knockout counterparts. The lessened disease in the 
absence of Gal-1 was corroborated by the significantly decreased cellular infiltrate in 
the knee when analysed microscopically by histology and a more subtle decrease in 
neutrophil numbers in the paw when analysed by flow cytometry.  
 
Interestingly there was a significant increase observed in the fast response paw 
oedema in Gal-1 KO mice. This initial inflammation that shortly follows the 
administration of K/BxN serum is driven by mast cells (Corr and Crain, 2002), which 
degranulate as early as 1h after intraperitoneal transfer of K/BxN serum, thus 
preceding the onset of clinical signs of inflammation (Lee et al., 2002). This early 
response has been likened to an Arthus reaction (Corr and Crain, 2002), indicative of 
a local type III hypersensitivity reaction involving the deposition of immune complexes 
initiating an inflammatory response that will then progress to drive pathogenesis of 
tissue injury (Sylvestre and Ravetch, 1994). The detection of immune complexes in 
human rheumatoid arthritis synovial fluid provides further evidence to the relevance of 
this response (Mathsson et al., 2006; Monach et al., 2009; Weissmann, 2009). This 
reaction to delivery of K/BxN serum is regularly encountered in experimental settings 
following the injection of autoantibodies so it is not unexpected that it functions in this 
model. Alongside immune complexes, mast cells have been demonstrated to play a 
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key role in the Arthus reaction (Sylvestre and Ravetch, 1996) and are known to be 
present in the synovium of mice. Furthermore, their importance in this model is 
evidenced by diminished arthritis in mice lacking tissue mast cells (Hayashi et al., 
1985; Huang et al., 1990; Corr and Crain, 2002).  
 
Current studies regarding Gal-1 interplay with mast cells have suggested that Gal-1 
downregulates recruitment and degranulation of mast cells (Rabinovich et al., 2000; 
Xie et al., 2017). Therefore, it is plausible that in the absence of Gal-1 these processes 
are elevated and as such are accountable for the significantly enhanced mast cell 
driven response in the Gal-1 KO mice seen here. Furthermore a study looking at 
uterine mast cells in the context of embryo implantation revealed that mast cells are 
capable of secreting endogenous Gal-1 (Woidacki et al., 2013), However, whether this 
ability is shared by mast cells at inflammatory sites and what effect it may have in this 
environment is yet to be determined.  
 
Mast cells have been proposed to function as an important cellular link between 
autoantibodies, soluble mediators and other effectors in inflammatory arthritis (Lee et 
al., 2002). Aside from their aforementioned link to immune complexes and their 
degranulation, the latter potentially modulated by Gal-1, stimulated mast cells present 
at the inflammatory site also release leukotriene B4 (LTB4), a potent neutrophil 
chemoattractant  (Malaviya and Abraham, 2000; Miyahara et al., 2009). Although 
plasma levels of this lipid mediator were not significantly reduced in Gal-1 KO mice 
this does not necessarily imply that levels at the inflammatory site would also be 
indifferent in the absence of Gal-1. It could be the case that the significantly increased 
oedema in Gal-1 KO resulting from the early activation and degranulation of these 
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cells in response to transfer of K/BxN serum, influences mast cell survival, phenotype 
and/or inflammatory environment in such a way to impair the actions of LTB4. 
Specifically, a reduction in the release of LTB4 or a dampening of its chemoattractant 
effect within the inflammatory milieu would subsequently impact on neutrophil 
recruitment to the inflammatory site and thus provide explanation for the lessened 
disease seen in the Gal-1 KO mice. Although assessment of neutrophil percentage at 
day 4 indicated no significant alteration in the absence of Gal-1, this analysis was 
performed without total cell enumeration and thus the data does not reveal whether 
there was an altered number of total CD45+ cells within the joint. Indeed, a possible 
explanation for the decreased infiltrate detected by histology or the lessened 
inflammation and disease detected in the absence of Gal-1 could be ascribed to the 
role of mast cell leukotrienes in neutrophil recruitment. 
 
Significant differences were also detected for the T cell populations within the draining 
lymph nodes collected from Gal-1 KO mice compared to WT. Here it was shown that 
in the absence of Gal-1 a significantly lower percentage of lymphocytes were CD8+ 
whereas CD4+ cells were slightly increased with a notable shift in the phenotype of 
these cells. The decrease in CD8+ cells in the KO compared to lymph nodes from WT 
mice is in line with evidence that patients with active rheumatoid arthritis have 
increased numbers of CD8+ T cells within the draining lymph node and that this is 
likely due to  their recirculation to the inflamed synovium (Kondratowicz et al., 1990). 
Indeed, as a result of their activated effector memory phenotype, preferential homing 
to the inflamed tissue and subsequent production of proinflammatory cytokines, CD8+ 
lymphocytes have been shown to have an essential role in maintaining chronic 




CD4+ T cells are known to have broad spectrum local and systemic roles in the 
induction, regulation and maintenance of inflammatory joint disease (as reviewed by 
(Alzabin and Williams, 2011)). In K/BxN mice the CD4+ T cells specific for recognising 
the self-protein glucose-6-phosphate isomerase (G6PI) are essential for initiating joint 
pathology (Matsumoto and Staub, 1999). Furthermore when tissue resident these cells 
have an activated state inferring their role in disease (Hovdenes et al., 1989). In this 
case the reduced inflammation in Gal-1 KO mice, could be an indication of a reduced 
population of inflammatory lymphocytes residing in the joints, thus increased detection 
of CD4+ lymphocytes in the draining lymph node may be due to their departure from 
the inflammatory site.  
 
Importantly, lymphatic drainage to the lymph node has been proposed to have a 
protective effect on synovitis, bone erosion and cartilage loss and evidence implicates 
a fundamental role for VEGF in controlling lymphatic drainage (Guo et al., 2009; Zhou 
et al., 2011). In line with this it has been shown that VEGF and the receptors VEGFR-
2 and VEGFR-3 are abundantly expressed in the blood vessels of the synovial 
sublining in rheumatoid arthritis (Paavonen et al., 2002). Interestingly, Gal-1 has been 
shown to bind to VEGFR-2 receptor (Hsieh et al., 2008). However, studies on this 
interaction have focused primarily on the tumour microenvironment, where Gal-1 acts 
as an alternative ligand when anti-VEGF treatments are applied (Croci and 
Rabinovich, 2014).  Whether Gal-1 interacts with VEGFR on endothelial cells and 
modulates its effects in the context of inflammation are currently unreported. Increased 
levels of VEGF were detected in Gal-1 KO mice in the acute peritonitis model, 
suggesting that modulation of the growth factor and/or receptor(s) occurs in the 
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absence of Gal-1. Further investigation is required to determine the role of cellular 
glycosylation signatures on the angiogenesis and the vasculature in response to Gal-
1, however it appears to be an intriguing area of research (Croci et al., 2014). 
 
An alternative and more probable possibility for the increased number of effector T 
cells seen in the absence of Gal-1 correlates with well-established reports in the 
literature of the ability of Gal-1 to induce the apoptosis of effector T cells. Specifically, 
Gal-1 expressed by endothelial cells and stromal cells has been shown to induce the 
apoptosis of T cells bound to the endothelium and those present in the thymus and 
lymph nodes respectively (Perillo et al., 1995). In addition to the increased population 
of these effector T cells in the absence of Gal-1, consideration should also be paid to 
their role within this model of arthritis. Of the CD4+ population of lymphocytes a 
significantly increased percentage of effector (CD62L-CD44-) T cells were seen in the 
lymph nodes from Gal-1 KO mice whereas the naive (CD62L+CD44-) T cell population 
was significantly decreased. Importantly, CD4+ effector cells can differentiate into 
many phenotypes, broadly speaking these fall in to four main categories: those with 
pro-inflammatory effector characteristics, those with regulatory/anti-inflammatory 
actions, those that promote B cell follicle development and those that provide long 
term memory (Eagar and Miller, 2019). The lessened disease evidenced in the Gal-1 
KO mice compared to WT would suggest expansion of the population of effector T 
cells that have a regulatory/anti-inflammatory phenotype in the absence of Gal-1.  
 
On the basis that naïve T cells are precursors for differentiation into effector and 
memory T cell subsets the significant increase in effector T cells and the slight increase 
in memory T cells likely serves as the explanation for the corresponding decreased 
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population of naïve T cells in the draining lymph nodes from Gal-1 KO mice. Naive T 
lymphocytes are activated through their T cell receptors (TCRs) by peptide–MHC 
complexes, and only upon activation, undergo rapid proliferation differentiating into 
effector cells (Catron et al., 2006). MHC class II (MHC-II) molecules expressed on 
dendritic cells, monocytes and macrophages present antigen to CD4+ T cells (Holling 
et al., 2004), an essential interaction for the initiation of an antigen-specific immune 
response. As part of the scope of this thesis MHC-II expression was assessed on 
(bone marrow derived) macrophages from WT and Gal-1 KO mice, here it was shown 
that expression was higher on macrophages absent of Gal-1, a result which 
corroborates with existing literature (Barrionuevo et al., 2007). It could be postulated 
that the enhanced MHC-II expression seen in Gal-1 KO mice could directly encourage 
the differentiation of naïve T cells to effector T cells as a result of the increased antigen 
presentation during the inflammatory response in these mice. 
 
The delayed progression of disease observed in Gal-1 KO mice in this model of K/BxN 
serum transfer induced arthritis was contrary to expectation and indicates a 
divergence for the role of the endogenous Gal-1 in neutrophil-driven pathologies 
compared to T cell-driven models, such as collagen-induced arthritis (CIA). Gal-1 KO 
mice exhibit accelerated onset and increased severity of disease compared to WT 
mice in a model of CIA, suggesting that endogenous Gal-1 acts to dampen the T cell 
activation driving disease (Iqbal et al., 2013). Conversely, in this current study absence 
of Gal-1 does not increase either the rate of disease onset or the maximum clinical 
severity in a neutrophil-driven model. This suggests that the effect of Gal-1 and its role 
in inflammatory pathologies is likely dependent on the cellular mechanisms initiating 
and driving disease progression. In line with this Gal-1 KO mice also displayed a 
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reduced response to inflammatory stimuli in a model of carrageenan induced paw 
oedema (Iqbal et al., 2011). The disease profile of this model displays a biphasic 
response, in support of what was seen in the K/BxN arthritis model presented here the 
immediate response to administration of stimuli evidenced increased oedema in the 
absence of Gal-1. Furthermore, during the second phase of the response the intensity 
of the oedema was significantly lower in the Gal-1 KO mice compared to WT, as was 
found in this study for the progression of arthritis. Analysis of the leukocyte infiltrate in 
the paw oedema model revealed a reduced infiltration and increased apoptosis of 
neutrophils in the Gal-1 KO mice. These findings appear to conflict with the anti-
inflammatory properties reported for Gal-1 (Norling et al., 2009) which may suggest 
that other pathways and/or mediators are involved in the inflammatory response in 
these models. It was found in the paw oedema model that Gal-9 mRNA expression 
significantly increased in Gal-1 KO mice at the onset of resolution indicating potential 
compensatory mechanisms between galectins in these global knockouts (Iqbal et al., 
2011). This increase in mRNA, although absent of any effect at the level of protein 
expression, indicates a potential interplay between members of the galectin family with 
endogenous roles in inflammation and provides further evidence that levels of 
endogenous galectins are modulated at different phases of the inflammatory 
response.  
 
As was observed in the model of zymosan-induced peritonitis, remission indices in the 
K/BxN model of arthritis were increased in Gal-1 KO mice compared to WT, suggesting 
again that Gal-1 has a pro-resolving function. Interestingly, the potential pro-resolving 
role of Gal-1 was also apparent in the model of paw oedema, with increased 
expression at both the gene and protein level detected in WT mice at the later time 
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points, with peak expression correlating with the onset of resolution (Iqbal et al., 2011). 
In line with this theory and suggestive of the translational relevance of these findings, 
Gal-1 levels are significantly reduced in the synovial fluid from rheumatoid arthritis 
patients compared to healthy controls (Mendez-Huergo et al., 2019). A corresponding 
increase in the titres of anti-Gal-1 autoantibodies has been proposed to be responsible 
for limiting the amount Gal-1 and thus blocking its biological effect (Mendez-Huergo et 
al., 2019). As such the pro-resolving function of Gal-1 could be limited in arthritic joints, 
which may in turn contribute to the uncontrolled inflammatory responses driving 
chronic disease (Xibillé-Friedmann et al., 2013). Still, additional findings suggest a 
divergence in the role of the protein dependant on its localisation.   
 
Interestingly, levels of Gal-1 detected in the serum of rheumatoid arthritis patients has 
been shown to be significantly higher compared to healthy controls, correlating with 
disease activity (Vilar et al., 2019). Here it could be suggested that the elevated Gal-1 
levels in the peripheral blood are detected due to increased release of the endogenous 
protein from the chronically activated endothelium as has previously been revealed 
(Baum, Seilhamer, et al., 1995). One theory would be that release of endogenous Gal-
1 is upregulated in a physiological process by endothelial cells in their attempt to inhibit 
aberrant leukocyte trafficking and regain control of recruitment to the inflamed site. 
However, it is also a possibility that the high levels of Gal-1 found in the sera of the 
rheumatoid arthritis patients is directly due to the protein having a role in the anti-
inflammatory effects of the DMARDS and corticosteroids that have been used to treat 
the inflammation in these patients (Mendez-Huergo et al., 2019). In any case, aside 
from the modulated expression the precise mechanism(s) behind the anti-
inflammatory and/or pro-resolving effect of Gal-1 is yet to be elucidated. 
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4.2.2. Local Administration of Exogenous Gal-1 did not Modulate the Course of
 Arthritis. 
 
In this current study local therapeutic treatment with exogenous Gal-1 from clinical 
onset of disease had no significant effect when assessed at peak (day 7) and resolving 
(day 11) inflammation. These findings were contrary to my prediction that an anti-
inflammatory and/or pro-resolving role would be evidenced in this model in response 
to Gal-1.  
 
Previous studies of exogenous Gal-1 were in the collagen-induced arthritis (CIA) 
model. In this model immunisation of mice with type II collagen (CII) resulted in 
development of arthritis that has both clinical and histological similarities to human 
rheumatoid arthritis (Brand et al., 2004). The development of autoimmune polyarthritis 
in CIA is linked to MHCII and the immune response to CII, including stimulation of CII 
specific T cells and production of CII specific antibodies (Brand et al., 2004). Similar 
to the K/BxN model, clinical onset of disease coincides with severe synovitis, mass 
accumulation of inflammatory cells (neutrophils and lymphocytes) and progresses to 
destruction of the joint. Despite the pathological similarity of the two models, both to 
one another and to human rheumatoid arthritis, there was significant disparity in the 
effect of exogenous Gal-1. In contrast to the findings obtained in this current study 
administration of rGal-1 was able to reduce disease severity in a model of CIA 
(Rabinovich, Daly, et al., 1999). Two therapeutic protocols were used at onset of 
arthritis with both a gene therapy protocol (with a single injection of synovial fibroblasts 
expressing mGal-1) and a protein therapy protocol (injecting hrGal-1 (100μg) daily) 
successfully suppressing arthritis (Rabinovich, Daly, et al., 1999). The diminished 
inflammation was suggested to be the result of a shift from a Th1 pathogenic response 
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towards a Th2 profile, impaired T cell function during antigen presentation and an 
increased susceptibility of T cells to apoptosis (Rabinovich, Daly, et al., 1999). 
 
The lack of effect of the exogenous protein in the current model strongly suggests 
divergence in the actions of Gal-1 on T cells compared to neutrophils, indicative of 
different roles for the protein in inflammation dependent on what is driving the 
response. Nonetheless, it has been shown that exogenous Gal-1 has the ability to 
induce apoptosis of neutrophils from synovial fluid of patients with rheumatoid arthritis 
(Cedeno-Laurent et al., 2010), thus the lack of effect of the exogenous protein in this 
model was disappointing. It could be the case that the amount of protein administered 
in this study was insufficient to have a significant pharmacological effect in the K/BxN 
serum induced arthritis model. Here 3µg of hrGal-1, a dose that was shown to be 
effective in the carrageenan induced paw oedema model (Iqbal et al., 2011), was 
administered. This dose was given therapeutically from established disease (day 3) 
by intraplantar injection into the right foot pad every alternate day. Indeed, the dosing 
strategy used in this current study differs in several aspects to the protein therapy 
protocol that was used in the CIA model where 100µg of hrGal-1 was given by daily 
intraperitoneal injection. The difference in route and amount of protein administered in 
the CIA model would allow for the protein to have a systemic effect, whereas the low 
dose at the site of inflammation used in the K/BxN model here provides for a local 
effect of the exogenous protein only, thus not accounting for the effect of Gal-1 on 
leukocytes trafficking along the endothelium (Baum, Seilhamer, et al., 1995; Cooper 
et al., 2008; Norling et al., 2008). Furthermore, the study by Cedeno-Laurent et al., 
also used a notably higher amount of hrGal-1, specifically 0.25µM - 2.5µM (Cedeno-
Laurent et al., 2010), whereas the 3µg administered in the K/BxN model here is 
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equivalent to 214pM and is thus below the lowest concentration shown to induce the 
apoptosis of neutrophils from synovial fluid of rheumatoid arthritis patients. Thus 
despite its effective anti-inflammatory effects in the model of paw oedema (Iqbal et al., 
2011) perhaps in the K/BxN arthritis model 3µg was below the required amount for a 
significant pharmacological effect to be had in this chronically inflamed system.  
 
The persistent infiltration and prolonged survival of neutrophils in the synovial fluid 
contributes to the pathogenesis of human rheumatoid arthritis and thus this aspect of 
the disease is an important target and further study is required to determine the role 
of the protein on neutrophils in the joint. Although findings from this study were not 
indicative of an effect of the exogenous protein in this model, additional assessment 
is required under adjusted parameters, including dosage and duration, to determine 
with more certainty whether an effect of the recombinant protein exists here. Previous 
studies in the CIA arthritis model have utilised more novel delivery mechanisms, 
including rGal-1 conjugated to gold nanoparticles (Huang et al., 2012) and intra-
articular administration of lentiviral vectors (Wang et al., 2010), which in addition to 
direct protein administration have also evidenced reduced disease severity in 
response to exogenous Gal-1. It would be interesting to determine if these approaches 
have the same therapeutic effect in the K/BxN serum induced arthritis model. 
 
Another important difference which may explain the lack of effect of exogenous Gal-1 
in the K/BxN model is the experimental setting. In comparison to the CIA study the 
mice used for K/BxN serum induced arthritis are of a different strain, with DBA/1 mice 
used in the former and C57Bl6 in the latter. Interestingly, in both cases the genotype 
of mouse is selected for their response to disease induction, for example lymphocytes 
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from C57Bl6 mice fail to respond to the collagen peptide responsible for initiating 
disease in the CIA model, indicating differences in the T cell epitope specificities 
between the two strains (Inglis et al., 2007). Likewise, DBA/1 mice showed a lesser 
response in the K/BxN model (Ji et al., 2001). It is well established that during 
inflammation Gal-1 interacts with T cells, thus it is possible that the differences in the 
lymphocyte phenotype may account for the effectiveness of Gal-1 in the CIA model in 
DBA/1 mice and the lack of effect in the C57Bl6 mice in the K/BxN serum induced 
arthritis. Furthermore, the success of the exogenous protein in inducing apoptosis of 
rheumatoid arthritis synovial fluid neutrophils was shown in an ex vivo setting where 
leukocytes were collected and incubated with hrGal-1 for 12h/24h prior to analysis 
(Cedeno-Laurent et al., 2010), consequently the levels of inflammatory cytokines and 
persistent infiltration of new leukocytes were not present in this system. It could be 
postulated that the inflammatory environment surrounding neutrophils in vivo, 
specifically within the inflamed synovium of the K/BxN model, provides the cells with 
pro-survival signals too strong for exogenous Gal-1 to overcome. Indeed, hrGal-1 
successfully increased the rate of spontaneous apoptosis in the ex vivo study by 
Cedeno-Laurent et al., but whether this finding is translatable to an in vivo setting 
where pro-survival cytokines present in the inflammatory milieu afford neutrophils a 
prolonged lifespan requires further investigation. As such, the effect of hrGal-1 on the 
spontaneous apoptosis of neutrophils, in the presence of pro-survival cytokines has 
been studied as part of the scope of this thesis and will later be discussed in detail 







The divergence between the function of the intracellular, extracellular and exogenous 
forms of Gal-1 mean that the results obtained from global knockout mice may not be 
directly comparable with those that have used the recombinant protein. In most 
systems Gal-1 typically acts in an anti-inflammatory and/or pro-resolving manner and 
has been shown to curb the actions of both innate and adaptive immune responses. 
Gal-1 has been shown to dampen production of pro-inflammatory cytokines, inhibit 
neutrophil trafficking, modulate eosinophil migration and survival and reduce mast cell 
degranulation and is thus considered to act as a resolution associated molecular 
pattern (RAMP) in the innate response (Shields et al., 2011; Sundblad et al., 2017). In 
the context of the adaptive immune response Gal-1 has been shown to act at a 
regulatory checkpoint and modulate receptor clustering and signalling on T and B 
cells, as well as affect the recruitment and survival of activated T cells. Certainly, these 
actions would suggest that harnessing the properties of Gal-1 might provide a 
mechanism to regulate the inflammatory response, offering a promising therapeutic 
strategy for chronic autoimmune inflammatory diseases such as rheumatoid arthritis.  
 
The delayed remission of disease observed in the absence of endogenous Gal-1 in 
this model strongly suggests a role for the protein in the resolution process. Likewise 
results obtained from the zymosan peritonitis model of acute self-resolving 
inflammation, demonstrated a marked reduction in the resolution interval in response 
to therapeutic treatment with hrGal-1 from the peak of inflammation. Taken together 
these findings support a pro-resolving role for Gal-1 by enhancing neutrophil clearance 
from the site of inflammation and indicate that the protein influences the inflammatory 
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profile in a model of rheumatoid arthritis, consequently reinforcing the therapeutic 




4.3. Macrophage Efferocytosis was not Altered by the Absence of Gal-1. 
 
Assessment of efferocytosis in vivo in the absence of inflammatory challenge revealed 
that Gal-1 KO mice had a significantly lower percentage of macrophages found within 
the peritoneum compared to WT mice. A limitation of these values is that by reporting 
the populations as percentage it does not factor for the total number of leukocytes 
within the cavity of the mice. However, there are no reports to suggest that a difference 
in total leukocyte counts exists in naïve Gal-1 KO mice thus it could be postulated that 
this is an effect of efferocytosis and that these cells have already left the cavity having 
engulfed apoptotic cells. As previously discussed, it has been evidenced that Gal-1 
KO macrophages phagocytose more effectively than WT cells when cultured ex vivo 
(Barrionuevo et al., 2007), thus perhaps in this scenario they have done so and already 
departed the cavity. Furthermore, it has also been demonstrated that activated 
macrophages are the predominant source of endogenous Gal-1 (Rabinovich et al., 
1996, 1998) within the peritoneal cavity, thus perhaps they are retained in WT mice 
due to an altered phenotype. The difference in percentage of macrophages seen in 
this study was an unpredicted find, in line with the NC3Rs principles it was not 
considered essential for this assay to be repeated with an additional group of naïve 
WT and KO mice simply to determine the basal leukocyte counts within the peritoneal 
cavity, however if it could be incorporated into future work with the KO mice it would 
be useful for added perspective on the results obtained here.  
 
The percentage of apoptotic neutrophils remaining in the cavity was also analysed and 
results were comparable between genotypes with an expected decline in percentage 
of free apoptotic neutrophils at 60 mins compared to 30 mins. In accordance with this 
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the percentage of macrophages positive for human neutrophils increased when 
assessed at 60 mins compared to 30 mins post injection of cells. Therefore, it is 
interesting that the decrease in percentage of macrophages in Gal-1 KO mice did not 
yield a significant effect on the subsequent percentage positive for ingesting apoptotic 
neutrophils. Indeed, it might be expected that if there was a reduction in macrophage 
numbers populating the peritoneum of Gal-1 KO mice that being challenged with an 
equal number of apoptotic neutrophils as WT mice (with their larger macrophage 
population) would result in an increased percentage of the macrophages having 
ingested neutrophils in Gal-1 KO mice, as a result of their increased ratio of neutrophils 
to macrophages. Likewise, there was no significant effect of genotype on relative 
number of apoptotic cells that had been engulfed per macrophage at either 30 mins or 
60 mins, although arguably a subtle trend towards more apoptotic neutrophils ingested 
by Gal-1 KO macrophages was detected for the latter but this did not reach 
significance.  
 
To reiterate what has been discussed earlier it is well established that following their 
ingestion of apoptotic neutrophils macrophages swiftly depart the inflammatory site 
consequently making efferocytosis a tricky process to capture in vivo. Certainly, this 
assay was a good attempt to establish whether the absence of Gal-1 has any 
significant effect on the ability of macrophages to recognise and ingest apoptotic 
neutrophils, a question which had not previously been addressed in vivo. None the 
less it is possible that some of the cells will have escaped analysis. Assays performed 
ex vivo have looked at phenotyping Gal-1 KO macrophages and have revealed 
significantly higher levels of MHC-II (Barrionuevo et al., 2007) and a more ‘M2’ like  
phenotype, the latter demonstrated in this thesis by significantly higher CD206 and 
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lower CD86 than WT macrophages. Likewise, levels of the scavenger receptors CD36 
and MerTK, showed a visible trend for increased expression on cells from Gal-1 null 
mice. These findings provide evidence in support of an enhanced phagocytic 
phenotype Gal-1 KO macrophages which may in turn suggest more efficient 
efferocytosis and subsequent departure from the site. Consequently, this may provide 
explanation for the lower macrophage percentage detected in Gal-1 KO mice in this 
experimental setting. 
 
Regarding the production and release of endogenous Gal-1 by peritoneal 
macrophages in this assay it is important to reiterate that for this process to occur 
activation of macrophages is required. In this setting the naïve peritoneal cavity does 
not provide the required stimulation to activate these cells, indeed it is not until addition 
of apoptotic neutrophils into the system that such a signal is received. Thus, in this set 
up the secreted endogenous Gal-1 will not come into action until after the introduction 
of apoptotic neutrophils. Current literature reports that Gal-1 facilitates neutrophil 
clearance via a process termed “preaperesis” whereby neutrophils are efferocytosed 
without undergoing apoptosis (Dias-Baruffi et al., 2003; Stowell et al., 2007, 2009) via 
induction of PS exposure on the outer membrane of neutrophils independently of their 
apoptosis (Stowell et al., 2009). However, the neutrophils in this assay are already 
apoptotic and consequently PS positive. As such, if endogenous Gal-1 is released by 
WT macrophages in response to their activation and induction of PS exposure is the 
sole role for the protein regarding clearance of neutrophils then its presence in this set 
up would appear redundant. It would be interesting to explore alternative ways in which 
the anti-inflammatory actions of Gal-1 might regulate efferocytosis, for example Gal-3 
has been shown to function as an opsonin (Karlsson et al., 2008), whether Gal-1 
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shares this behaviour is yet unreported in the literature however has been investigated 
as part of the scope of this thesis and will later be discussed in further detail (see 
section 4.6).  
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4.4. Gal-1 Overrides Neutrophil Pro-Survival Factors and Induces Apoptosis. 
 
4.4.1. Gal-1 Increases Phosphatidylserine Expression on Neutrophils. 
 
When viable neutrophils were assessed for surface PS exposure following short 
incubation periods with hrGal-1 significantly increased expression was detected on 
cells exposed to hrGal-1 in vitro. Contrary to the literature which reports that only 
activated and not resting neutrophils respond to exogenous Gal-1 by exposing PS on 
their surface (Stowell et al., 2007), in this study it was shown that neutrophils freshly 
isolated from human peripheral blood had increased PS after just 1h with hrGal-1 in 
the absence of any additional stimulation and at much lower concentrations (1µM vs 
10µM). This effect was also observed after only 30mins (data not included). It has 
been reported that induction of PS exposure by hrGal-1 is reversible and occurs in the 
absence of apoptosis (Stowell et al., 2009), indeed the data reported in this current 
study is in line with this theory as the percent of PS positive cells was considerably 
higher than the percentage of the population likely to undergo spontaneous apoptosis 
within the short incubation period, particularly given the presence of serum in the 
media. The study by Stowell et al., incubated cells with exogenous Gal-1 for 12h, 
assessed PS positivity and then used a lactose wash to remove exogenous Gal-1 
bound to these cells, which were then incubated in complete media for 2 days and 
assessed again for PS exposure. The results showing reduced PS on this second 
assessment were used to deduce that the cells had not undergone apoptosis. 
However, their assay was performed on HL-60 cells, which although regarded as 
neutrophil-like, are a proliferating cell line and so the translatability of this finding to 
human neutrophils with a finite lifespan remains questionable. With regards to the 
unlikely scenario that the PS exposure seen in this current assay is the result of 
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neutrophils undergoing spontaneous apoptosis it could be postulated that Gal-1 is 
maintaining PS exposure as opposed to induction. Although a calcium dependent 
process, PS exposure has been associated with non-specific flip-flop of phospholipids 
(Bratton et al., 1997), in this manner perhaps binding of Gal-1 to the cell surface is 
prohibiting the PS molecules ‘flopping’ back inwards. Indeed, it has been reported that 
galectin lattice formation following binding can effectively trap glycoprotein receptors 
at the cell surface (Rabinovich et al., 2007), perhaps a similar action occurs as hrGal-
1 binds to neutrophils, thus trapping the externalised PS. Likewise this explanation 
may provide rationale for the results from the study by Stowell et al. showing the 
reversal of PS exposure following removal of exogenous Gal-1 (Stowell et al., 2009). 
 
To investigate this phenomenon of early PS exposure further, neutrophils were also 
assessed after a 4h incubation. To mimic the scenario found in the rheumatoid joint, 
whereby mediators such as GM-CSF are known to prolong neutrophil lifespan the 
effect of Gal-1 was tested in combination with GM-CSF on PS exposure and/or early 
apoptosis of human neutrophils in vitro. Here it was shown that neutrophils treated 
with hrGal-1 still maintained increased phosphatidylserine exposure compared to 
unstimulated cells after a 4h incubation. Furthermore, the increased PS externalisation 
in response to hrGal-1 was maintained in the presence GM-CSF. As anticipated, PS 
exposure was notably less on cells with GM-CSF alone. In line with findings in the 
literature neutrophils incubated in low dose autologous serum are not yet PI+ positive 
at this early time point (Leitch et al., 2010). Thus, in the absence of progression to a 
loss of membrane integrity it is difficult to determine whether these cells are early 
apoptotic or simply PS positive, particularly given that the latter marks the first step of 
the former. However, the existence of the GM-CSF pro-survival effect in this assay 
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suggests that after 4h neutrophils are beginning to undergo spontaneous apoptosis. 
The increased PS exposure in the presence of hrGal-1 alone at this time point supports 
the aforementioned theory of the externalised molecules being trapped and 
maintained on the external membrane. Neutrophils co-incubated with GM-CSF and 
hrGal-1 for 4h had significantly increased PS compared to GM-CSF only treated 
neutrophils and a notable increase compared to untreated cells, suggesting that 
exogenous Gal-1 has the dominant effect. Certainly the delay in neutrophil PS 
exposure linked with GM-CSF treatment was considerably less striking in the presence 
of hrGal-1, nonetheless its subtle effect compared to neutrophils incubated with hrGal-
1 alone provides further support for commencement of apoptosis taking place at this 
time point.  
 
In any case, analysis at a later time point was neccesary to determine if the actions of 
hrGal-1 on GM-CSF activated cells was simply an effect on PS exposure in the 
presence of exogenous Gal-1, as has been suggested (Stowell et al., 2009), or 
whether exogenous Gal-1 influences the apoptotic process of neutrophils exposed to 
pro-survival factors, as has been demonstrated for neutrophils from the rheumatoid 
synovium  (Cedeno-Laurent et al., 2010). Thus, I examined the progression of 
neutrophils to late apoptosis following their extended incubation with or without GM-
CSF and/or hrGal-1 by investigating morphology, mitochondrial membrane potential 
(ΔΨm), and outer membrane integrity in addition to PS exposure to ascertain the 





4.4.2. Gal-1 Induces Apoptosis of Stimulated Neutrophils.  
 
Neutrophil survival and apoptosis are largely influenced by the microenvironment, and 
at sites of chronic inflammation the presence of pro-inflammatory mediators are 
effective at delaying the spontaneous apoptosis of neutrophils (Simon, 2003). To 
resemble the inflammatory environment of neutrophils within the rheumatoid joint, GM-
CSF and the apolipoprotein SAA, both known to prolong neutrophil lifespan (Klein et 
al., 2000; El Kebir et al., 2007), were supplemented and the effect of hrGal-1 on the 
apoptosis of human neutrophils was investigated in vitro. Following overnight 
incubation in low serum, neutrophil apoptosis was primarily assessed by AnxV/PI 
staining and flow cytometry, cells that were positive for both AnxV and PI displayed 
externalised PS and membrane permeability respectively, indicative of cells in the late 
stage of apoptosis. In agreement with the literature, hrGal-1 did not alter the rate of 
spontaneous apoptosis of peripheral blood neutrophils (Stowell et al., 2007), whilst 
GM-CSF significantly delayed this process (Klein et al., 2000; Derouet et al., 2004). 
HrGal-1 was able to partially reverse this effect of GM-CSF, suggesting, as was 
observed by Cedeno-Laurent et al. that in some environments exogenous Gal-1 
facilitates induction of neutrophil apoptosis. Likewise, SAA also afforded neutrophils a 
notable degree of protection from their spontaneous apoptosis, with reversal of this 
evident following addition of hrGal-1. These results were supported by analysis of cell 
morphology and in line with the order of events following apoptosis, whereby nuclear 
condensation and cell shrinkage occur prior to loss of membrane integrity (Denecker 
et al., 2000).  
 
Besides PS exposure another early event as neutrophils undergo apoptosis is the 
disruption to mitochondrial membrane potential (ΔΨm) (Kroemer et al., 1998). Thus, 
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for verification of findings, neutrophils were also assessed by 3,3′-
dihexyloxacarbocyanine iodide (DiOC6) staining, a cell-permeant fluorescent dye that 
is selective for the mitochondria of live cells. As expected, cells that were left to 
apoptose overnight had a reduced DiOC6 signal indicative of reduced ΔΨm compared 
to those treated with GM-CSF. Interestingly, this method revealed discordant results 
for the effect of hrGal-1. Here it was shown that neutrophils undergoing apoptosis in 
the presence of hrGal-1 had increased ΔΨm, an effect which was concentration 
dependent with a positive correlation between concentration of hrGal-1 and ΔΨm. 
Furthermore, this was shown to be additive to the effect of GM-CSF, with neutrophils 
incubated with both GM-CSF and the highest concentration of hrGal-1 revealing the 
greatest ΔΨm. Commonly, disruption of the GM-CSF signalling pathway by 
immunosuppressive mediators induces a loss of ΔΨm in addition to PS exposure and 
nuclear changes (Woltman et al., 2003), it is intriguing that hrGal-1 did not function in 
this way.  
 
Existing literature on the influence of exogenous Gal-1 on ΔΨm is surprisingly limited, 
however findings from one study revealed that treatment with Gal-1 resulted in a 
significant increase in ΔΨm and an increase in cells with a hyperpolarised 
mitochondrial membrane (Matarrese et al., 2005). When time-dependent changes in 
ΔΨm were assessed results showed that initially (6h-18h) an increased ΔΨm and 
hyperpolarization was shown in response to exogenous Gal-1 and that typical 
depolarization was a much later event (36h-72h) (Matarrese et al., 2005). Although 
these findings are from assaying apoptosis in lymphocytes, it is possible that 
exogenous Gal-1 has the same effect on neutrophil ΔΨm. As such, it could be 
suggested that at the timepoint when ΔΨm was assessed by DiOC6 in the current 
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study that cells treated with Gal-1 may still have been within the phase of 
hyperpolarization of the mitochondrial membrane, thus providing an explanation of the 
increased staining of DiOC6. Furthermore, findings from another study have shown 
that Gal-1 induced apoptosis of cells independent of the activation of caspase-3 but 
instead involving the rapid nuclear translocation of endonuclease G (EndoG) from 
mitochondria (Hahn et al., 2004). Here it was shown that EndoG translocation 
occurred prior to loss of ΔΨm, with an eventual loss of ΔΨm detected much later. 
Additionally, it was shown that Gal-1 did not activate caspases, nor was cell death 
blocked by inhibiting caspases indicating an alternative pathway (Hahn et al., 2004). 
Again, this study was performed using lymphocytes but nonetheless strongly suggests 
that the actions of Gal-1 on apoptosis involves a unique pattern of mitochondrial 
events, an area which requires further investigation, particularly with regards to 
neutrophils.  
 
Taken together the data obtained from the neutrophil apoptosis assays performed as 
part of this current study indicate that in the absence of activating stimuli (GM-CSF or 
SAA) hrGal-1 had no effect on cell viability. Importantly, this provided support for the 
existing finding that neutrophils from the synovial fluid of rheumatoid arthritis patients 
are susceptible to Gal-1 induced apoptosis (Cedeno-Laurent et al., 2010). Indeed, an 
activated phenotype appears to render neutrophils susceptible to Gal-1-induced 
apoptosis. Curiously, an activated phenotype was not shown to be a requirement for 
modulating ΔΨm, in fact hrGal-1 was shown to augment ΔΨm in a manner seemingly 
independent of cell viability. Indeed, exogenous Gal-1 hyperpolarises the 
mitochondrial membrane and delays the loss of ΔΨm but it does not completely inhibit 
this process nor does this action influence cell survival (Matarrese et al., 2005). This 
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would suggest that exogenous Gal-1 alters the pattern of mitochondrial events, a 
theory conflicting the current and long established understanding that reduction in 
ΔΨm in an essential early and irreversible step of programmed cell death (Zamzami 
et al., 1995).  
 
4.4.3. Gal-1 Delays GM-CSF Induced Phosphorylation of Signalling 
Pathways. 
 
Neutrophil apoptosis is controlled by an intricately connected and complex network of 
signalling pathways, including the ERK, AKT, and p38 MAPK pathways (Colotta et al., 
1992; Klein et al., 2000; Khreiss et al., 2002; József et al., 2004). As part of this study 
these intracellular signalling pathways involved in neutrophil apoptosis were 
investigated by Western blot to determine the effect of hrGal-1 on neutrophils with or 
without stimulation from the pro-survival factor GM-CSF. In line with findings in the 
literature GM-CSF was shown to induce rapid phosphorylation of AKT within 1min 
(Klein et al., 2000), with the same signalling response also evident for p38 MAPK and 
ERK phosphorylation. In line with reports in the literature, activation of neutrophil 
signalling by GM-CSF peaks early in the AKT and p38 MAPK pathways followed by a 
drop in phosphorylation at 15mins (McLeish et al., 1998). Interestingly, when this 
signal began to decline in GM-CSF stimulated neutrophils, cells that had also been 
stimulated with hrGal-1 displayed an overall lessened depreciation from peak 
phosphorylation signal. At the earliest timepoint phosphorylation of AKT was notably 
higher in neutrophils stimulated with GM-CSF only, whereas later timepoints show 
hrGal-1 and GM-CSF co-treated neutrophils evidenced likewise phosphorylation to 
GM-CSF alone. Like AKT signalling at 1min, phosphorylation of ERK was also 
increased in neutrophils stimulated with GM-CSF only, however the inverse was 
324 
 
shown for neutrophils when stimulated for longer. Intriguingly, hrGal-1 co-stimulation 
with GM-CSF for 15mins resulted in increased phosphorylation of ERK, whether this 
signalling is potentiated or drops off in response to longer stimulation was not 
assessed as part of this study and thus remains of interest to investigate. Overall, this 
data suggests that hrGal-1 delayed GM-CSF induced activation of the AKT and ERK 
signalling pathways. Stimulating naïve neutrophils with hrGal-1 alone caused a 
modest signalling response with a slight increase in phosphorylation across sequential 
timepoints compared to unstimulated cells, however this was donor specific and 
requires further examination. 
 
It is well established that tyrosine kinases are essential for the transduction of GM-
CSF anti-apoptotic signals in neutrophils (Yousefi et al., 1994; Vlahos et al., 1995) and 
in line with existing findings results from this current study demonstrated GM-CSF 
induced tyrosine phosphorylation of intracellular proteins. Phosphoinositide 3-kinases 
(PI3-kinase) have been identified to have a significant intracellular role in controlling 
cell survival/death signalling with robust evidence existing for phosphorylation of AKT 
having a suppressive action on neutrophil apoptosis (Martínez et al., 2006; Levett et 
al., 2014). Mitogen-activated protein kinases (MAPKs) are another family of kinases 
involved with regulating cell viability. Activation of ERK has been primarily defined as 
inhibiting apoptosis, however the role for p38 MAPK remains more controversial (Xia 
et al., 1995; Frasch et al., 1998; Jarpe et al., 1998). In general activation of p38 MAPK 
promotes cell death yet it has also been proposed to have anti-apoptotic functions 
upon phosphorylation (Klein et al., 2000; Alvarado-Kristensson et al., 2002). One 
explanation proposed for this is that apoptosis of neutrophils can either be stress-
activated or spontaneous, the former reliant on activation of p38 MAPK the latter 
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independent of this requirement (Frasch et al., 1998). An alternative theory to the 
presence of two distinct pathways leading to neutrophil apoptosis that may explain the 
dual effect of p38 MAPK is that phosphorylation of this MAPK does not guarantee its 
activation (Kumar et al., 1999), indeed the downstream phosphorylation of the p38 
MAPK specific substrate MAPK-activated protein kinase 2 (MK2) is required for p38 
MAPK activity. It has been shown that GM-CSF induced phosphorylation of p38 MAPK 
in neutrophils is not suppressed by the pharmacological inhibitor of the p38 MAPK 
pathway SB203580 whereas the downstream phosphorylation of MK2 was (ten Hove 
et al., 2007). Additionally treatment with SB203580 alone suppressed neutrophil 
apoptosis, which interestingly did not have an additive effect on survival in the co-
presence of SAA (El Kebir et al., 2007). These findings suggest that the pathway 
between p38 MAPK and MK2 is particularly susceptible to disruption, consequently it 
would be interesting to investigate this step of the apoptosis signalling cascade in GM-
CSF stimulated neutrophils in response to hrGal-1.  
 
However, in line with the data obtained in this study, it is worth noting that GM-CSF 
induced tyrosine-phosphorylation of p38 MAPK has been shown to be a comparatively 
weaker signal in neutrophils than other kinases (Suzuki et al., 1999), whereas GM-
CSF has been shown to activate both the PI3-kinase/AKT and ERK pathways in a 
number of cell types including robust activation in neutrophils (Tilton et al., 1997; 
McLeish et al., 1998). Likewise SAA has also been shown to induce a rapid, transient 
phosphorylation of AKT and ERK in freshly isolated neutrophils relative to 
unstimulated cells as well as enhanced phosphorylation of p38 MAPK (El Kebir et al., 
2007). It was shown that SAA suppression of neutrophil apoptosis is mediated via AKT 
and ERK signalling, which signal downstream targeting of BAD (El Kebir et al., 2007). 
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Importantly, inhibiting the phosphorylation of either AKT or ERK kinase alone 
attenuated, though did not completely reverse, the apoptosis-delaying action of SAA 
(El Kebir et al., 2007). Interestingly, it was also shown that inhibiting both kinases 
together did not produce an additive effect thus suggesting that AKT and ERK act in 
accordance with one another. Findings from the study by El Kebir et al., also revealed 
that the aspirin triggered lipoxin 15-epi-LXA4 can oppose SAA delayed neutrophil 
apoptosis and that SAA induced phosphorylation of ERK and AKT was attenuated by 
the lipoxin. Comparable findings in this current study may suggest that hrGal-1 is 
working by a similar mechanism of attenuating the initial phosphorylation to partially 
override the effect of GM-CSF on neutrophils.   
 
Further investigation is required to determine the exact mechanism by which hrGal-1 
is interrupting the pro-survival signal.  From the findings of El Kebir et al. for 15-epi-
LXA4 on SAA stimulated neutrophils it is known that the opposing regulation of 
apoptosis occurs at the level of the receptor expression on the neutrophil surface, 
specifically through the formyl peptide receptor 2/lipoxin A4 receptor to which both 15-
epi-LXA4 and SAA bind (Su et al., 1999; He et al., 2003; Chiang et al., 2006; El Kebir 
et al., 2008). Certainly, the pattern of tyrosine kinase phosphorylation is remarkably 
similar between the aforementioned study and the results obtained, with both GM-CSF 
and SAA phosphorylating all three of the kinases assayed, and an initially attenuated 
response with the addition of hrGal-1 and 15-epi-LXA4 respectively. These kinases 
have a relatively early position with regards to the complete signalling cascade and 
their modulation suggests that hrGal-1 interferes with GM-CSF signalling further 
upstream than these molecules. Thus, it could be postulated that hrGal-1 exerts its 




Indeed, CD45 which is a member of the tyrosine phosphatase family and is known to 
dephosphorylate Src kinases involved in the GM-CSF signal transduction pathway is 
also a known receptor for Gal-1 on the surface of neutrophils. Specifically, CD45 
regulates the Src kinase family member Lyn by reducing phosphorylation of the 
tyrosine inhibitory site (Y507) with dephosphorylation at this site resulting in activation 
of Lyn (Young et al., 2003). On the other hand, phosphorylation of Lyn at this site 
correlates with inefficient signalling through the GM-CSF receptor (Wei et al., 1996; 
Hibbs and Harder, 2006; Scapini et al., 2009). Consistent with this finding a study by 
Wei et al., identified Lyn as a critical tyrosine kinase responsible for transducing GM-
CSF survival signals in neutrophils. Results revealed that Lyn is physically coupled to 
the intracellular portion of the beta subunit of the GM-CSF receptor and that only the 
antisense of Lyn and not any other Src family member could reverse the GM-CSF 
stimulated pro-survival effect (Wei et al., 1996). Importantly binding of Gal-1 to CD45 
inhibits its protein phosphatase activity and therefore the dephosphorylation of Lyn 
kinase (Fouillit et al., 2000). The identification of two tyrosine phosphorylation sites on 
Lyn kinase infers the complexity of regulation of its signalling, the autophosphorylation 
site is stimulatory while the C-terminal phosphorylation site has been indicated to be 
inhibitory, with the former constitutively phosphorylated in untreated cells and the latter 
dominant for its activity (Yanagi et al., 1996). In this manner, CD45 regulates activity 
of Lyn by maintaining an unphosphorylated state at the C-terminal site, whereas the 
presence of Gal-1 results in phosphorylation of this site (Fouillit et al., 2000). 
Furthermore, downstream of Lyn sits the PI3 Kinase/AKT pathway, whereby increased 





Regarding the hrGal-1 mediated reversal of SAA pro-survival signals (see section 
4.4.2) reported as part of this thesis, there are currently no published studies on SAA 
or its receptor on neutrophil FPR2 being linked to activation of the Lyn signalling 
pathway. Interestingly it has been reported that Lyn is coupled to the intracellular 
domain of CD36 in a similar manner to which it is paired with the GM-CSF receptor on 
neutrophils (Baranova et al., 2010). Importantly, CD36, which acts as a scavenger 
receptor and is expressed on the surface of macrophages, is also a known SAA 
receptor on these cells, furthermore SAA binding to CD36 is suggested to induce 
activation of Lyn (Baranova et al., 2010). An additional study has also shown that 
exposure of microglia to amyloid peptides results in activation of Lyn (McDonald et al., 
1997). However it has not been reported that Gal-1 interacts with these receptors, as 
such it may be more feasible in the case of SAA that two separate pathways are being 
initiated, SAA binding to FPR2 inducing pro-survival and hrGal-1 binding to CD45 
inhibiting the dephosphorylation and subsequent activation of Lyn, with AKT 
downstream of both pathways. To establish whether this hypothesis or any of the 
theories put forward are correct further investigation of the signalling pathways which 
may be harnessed as the mechanism of action for hrGal-1 are required.  
 
4.4.4. Potential Role for AnxA1 in Mediating Gal-1 Reversal of Pro-Survival.  
 
Annexin A1 (AnxA1), an endogenous anti-inflammatory protein, contributes to the 
resolution of inflammation through various ways, including dampening neutrophil 
recruitment, overriding pro-survival signals and promoting clearance (Perretti et al., 
1996; Solito et al., 2003; Damazo et al., 2006; Vago et al., 2012), as well as increasing 
monocyte recruitment and efferocytosis (Arur et al., 2003; Scannell et al., 2007; 
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McArthur et al., 2015). It is well established that neutrophils contain high levels of 
AnxA1 in their cytoplasm and granules and that upon cell stimulation AnxA1 is 
secreted (Perretti et al., 1996; Perretti and D’Acquisto, 2009). Particularly relevant to 
this study is the finding that AnxA1 is released from neutrophils as they undergo 
apoptosis (Arur et al., 2003; Scannell et al., 2007). Furthermore, neutrophil AnxA1 
expression has been shown to decrease in response to GM-CSF stimulation, a finding 
which may suggest its secretion (Langereis et al., 2011). As such this was investigated 
as part of the current study to establish whether modulation of AnxA1 expression may 
be a mechanism utilised by hrGal-1 to exert its anti-inflammatory actions. 
 
Neutrophils demonstrated a trend for the reduction of surface AnxA1 after 4h and 
sequentially at 20h compared to levels expressed on freshly isolated cells, with no 
significant modulation resulting from stimulation with GM-CSF and/or hrGal-1. 
However, it is worth noting that following 4h incubation surface AnxA1 was lower on 
neutrophils incubated with GM-CSF compared to control cells, a trend which although 
subtle was shown to reverse at the 20h timepoint. Relative to total expression, surface 
levels of AnxA1 are low indicating that the protein is not maintained on the neutrophil 
surface and suggesting that its detection here may be the result of capturing the 
protein as it is being secreted through the neutrophil membrane. Indeed, translocation 
of AnxA1 to the cell membrane has been observed upon cell activation (Perretti et al., 
1996). 
 
It is well established that AnxA1 is predominantly intracellular; in resting neutrophils, 
monocytes and macrophages high levels of cytoplasmic AnxA1 have been detected 
(Morand et al., 1995; Perretti et al., 2000). In this current study the total AnxA1 levels 
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of unstimulated neutrophils was revealed to increase with time, with the highest 
expression of the protein detected at 20h, suggesting that synthesis of the protein is 
increased in neutrophils as they undergo apoptosis. In line with this suggestion 
endogenous AnxA1 release from apoptotic neutrophils has been reported (Scannell 
et al., 2007). The findings presented as part of this thesis show a trend towards a 
reduction in total AnxA1 levels for neutrophils stimulated with GM-CSF, which 
increases over time. Interestingly, data for apoptotic neutrophils at 20h reveals the 
GM-CSF induced reduction of AnxA1 was partially reversed by the co-incubation of 
cells with hrGal-1. However, there appeared to be no effect of hrGal-1 alone. One 
theory which may explain these results is that the expression of AnxA1 increases as 
neutrophils undergo apoptosis, as the 0h, 4h and 20h data here suggests, and 
consequently the GM-CSF induced rescue from apoptosis of neutrophils directly 
results in, or from, a reduction in AnxA1 expression. Alternatively, it could be 
suggested that GM-CSF stimulation of neutrophils did not modulate expression levels 
but caused increased secretion, as previously suggested  (Langereis et al., 2011). To 
attempt to establish which of these hypotheses likely explains the modulation of AnxA1 
expression in response to GM-CSF, and thus determine the actions of hrGal-1 in this 
setting, neutrophil release of AnxA1 was quantified.  
 
It was shown that GM-CSF reduced neutrophil release of AnxA1, an effect that was 
particularly apparent in apoptotic neutrophils at 20h and shown to be markedly 
reversed in neutrophils co-incubated with hrGal-1. Taken together these findings lend 
support to the former argument that GM-CSF stimulated neutrophils express and 
release less AnxA1 and that this is most likely a direct result of their increased viability. 
In line with this suggestion the opposite effect has been reported for pro-apoptotic 
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stimuli whereby induction of AnxA1 expression and externalization was shown to be 
coupled with the proapoptotic effect of a histone deacetylase inhibitor (FK228) in 
leukaemia cells (Tabe et al., 2007). 
 
Certainly, in the context of inflammation it could easily be argued that GM-CSF 
reduces the release of anti-inflammatory AnxA1 by neutrophils removing an 
endogenous braking system from an already self-perpetuating inflammatory response, 
the explanation for this being three-fold by affecting recruitment, survival and 
clearance. Firstly, the externalised form of endogenous AnxA1 has been shown to 
inhibit trans-endothelial migration of neutrophils consequently abating their infiltration 
to the inflammatory site (Perretti et al., 1996; Gastardelo et al., 2009; Pederzoli-Ribeil 
et al., 2010). Secondly, endogenous AnxA1 has an important pro-apoptotic function 
and blocking this pathway abolishes both morphological and biochemical changes 
associated with apoptosis (Vago et al., 2012). Thirdly, following neutrophil release of 
endogenous AnxA1 it colocalises with PS on the apoptotic cell surface and promotes 
efferocytosis (Arur et al., 2003; Scannell et al., 2007). As such the ability of hrGal-1 to 
reverse the effect of GM-CSF on reducing AnxA1 expression may be a previously 
undiscovered mechanism by which Gal-1 overrides pro-survival signals in neutrophils. 
Furthermore, as well as the increase of AnxA1 resulting from the addition of hrGal-1 
to GM-CSF treated neutrophils there is also increased expression of PS on these cells, 
(as previously discussed in sections 4.4.1 and 4.4.2). Indeed, the correlation of these 
two results is notable due to the colocalization of PS and AnxA1 being important for 






In contempt of the fact that externalised PS is conventionally associated with apoptosis 
the data presented here indicates that the effect of hrGal-1 on PS exposure and its 
ability to override neutrophil pro-survival signals to induce apoptosis are distinct and 
unconnected actions. It is known that hrGal-1 binding to viable neutrophils results in 
enhanced expression of PS on the extracellular membrane. However, in disagreement 
with previous reports suggesting that exogenous Gal-1 ‘induces’ PS exposure it is 
perhaps more perceivable that it simply retains the molecules on the outer membrane. 
The phospholipid membrane has a degree of fluidity and consequently non-specific 
flip-flop of phospholipids can occur with no net impact on membrane integrity. 
Furthermore, the binding and subsequent crosslinking of galectins at the cell surface 
has been shown to maintain receptor externalisation/expression. This theory would 
also fit with the findings of PS exposure in the presence of other galectins and its 
subsequent reversal on galectin removal (Stowell et al., 2007, 2009). Additionally it 
has also been suggested that galectins need to be in their dimerized form to have an 
action on PS exposure, which likewise has been shown to be required for efficient 
galectin receptor cross-linking and lattice formation at the cell surface (Demetriou et 
al., 2001; Brewer et al., 2002; Nieminen et al., 2007). 
 
It has been put forward that PS exposure in the absence of apoptosis may function in 
the resolution of inflammation to aid efferocytosis, importantly not just of apoptotic cells 
but also of healthy neutrophils present at the inflammatory site. This process whereby 
neutrophils are efferocytosed without undergoing apoptosis has been termed 
“preaperesis”  (Dias-Baruffi et al., 2003; Stowell et al., 2007, 2009), however it is yet 
to be definitively proven as a mechanism of clearance. Indeed, phospholipid exposure 
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has been reported to provide  'find-me', 'eat me' and 'tolerate me' signals to 
phagocytes and typically considered an eat me signal PS exposure can also act as a 
'tolerate me' signal to stimulate release of anti-inflammatory cytokines (Biermann et 
al., 2013). As a result of membrane remodelling PS has a higher lateral mobility on the 
surface of apoptotic cells, thus phagocytes are able to distinguish between living and 
apoptotic cells, with specific PS distribution required to trigger the correct receptor 
clustering on the phagocyte to facilitate efferocytosis (Biermann et al., 2013). These 
findings would imply that the concept of ‘preaperesis’ may not be a successful 
mechanism for clearance of non-apoptotic neutrophils. Perhaps, galectin binding to 
the surface of neutrophils is instead a strategy to hold PS on the outer membrane, 
promoting its exposure to macrophages to stimulate their release of anti-inflammatory 
cytokines. This would suggest an important pro-resolving behaviour for Gal-1 in 
triggering the premature release of anti-inflammatory cytokines which would ordinarily 
be dependent on PS exposure by neutrophils as they initiate apoptosis. In line with 
this theory the increased PS expression on hrGal-1 treated cells started to plateau at 
4h compared to 1h and appeared to be completely ablated by 20h, having no effect 
on progression of apoptosis. Certainly, unstimulated neutrophils begin to undergo 
spontaneous apoptosis thus their natural PS exposure negates the requirement for 
involuntary expression. 
 
In addition to its initial effect, hrGal-1 also has a later purpose and mediates reversal 
of delayed neutrophil apoptosis. Findings from this study have confirmed the ability of 
hrGal-1 to override pro-survival signals and induce apoptosis of neutrophils. This has 
been indicated by changes in cell morphology and outer membrane integrity in addition 
to PS exposure. Importantly hrGal-1 was shown to modulate the intracellular signalling 
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pathways involved in controlling cell survival as well as modulate the expression and 
subsequent release of endogenous AnxA1, an action associated with neutrophil 
apoptosis and endowed with anti-inflammatory functions. It is well established that 
delayed neutrophil apoptosis facilitates many acute and chronic inflammatory 
diseases and appears to be largely mediated by excessive production of GM-CSF 
(Dibbert et al., 1999; Saba et al., 2002). However, the activated phenotype of these 
neutrophils appears to render them susceptible to Gal-1-induced apoptosis, a 
discovery first suggested from a study on neutrophils from the synovial fluid of 
rheumatoid arthritis patients (Cedeno-Laurent et al., 2010). The ability of hrGal-1 to 
reverse the effects of GM-CSF (and other neutrophil pro-survival factors) is a 
promising finding and indicates the potential therapeutic application of Gal-1 in 
inflammatory diseases whereby the accumulation of chronically activated neutrophils 




4.5. Gal-1 Binds to a Receptor on Neutrophils that is Upregulated by GM-CSF.  
 
4.5.1. Gal-1 Binds Viable but not Apoptotic Neutrophils. 
 
It is well established and has been demonstrated within this study, that exogenous 
Gal-1 can bind to the surface of viable neutrophils and that this occurs through a  
carbohydrate dependent interaction (Cooper et al., 2008). However, there are 
conflicting suggestions as to whether Gal-1 binding to neutrophils occurs more readily 
when cells are of an activated phenotype. In an assay where freshly isolated 
neutrophils were incubated with Gal-1 in the presence or absence of platelet activating 
factor (PAF), there was no notable increase in Gal-1 binding to the activated cells 
(Cooper et al., 2008). In an alternative study neutrophils that were stimulated with N-
Formyl-Methionyl-Leucyl-Phenylalanine (fMLP) exhibited increased Gal-1 binding 
compared to unstimulated resting cells (Dias-Baruffi et al., 2003) interestingly the latter 
study also revealed that exogenous Gal-1 binding was most abundant on 
enzymatically desialylated resting neutrophils, a finding which in addition to lactose 
inclusion inhibiting Gal-1 binding (even to activated cells) provided further verification 
of the carbohydrate dependent nature of the binding. Another important consideration 
is that mobilisation of different neutrophil granules is also stimuli specific and results 
in modulation of cell surface receptor expression (Borregaard et al., 1994; Bratt et al., 
1999).  Taken together these findings indicate that the impact of neutrophil activation 
on Gal-1 binding is stimuli dependent and more directly linked to differentially 
modulating the glycophenotype (expression of glycolipids and glycoproteins) on the 




The effect of stimulation with GM-CSF and apoptosis of neutrophils on surface Gal-1 
has not previously been reported, as such it was examined as an aspect of this study. 
Here it was shown that in the absence of stimuli apoptotic neutrophils had similar levels 
of endogenous Gal-1 on their surface as viable cells, a finding that indicates that Gal-
1 surface expression is not modulated on naive neutrophils as they undergo apoptosis, 
and also implies that in the absence of stimuli intracellular Gal-1 is not externalised. 
Strikingly, the addition of GM-CSF to this assay resulted in increased endogenous 
Gal-1 being detected on the neutrophil surface. In line with this finding Gal-1 has 
previously been detected in the cytoplasm, nucleus and outer plasma membrane of 
activated neutrophils (Kurihara et al., 2010) despite not being  constitutively expressed 
in resting neutrophils (Dias-Baruffi et al., 2010).  
 
Neutrophils that had undergone apoptosis in the presence of hrGal-1 showed 
increased Gal-1 on their surface compared to naïve apoptotic neutrophils. Although it 
is unsurprising that bound Gal-1 was detected on the cell surface it is interesting that 
less exogenous Gal-1 bound to the surface of apoptotic cells than viable neutrophils, 
despite the considerably longer incubation period. This might suggest that no 
additional binding of Gal-1 occurs as neutrophils progress through apoptosis and/or 
that already bound Gal-1 dissociates from the surface of neutrophils as they undergo 
this process. In either case these results would suggest that changes to the neutrophil 
glycophenotype take place in parallel with apoptosis. Indeed, data obtained from lectin 
binding assays performed in collaboration with another member of the lab detected 
notable modulations between viable and apoptotic cells, yet there appeared to no 
consistent effect of GM-CSF and/or hrGal-1. However further investigation is required 
to verify these preliminary results. To address whether it was likely that Gal-1 easily 
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dissociates from the surface of apoptotic neutrophils lactose was added, but the lack 
of effect indicates that Gal-1 binding to the neutrophil surface is not easily disrupted.  
 
It is also feasible that expression of the Gal-1 receptor(s) on neutrophils is modulated 
during the apoptotic process. Analysis of apoptotic neutrophils revealed two distinct 
subpopulations, Gal-1 high and Gal-1 low. The Gal-1 high population was detected 
irrespective of whether the exogenous protein had been added to the neutrophils 
indicating that the increased expression of Gal-1 likely represented mobilisation of the 
endogenous protein.  To establish whether the cell surface of apoptotic neutrophils 
was modified in a manner to modulate Gal-1 receptor expression and effect the ability 
of the exogenous protein to bind, apoptotic cells were incubated with hrGal-1. The 
detected increase in Gal-1 was suggestive of exogenous Gal-1 having bound to the 
surface of the apoptotic neutrophil population. However, regardless of the addition of 
hrGal-1, there were two distinct subpopulations, Gal-1 high and Gal-1 low. The Gal-1 
high population was comparable in hrGal-1 treated to control neutrophils, with no 
change in Gal-1 expression in response to hrGal-1 thus indicating that it did not bind 
the Gal-1 high subpopulation. Conversely the Gal-1 low population demonstrated a 
clear shift in the histogram peak, here increased Gal-1 was detected following 
incubation with hrGal-1, suggesting that the exogenous protein had bound to the Gal-
1 low population. Importantly, when Gal-1 high and Gal-1 low subpopulations were 
assessed by size and granularity it was apparent that the Gal-1 high neutrophils with 
their decreased size and granularity were late apoptotic whereas the Gal-1 low 
population formed a tight cloud of larger and more granular cells indicative of viable or 




Taken together these findings support the earlier suggestion that hrGal-1 freely and 
rapidly binds to the surface of viable neutrophils and that this can be differentially 
modulated on activated cells, yet it does not bind to the surface of neutrophils 
undergoing apoptosis. Importantly, in the context of neutrophils present at the 
inflammatory site the existence of nearby apoptotic cells and their released mediators 
does not impede hrGal-1 binding the remaining viable cells, a significant virtue further 
illustrating its therapeutic potential. 
 
4.5.2. Gal-1 Receptor CD45 is Upregulated on GM-CSF Stimulated
 Neutrophils. 
 
Members of the galectin family are carbohydrate binding proteins with a general 
specificity for β-galactosides. Each galectin exhibits subtle preferences in 
oligosaccharide-binding specificity with Gal-1 known to favour poly-N-acetyllactosame 
(poly-LacNAc) chains (Caron et al., 1990). As such, glycoconjugate ligands for Gal-1 
include the extracellular matrix proteins laminin and fibronectin, as well as the serum 
glycoprotein Mac-2 binding protein (90K/Mac-2BP) and the cell surface receptors 
CD45, CD43, CD7, CD2, CD3 and GM1 (reviewed in (Rabinovich et al., 2002)). 
 
CD43 and CD45 are the main Gal-1 specific transmembrane glycoproteins highly 
expressed on neutrophils. Expression of these receptors was assessed following 
incubation with GM-CSF to determine if this was modified by stimulation with the pro-
survival protein. CD45, but not CD43, was markedly upregulated on the neutrophil 
surface in response to GM-CSF. In line with this finding a previous study has shown 
that activated neutrophils exhibit increased expression of Gal-1 receptors (Almkvist et 
al., 2002). Furthermore, within the same study it was proposed that neutrophil granule 
mobilisation is the mechanism behind this. It is well established that activation of 
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neutrophils results in mobilisation of their intracellular granules, and it has previously 
been demonstrated that the mobilization of receptor-storing granules and their 
subsequent fusion with the neutrophil plasma membrane results in increased receptor 
expression on the cell surface (Sengeløv et al., 1995). Indeed, studies have shown 
that GM-CSF induces neutrophil granule exocytosis and receptor expression (Smith 
et al., 1990; Graves et al., 1992). In a study by Almkvist et al. it was suggested that 
Gal-1-binding epitopes that are not already expressed on the neutrophil surface are 
stored elsewhere in the cell. Additionally the evidence that CD45 antigens are involved 
in the regulation of stimulation by GM-CSF (Broxmeyer et al., 1991; Suh et al., 2005), 
provides further rationale that CD45 receptor mobilisation occurs in neutrophils 
activated by GM-CSF stimulation. Likewise, from the perspective of the intracellular 
signalling response if the Src family kinase Lyn is governing the pathway, then GM-
CSF requires the tyrosine phosphatase CD45 to regulate activity of Lyn by maintaining 
an unphosphorylated state at the active C-terminal site for the pro-survival signal to 
proceed. Therefore, increasing expression of CD45 is advantageous for perpetuating 
the GM-CSF induced signalling cascade. 
 
Detection of CD45 using an anti-CD45 antibody was compromised by hrGal-1 in a 
concentration dependent response. The affinity of Gal-1 binding to CD45 shown here 
was not unexpected given that it is such a heavily glycosylated protein. Alternative 
splicing has resulted in the generation of multiple CD45 isoforms (Thomas, 1989), yet 
analysis of the sugar chains has revealed that these isoforms ubiquitously contain 
large amounts of poly(N-acetyllactosamine) (Sato et al., 1993; Furukawa et al., 1998), 
to which Gal-1 will bind. Incubation with increased concentrations of hrGal-1 reduced 
anti-CD45 binding to the neutrophil irrespective of whether GM-CSF was included in 
the assay, suggesting that hrGal-1 binding prohibits the antibody binding to its antigen. 
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In line with this finding, it has been shown in a study on B cells that an antibody to 
CD45 was able to dissociate Gal-1 (Fouillit et al., 2000). Furthermore, the binding of 
exogenous ligands to CD45 has been shown to result in CD45 dimerization (Weiss 
and Schlessinger, 1998). Importantly, ligand induced dimerization of CD45 has been 
suggested to block the catalytic site thus preventing the required substrate binding 
necessary for phosphatase activity (Weiss and Schlessinger, 1998). In this manner 
CD45 function may be negatively regulated by hrGal-1 binding.  
 
Conversely very little modulation was detected for CD43 expression in this assay. In 
opposition to CD45 the glycoprotein CD43 is rapidly shed from the neutrophil 
membrane upon activation (Rieu et al., 1992; Mambole et al., 2008). Thus, the 
decrease in CD43 expression that was observed in response to GM-CSF in this 
present study was not unexpected. Here, in line with findings in the literature, the effect 
of GM-CSF stimulation on neutrophil CD43 membrane expression was only very 
moderate (Rieu et al., 1992). Interestingly, existing evidence suggests that CD43 has 
an important role in neutrophil trafficking and generally serves as an anti-adhesive 
molecule to attenuate neutrophil-endothelial interactions (Matsumoto et al., 2008). 
Thus, it is plausible that a ligand-receptor binding interplay between Gal-1 and CD43 
may play an important role in facilitating the inhibitory effect of Gal-1 on neutrophil 
recruitment. Furthermore, CD43 has also been demonstrated to serve as a ligand and 
provide pro-adhesive actions on neutrophil recruitment, a behaviour which is context 
dependent (Matsumoto et al., 2008), but may explain the divergence in the effect of 







In this assay it was shown that Gal-1 does not bind to late apoptotic neutrophils. It 
could be suggested that this is due to changes in the glycophenotype that result from 
the rearrangement of phospholipids and loss of membrane integrity of these cells. Due 
to the loss of CD43 in response to activation of neutrophils it is possible that this 
receptor is also shed as neutrophils undergo apoptosis, although this hypothesis is yet 
to be investigated. Regarding the loss of Gal-1 binding to the neutrophil surface via 
CD45 it could be suggested that changes to the extracellular membrane during 
apoptosis results in either rearrangement or masking of the required glycan epitopes. 
It could be postulated that CD45 undergoes dimerization during neutrophil apoptosis, 
which would explain not only the loss of ligand binding potential but also the loss of 
tyrosine phosphatase activity.  
 
Taken together these findings suggest that hrGal-1 binds only to viable neutrophils 
and that this occurs predominantly via CD45 expressed on the outer membrane of the 
cell. The activation of neutrophils by GM-CSF stimulation mobilises neutrophil 
intracellular granules to migrate to the outer membrane. Once positioned, these 
granules bind to the membrane allowing the release of their contents. Previous 
findings and results from this present study suggest that intracellularly contained Gal-
1 binding epitopes, such as CD45 and low levels of endogenous Gal-1 may be 
exposed at the cell surface in this manner. Here the increased expression of CD45 
provides for enhanced hrGal-1 binding and crosslinking resulting in ligand induced 
receptor dimerization of CD45. As a consequence of this change in formation the 
catalytic site of CD45 is masked, thus inhibiting substrate binding and the tyrosine 
phosphatase activity of CD45. By this mechanism the Src family kinase Lyn, which is 
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coupled to a GM-CSF receptor subunit, ceases to remain dephosphorylated at its 
inhibitory C-terminal site. Phosphorylation at this site renders the kinase inactive and 
thus signalling to the downstream PI3K/AKT pathway is discontinued and the GM-CSF 
induced pro-survival signal desists (figure 64).   
 
Indeed, this mechanism is suggestive of a promising therapeutic application of 
exogenous Gal-1 for targeting GM-CSF stimulated neutrophils and inducing their 
apoptosis. Although the ligand receptor binding for Gal-1 and CD45 have been 
investigated in this study further work is required to assess the potency of this 
interaction to establish if it would still have effect in an inflammatory environment where 
GM-CSF production is sustained. The pro-survival effect of GM-CSF requires ongoing 
ligand-receptor interaction however due to neutrophils utilisation of GM-CSF 
exogenous GM-CSF is depleted (De Alessandris et al., 2019). These findings may 
suggest in the in vitro assay presented in the current study that the availability of the 
growth factor is depleted over time. As GM-CSF levels within the culture media were 
not measured it is unknown whether this would be the case, but a high concentration 
was used (50ng/ml) so this seems unlikely. However, it does raise the question 
whether in a chronically inflamed environment (with excess GM-CSF) Gal-1 would still 
be capable of overriding the growth factor to induce neutrophil apoptosis. In this 
context GM-CSF ligand to receptor binding actions may need to be investigated and 
additionally targeted in order to maximise the efficacy of Gal-1 and promote the 








Figure 64. Proposed signalling pathway of Gal-1 reversal of GM-CSF signalling. 
(A) Lyn kinase is coupled to the intracellular portion of the β subunit of the GM-CSF receptor. CD45 is a tyrosine 
phosphatase present on the neutrophil membrane that maintains Lyn activity by dephosphorylating the inhibitory site 
(Pi). (B) The binding of Gal-1 to CD45 results in CD45 dimerization and galectin lattice formation, blocking 
phosphatase activity at the inhibitory site (Pi) on Lyn and trapping receptors and exposed PS on the outer membrane. 
(C) GM-CSF requires CD45 to regulate activity of Lyn by maintaining an unphosphorylated state at the inhibitory site 
(Pi) for the pro-survival signal to proceed. (D) GM-CSF stimulates mobilization of receptor storing granules and their 
subsequent fusion with the plasma membrane, resulting in increased CD45 receptor expression on the cell surface 
to perpetuate the GM-CSF induced signalling cascade. (E) The presence of Gal-1 competes with the pro-survival 
signals of GM-CSF by inhibiting Lyn activity. (F) Downstream of Lyn sits the PI3 Kinase/AKT pathway. GM-CSF and 
increased Lyn signalling induce phosphorylation of AKT which delays apoptosis via inhibition of BCL2 activity. (G) 
Gal-1 binding to CD45 inhibits phosphatase activity. Lyn becomes phosphorylated at the inhibitory site, rendering 





4.6. Efferocytosis was not Influenced by Gal-1 Treatment of Neutrophils. 
 
Findings in the literature have predominantly focused on the effect of exogenous Gal-
1 on macrophages or on neutrophils alone, with studies on the process of their 
efferocytosis being particularly limited. One study which has investigated efferocytosis 
was tailored to the effect of exogenous Gal-1 on macrophages in this setting. Here it 
was revealed that Gal-1 promotes an anti-inflammatory pro-resolving (CD11blow) 
phenotype in macrophages resulting in their efferocytic satiation being reached more 
quickly (Rostoker et al., 2013). Likewise studies which have not assessed 
efferocytosis but have investigated the effect of Gal-1 on macrophages also indicate 
a pro-resolving phenotype, revealing that Gal-1 treated macrophages favour the 
alternative activation pathway, have a more M2 like phenotype, have reduced MHC-II 
expression and release lower amounts of pro-inflammatory mediators (Rabinovich et 
al., 2000; Correa et al., 2003; Barrionuevo et al., 2007; Kogawa et al., 2011; 
Abebayehu et al., 2017). Regarding the role of neutrophils in efferocytosis a number 
of studies exist suggesting exogenous Gal-1 induces PS exposure alongside the 
hypothesis that this facilitates preaperesis, a process whereby these PS exposing 
neutrophils are efferocytosed in the absence of their apoptosis (Dias-Baruffi et al., 
2003; Stowell et al., 2007, 2009). However, this line of research has yet to be extended 
to the clearance of these neutrophils and therefore was addressed as part of the scope 
of this thesis. Due to the previously highlighted difficulties of capturing efferocytosis in 
vivo these assays were performed in vitro using human cells to determine if hrGal-1 




In the present study efferocytosis assays were performed with neutrophils that had 
been exposed to hrGal-1. No difference was detected in the phagocytic uptake of 
neutrophils by macrophages as a result of cells undergoing apoptosis ± hrGal-1 ± GM-
CSF. As previously discussed, assessment of the level of neutrophil apoptosis in 
response to GM-CSF and/or hrGal-1 revealed an increased percentage of viable cells 
in the GM-CSF treated population. However, this did not appear to have an impact on 
their efferocytosis, a finding which is likely explained by most of these neutrophils 
being PS positive and apoptotic, thus there was not enough difference in the viable 
percentage to confer a difference in efferocytosis. The lack of effect of hrGal-1 in this 
experimental setting is not altogether unexpected as the percentage of PS positive 
cells was not different between the hrGal-1 and hrGal-1 + GM-CSF groups when 
compared to unstimulated neutrophils. Previous assays have determined that 
unstimulated neutrophils have lower surface Gal-1 expression compared to stimulated 
cells. Yet, in this setting the level of surface Gal-1 expression on the neutrophil was 
not shown to influence their phagocytic uptake by macrophages, a finding which will 
be further discussed later.  
 
Reports in the literature suggest that Gal-1 promotes efferocytic satiation of 
macrophages (Rostoker et al., 2013), an effect that was established to be the result of 
Gal-1 acting directly on the macrophages. However, in the study by Rostoker et al. 
Gal-1 was administered into the peritoneal cavity during the resolving phase of 
peritonitis, therefore it had the potential to also modulate neutrophil phenotype and 
numbers. To further validate that the in vivo data was neutrophil-independent the in 
vitro set up performed as part of this present study was assayed at two different 
macrophages to apoptotic neutrophil ratios. As expected, a higher neutrophil to 
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macrophage ratio resulted in increased efferocytosis. Furthermore, the effect of 
neutrophils undergoing apoptosis ± hrGal-1 ± GM-CSF had no bearing on efferocytic 
uptake regardless of the number of apoptotic neutrophils overlaid. Thus, supporting 
that the effect evidenced in the in vivo model by Rostoker et al. was macrophage 
mediated.  
 
Interestingly, Gal-3 has been reported to function as an opsonin (Karlsson et al., 2008), 
to determine whether Gal-1 could behave in a mechanistically similar way both viable 
and apoptotic neutrophils were incubated with hrGal-1 immediately prior to and during 
their addition to macrophages. In these assays hrGal-1 did not modulate efferocytosis 
of neutrophils therefore establishing that, unlike Gal-3, Gal-1 was not shown to act as 
an opsonin.  
 
Furthermore, this experimental set up provided an opportunity to observe the effect of 
hrGal-1 induced PS exposure on non-apoptotic neutrophils in the context of 
efferocytosis. Here, viable neutrophils incubated for 1h with hrGal-1 had significantly 
increased PS displayed on their outer membrane compared to naïve cells and by 
overlaying them on macrophages it was possible to investigate the theory of 
‘preaperesis’  (Dias-Baruffi et al., 2003; Stowell et al., 2007, 2009). In this assay PS 
exposure was not shown to increase macrophage engulfment of these cells, thus 
suggesting that PS exposure in the absence of apoptosis did not provide the 
appropriate ‘eat me’ signal to macrophages and is not a mechanism for cell clearance. 
This finding is supported by previous studies where it has been shown that the 
constitutive exposure of PS on viable cells was not by itself sufficient for efferocytosis 
by macrophages (Segawa et al., 2011). In fact, reports in the literature suggest that 
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PS exposure on non-apoptotic cells may serve as a 'tolerate me' signal to stimulate 
release of anti-inflammatory cytokines (Biermann et al., 2013), this is not something 
that was investigated as part of the current study. Indeed, it would be interesting to 
measure cytokine release in this set up to establish if Gal-1 has an anti-inflammatory 
role via the mechanism of facilitating PS presentation on non-apoptotic neutrophils to 
macrophages to stimulate their release of anti-inflammatory cytokines. 
 
In summary these findings indicate that exogenous Gal-1 does not modulate the 
phenotype of neutrophils in a manner that encourages their phagocytic uptake despite 
the well-established finding that Gal-1 facilitates PS exposure on viable neutrophils.  
The exact mechanism for this and the outcome remains to be elucidated, however it 
would suggest an anti-inflammatory action for the protein which may still result in 
dampening inflammation and thus indirectly reducing inflammatory infiltrate. 
Importantly, current literature suggests that Gal-1 treatment of macrophages induces 
a pro-resolving phenotype (Rostoker et al., 2013) and improves their ability to 
phagocytose (Barrionuevo et al., 2007), therefore illustrating that the role of Gal-1 in 
efferocytosis is not redundant.  
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4.7. Concluding Remarks 
 
Protein glycosylation is fundamental to the immune response, with roles in antibody 
function, antigen presentation and leukocyte recruitment, however it is becoming 
increasingly obvious that during inflammation the cellular glycome is modified with 
aberrant glycosylation likely to play a role in numerous pathologies. Galectins have 
the ability to recognise and bind to sugar molecules and as such their actions are 
specifically dependent on the expression of distinct saccharides presented on cellular 
proteins and lipids. It is through binding these molecules that galectins cross-link on 
the cell surface in order to elicit their down-stream effects. Through further 
understanding the biology of Gal-1 (as a prototype of immune relevant carbohydrate 
binding proteins that recognise and bind to specific sugar molecules) anti-inflammatory 
therapies could capitalise on the sugar code that decorates the majority of 
inflammatory proteins and lipids modulating their actions. 
 
This research aimed to elucidate the actions of Gal-1 on cell trafficking as well as 
neutrophil apoptosis and clearance. Under the hypothesis that Gal-1 can reduce both 
the recurrent movement of white blood cells from the blood into the arthritic joint and 
the enhanced lifespan afforded to these cells, Gal-1 represents a potential new 
therapeutic strategy for treating RA. Furthermore, findings from this study will 
significantly increase the limited existing knowledge regarding the effects of Gal-1 on 
neutrophils and neutrophil-driven pathologies. 
 
Currently the role of Gal-1 in the resolution process remains to be fully clarified. The 
delayed remission of arthritis observed here in Gal-1 KO mice coupled with the ability 
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of Gal-1 to counter-regulate the neutrophil pro-survival signals of pro-inflammatory 
mediators found in RA synovial fluid is suggestive of a role in neutrophil clearance. 
Collectively these findings have important implications for the treatment of 
inflammatory arthritis, where the prolonged survival of neutrophils contributes to the 




Chapter 5. Future Direction 
 
5.1. Model of Acute Inflammation 
 
Co-administration or prophylactic treatment with hrGal-1 in the zymosan peritonitis 
model to verify that there is no difference in leukocyte and more specifically neutrophil 
recruitment in response to hrGal-1 in this model. 
 
5.2. Model of Rheumatoid Arthritis  
 
The lessened disease evidenced in the Gal-1 KO mice compared to WT in the K/BxN 
serum induced model of arthritis would suggest expansion of the population of effector 
T cells that have a regulatory/anti-inflammatory phenotype in the absence of Gal-1. 
Thus, further phenotyping of effector T cells present in the K/BxN serum induced 
arthritis model to determine the phenotype of the subpopulation driving the increase.  
 
Although findings from this study were not indicative of an effect of the exogenous 
protein in the K/BxN serum induced model of arthritis, additional assessment is 
required with adjusted dosing parameters and/or duration of disease, to establish 





5.3. Apoptosis and Phosphatidylserine Exposure. 
 
For ex vivo apoptosis to establish if viable neutrophils taken from Gal-1 KO mice would 
still progress through apoptosis quicker when plated at equal cell density as WT cells. 
It would be interesting to investigate this for both inflammatory stimulated and non-
stimulated neutrophils.   
 
For in vitro apoptosis further studies will look at the intracellular signalling pathways 
with specific focus on tyrosine phosphorylation of Lyn. Also, to verify that Gal-1 
reversal of pro-survival factors occurs through binding to CD45 on the neutrophils 
surface it would be interesting to block the receptor prior to incubation with hrGal-1 
and assess levels of apoptosis.  
 
Regarding increased PS expression seen on neutrophils in response to hrGal-1 it 
would be pertinent to establish if this was due to Gal-1 crosslinking at the cell surface, 
thus it would be interesting to look at PS and Gal-1 on the neutrophil surface by 
microscopy to establish if co-localisation and/or clustering of the molecules is 
occurring. 
 
Further investigation into the role of AnxA1 release in response to GM-CSF and hrGal-
1 is required. It would be interesting to look at granule mobilisation and the interplay 
of these molecules on this function. Alternatively, a FPR2 antagonist could be used to 





5.4. Macrophages and Efferocytosis 
 
Full characterisation of Gal-1 null macrophages and WT macrophages in response 
to exogenous Gal-1 is required in order to build a better picture of the role of Gal-1 
on macrophages. Investigating the release of endogenous Gal-1 in response to 
inflammatory stimuli present in the arthritic joint is still a relatively unexplored aspect 
of macrophage/Gal-1 biology and would provide further insight on their potential pro-
resolving role. 
 
5.5. Glycophenotype and Vasculature 
 
Findings from this study indicate that there may be changes to the vasculature in Gal-
1 KO mice compared to WT, thus it would be intriguing to perform permeability assays 
on Gal-1 KO (potentially endothelial cell specific) and WT mice.  
 
To extend this research, glycophenotyping of immune cells and endothelial cells 
should be performed to determine modifications in response to inflammation in Gal-1 
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